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Abstract 
 
The Tol-Pal complex of Gram-negative bacteria is a highly conserved family 
of interacting proteins that span the periplasm, from inner to outer 
membrane. Despite decades of work on this protein complex, only the 
structure of a small part of the Tol complex in E.coli (TolB, Pal, TolB-Pal 
complex, TolA domain 3) as well as part of TolA from Pseudomonas 
aeruginosa have been resolved, and the native function of the Tol-Pal 
system remains elusive. A key interaction of the Tol-Pal system is between 
TolA and TolB. These two proteins bridge the periplasm, linking the inner 
membrane complex of TolQ, TolR and TolA with the outer membrane 
through the outer membrane bound Pal and periplasmic TolB. The structure 
of the TolA-TolB complex is not known, and although the TolA binding 
epitope of TolB has been localised to the intrinsically disordered N-terminus 
of TolB, the binding site on TolA is also unknown (Bonsor et al. 2009). The 
aim of this work is to address a number of questions regarding a 
fundamental part of the Tol-Pal system: the interaction between TolA and 
TolB. This thesis reports that not only is the short 22 residue N-terminus of 
TolB important for its interaction with TolA domain 3, but that it is the sole 
site of interaction between E.coli TolA and TolB. This was shown by 
engineering the E.coli TolB N-terminus onto another protein to create a novel 
interaction with E.coli TolA. In addition, a synthetic peptide of the N-terminus 
of TolB binding TolA can recapitulate and serve as a model for the native 
interaction. This work also reports that the TolA-TolB interaction is 
conserved between Pseudomonas aeruginosa TolA and TolB, and that the 
N-terminus is also important for this interaction, the first work to suggest this. 
Finally, through use of nuclear magnetic resonance spectroscopy, residues 
perturbed on Pseudomonas aeruginosa TolA domain 3 through the binding 
of a synthetic peptide representing Pseudomonas aeruginosa TolB have 
been mapped onto the TolA protein to determine the potential binding site of 
TolB on TolA, something which until now has been unknown.
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1. Introduction 
 
1.1 Gram-negative bacteria 
 
One of the key ways of differentiating Gram-negative from Gram-positive 
bacteria is by the organisation of their membranes. Gram-negative bacteria 
have 3 distinct features; an inner membrane surrounding the cytosol, an 
outer membrane separating the cell from the extra-cellular medium, and a 
space between the two which is called the periplasm. Both the inner and 
outer membranes are lipid bilayers, although their specific composition and 
behaviour of their components differs. The inner membrane is comprised of 
a single symmetrical phospholipid bilayer (for review see Raetz 1978). In 
contrast, the outer membrane is more rigid, comprising of an asymmetric 
phospholipid bilayer on the periplasmic leaflet, and lipopolysaccharide (LPS) 
on the extracellular side. The outer membrane protein components are 
limited in their diffusion in comparison with the inner membrane (Spector et 
al. 2010). Although the periplasm acts as a buffering space between the two 
membranes, it is an organelle with a unique composition in it’s own right. 
The periplasm is a gel-like environment with it’s own set of soluble proteins, 
as well as a unique structure of peptidoglycan within it. The peptidoglycan 
adds structural strength and rigidity to the cell, helping the cell resist 
extracellular stresses, as well as internal turgor pressure (For review see 
Coyette et al. 2008). Gram-positive bacteria are contrasted with Gram-
negatives wherein they do not have an outer membrane; rather they have a 
lipid inner membrane that is surrounded by a thick wall of peptidoglycan 
(Zuber et al. 2006). 
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1.2 The outer membrane of Gram-negative bacteria 
 
The outer membrane is an asymmetric bilayer, the extracellular leaflet of 
which is composed of lipopolysaccharide (LPS); a core structural 
component. In E.coli, there are approximately 106 LPS molecules per cell. 
LPS covers approximately 75% of the cell surface and accounts for nearly 
30% of the gross weight of the outer membrane (Meredith et al. 2006). In 
addition to providing a structural role in the outer membrane, LPS is also 
required in Gram-negative bacteria to promote pathogenicity (Raetz 1996).  
 
LPS is both a highly complex and variable molecule, grouped into 3 
domains; a lipid A group, which acts as a hydrophobic anchor to secure the 
molecule in the bacterial outer membrane; a core oligosaccharide group that  
both links the lipid anchor to the O-antigen, and also acts to aid the outer 
membrane as a barrier to antibiotics (Raetz 1996). Finally the O-antigen 
which stretches into the extracellular medium is a polymer of saccharide 
groups that is variable, depending on the strain of bacteria. It should be 
noted the K-12 E.coli, the standard laboratory strain, does not synthesise or 
present on the surface O-antigen, nor do many of the non-pathogenic E.coli 
strains. Strains expressing O-antigen are categorised as “smooth”, whilst 
those without are classed as “rough” (Raetz 1996; Meredith et al. 2006). LPS 
can coordinate divalent metal ions (such as Mg2+) to counter the natural 
repulsion between LPS molecules due to the negative charge held by the 
molecule, which in turn adds rigidity to the outer membrane (Snyder et al. 
1999). 
 
The outer membrane serves to protect the cell from the harsh external 
environment, however, in doing so prevents the cell from accessing essential 
macromolecules (Ruiz et al. 2006). Thus the cell has a variety of porins and 
specialised protein transporters to allow transfer of these essential nutrients 
into the cell (Ruiz et al. 2006). Two classes of transmembrane transporters 
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and pores are found in Gram-negative bacteria. The first class are active 
protein transporters such as BtuB (a 22-stranded β-barrel protein which is 
coupled to the TonB transport system) which transports vitamin B12. The 
second class are outer membrane protein pores (termed Porins) that allow 
passive diffusion across the membrane (Spector et al. 2010). An example of 
porins is OmpF (a trimeric 16-stranded β-barrel protein) which allows 
passive diffusion of small polar molecules up to 700 Da, such as water and 
glucose) (Cowan et al. 1995). The BtuB transporter is relatively uncommon 
on the outer membrane, in the region of 300 BtuB molecules per cell. 
Conversely, the more generalised OmpF porin has over 1000 times more 
copies are present in the outer membrane, in the order of 105 copies per cell 
(Cowan et al. 1995; Spector et al. 2010).  
 
1.3 The periplasm of Gram-negative bacteria 
 
The periplasm is a semi-fluidic space between inner and outer membrane, 
which also includes a layer of peptidoglycan anchored to the outer 
membrane through Braun’s lipoprotein (Lpp) (Vollmer et al. 2008a). The 
periplasm can be seen as a buffering organelle between the extracellular 
medium and the carefully managed cytoplasm. Proteins that are located in 
the periplasm are expressed and translated in the cytoplasm with an 
encoded signal sequence, which tags them for transport across the inner 
membrane and into the periplasmic space, translocated by a protein 
apparatus such as the Sec or Tat systems (Pugsley 1993, Zalucki et al. 
2011). Numerous proteins involved in monitoring stress conditions are 
located in the periplasm, as well as proteins involved in nutrient transport 
(such as the TonB system for vitamin B12 transport) (Braun et al. 1993) and 
those that act in a protecting manner, such as proteases (Vollmer et al. 
2008b).  Additionally, as the periplasm contains peptidoglycan, many of the 
proteins involved in peptidoglycan synthesis and turn-over are present in the 
periplasm. Peptidoglycan consists of covalently linked murein peptide 
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subunits. These subunits are made up of β-1,4 N-acetylglucosamine 
(GlcNAc) and N-acetylmuramic acid (MurNAc) with alanine pentapeptide 
attached to the muramic acid (for review see Vollmer et al. 2008b). It is 
estimated that the periplasm spans between 100 and 150 Å, depending on 
the environmental conditions that the bacterial cell experiences (Collins et al. 
2007).  
 
Peptidoglycan precursors are synthesised in the cytoplasm from 
disaccharide peptide monomer subunits by the MurA-B-C-D-E-F protein 
pathway, to yield UDP-N-Acetylmuramic acid (UDP-MurNAc) attached to 
pentapeptide (Fiuza et al. 2008). This subunit is then transferred to the MraY 
inner membrane translocase which adds the lipid I component. This is then 
passed onto another inner membrane protein, MurG which adds UDP-N-
Acetylglucosamine onto the lipid I PG intermediate, creating lipid II. This 
intermediate is then flipped into the periplasm by the inner membrane FtsW, 
whereupon a glycotransferase polymerises a nascent peptidoglycan chain 
onto the lipid II. Following this, a series of transpeptidases trim and crosslink 
the peptidoglycan molecule to be part of the PG layer network (Fiuza et al. 
2008; Typas et al. 2012). 
 
1.4 Inner membrane 
 
The inner membrane is a phospholipid bilayer that surrounds the cytoplasm, 
and divides it from the periplasm. It is typically composed of 70-80% 
phosphatidylethanolamine, 15-20% phosphatidylglycerol and approximately 
5% diphosphatidylglycerol (Raetz 1978). By surrounding the cytoplasm, the 
inner membrane helps to maintain the delicate set of conditions in the 
cytoplasm required for cell viability. Unlike limited diffusion of the outer 
membrane, wherein outer membrane proteins are can diffuse only within a 
limited region, proteins within the inner membrane appear to be freely 
diffusing (Spector et al. 2010). It is estimated that up to 20% of all translated 
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proteins in E.coli are inner membrane proteins, with a diverse selection of 
structures and functions, although the majority of proteins seem to have 
alpha-helical structure (Luirink et al. 2005). Proteins of the inner membrane 
consist of 2 major groups; lipoproteins, which are proteins modified with a 
lipid on their N-terminus and inserted into the outer leaflet of the inner 
membrane through a signal sequence (Daley et al. 2005) and inner 
membrane proteins, which are proteins inserted and anchored to the inner 
membrane via transmembrane helices (Narita et al. 2004). Movement of 
macromolecules across the inner membrane from the periplasm to the 
cytoplasm (and vice versa) is dependant on active ATP driven transport 
(Pugsley 1993). Generation of ATP at the inner membrane for use in ATP-
dependant transport is by an inner membrane ATP-synthase. The ATP-
synthase is in turn dependent on the proton motive force, a proton gradient 
across the inner membrane (Capaldi et al. 2002). 
 
1.5 The E.coli Tol-Pal complex 
 
The Tol-Pal complex is a family of interacting proteins located in both the 
inner and outer membranes of most Gram-negative bacteria, as well as 
spanning the periplasmic space. Tol proteins are encoded on the same 
operon, in the following order: YbgC-TolQ-TolR-TolA-TolB-Pal-YbgF (figure 
1.1). The tol operon is located at 17 minutes on the +strand of the E.coli 
chromosome (Webster 1991).  Tol can be further divided into 2 
subcomplexes, Tol’s Q, R and A comprising of one group, TolB and Pal the 
other. Although encoded on the same operon, tolb-pal-ybgf also has an 
internal promoter. The tol-pal operon promoters are regulated is several 
ways, through either consituitive expression, iron-regulation (Muller et al 
1997), or by RcsC, a protein of RcsBC, a regulatory system involved in the 
regulation of the cps (capsular polysaccharide) genes. The cps genes 
encode biosynthesis machinery of cholanic acid, the major component of the 
capsule, which is induced in response to cell envelope stresses (Clavel et al. 
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1996). The stoichiometry of the Tol-Pal complex is poorly defined, although it 
is known that each gene is expressed at different levels. Pal is one of the 
most abundant outer membrane associated proteins, with estimates of 8000-
40000 copies depending on cell morphology (Sturgis et al. 2001). TolA and 
TolR abundance have been measured as about 600 (Levengood et al. 1991) 
and 2500 (Müller et al. 1993) copies per cell, respectively.  
 
tolb-pal-ybgf are mainly expressed independently of the other genes on the 
tol-pal operon through use of the internal promoter. The upsteam (P1) 
promotor is constituitive, whereas the internal promoter (PB) is iron 
regulated. It is estimated that 70% of tolb-pal-ybgf expression comes from 
the internal promoter (Muller et al. 1997). In addition, the expression of the 
other tol-pal genes (ybgc-tolq-tolr-tola) is tightly regulated; for example tolr is 
only expressed following the successful translation of tolq, allowing the 
production of these proteins to be co-ordinated, which is relevant as they 
form a complex together (Muller et al. 1997).  
 
 
Figure 1.1 The E.coli Tol operon 
 
1.6 E.coli TolA (eTolA) 
 
TolA is an inner membrane protein arranged in 3 domains, anchored by a 
single transmembrane domain (domain 1). The N-terminal domain 1 is very 
short and consists of a short cytoplasmic stretch of 13 residues, followed by 
a 21 residue transmembrane helix (Levengood et al. 1991). Domains 2 and 
3 are periplasmic, separated by a glycine rich region. The first domain after 
the membrane anchor has been predicted to be a triple stranded coiled-coil, 
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based on analytic ultracentrifugation, circular dichoism (Derouiche et al. 
1999) and solution X-ray scattering data (Witty et al. 2002). This allows the 
protein to span the periplasm and interact with outer membrane 
components. The second periplasmic domain is globular, located at the C-
terminus (Figure 1.2), and is essential for TolA function (Click et al. 1997). 
The C-terminal domain is also important in eTolA’s native interaction with 
eTolB, as well as being parasitized by both colicins and bacteriophages to 
facilitate their entry into the cell (described later) (Bonsor et al. 2008). 
 
 
Figure 1.2 Cartoon representation of E.coli TolA domain 3 structure as 
obtained from X-ray crystallography and nuclear magnetic resonance 
spectroscopy experiments. (A) E.coli TolA3 (residues 302-421) crystal 
structure, PBD ID: 3QDP (Li et al. 2012). (B) E.coli TolA3 (325-421) solution 
NMR structure, PDB ID: 1S62 (Deprez et al. 2005). 
 
1.7 E.coli TolQ and TolR 
 
TolR is a 142 residue protein that like TolA is anchored to the inner 
membrane via a single TMD, but unlike TolA only has a single periplasmic c-
terminal domain (Kampfenkel et al. 1993). E.coli TolR has been reported to 
have homology with both the inner membrane flagella motor protein MotB 
and shares not only homology with the TonB system component ExbD, but 
ExbD is also capable of limited complementation of TolR when tolr gene has 
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been deleted (Braun et al. 1993). TolR assembles with TolQ and TolA to 
form an inner membrane complex that may act as a molecular motor, or 
some form of inner membrane pore, and as such may be energised by the 
proton motive force (Cascales et al. 2001; Lloubes et al. 2001). TolQ is a 
membrane protein of 230 residues. It that spans the inner membrane three 
times, and has a large N-terminal region residing in the periplasm, and a 
large 90 residue cytoplasmic domain. eTolQ has been reported to have 
homology with both the inner membrane flagella motor protein MotA and the 
TonB system component ExbB (Braun et al. 1993). Work by Zhang et al. 
suggests that TolR may rotate within the membrane, and that TolQ may act 
as either a pore or stator, much like the association of the flagellal motor 
proteins MotA and MotB (Zhang et al. 2009). The stoichiometry of the E.coli 
TolR-TolQ-TolA complex is poorly defined, but is thought to be in the region 
of 1 TolA to 2 TolR’s to 4-6 TolQ’s (Guihard et al. 1994; Cascales et al. 
2001).  
 
1.8 E.coli TolB 
 
E.coli TolB is a 409 residue periplasmic protein that associates with the outer 
membrane via Pal. TolB is a 44 kDa protein consisting of 2 domains (Bonsor 
et al. 2008). When expressed by the cell, E.coli TolB has an additional 22 
residues on the extreme N-terminus that direct it for export into the 
periplasm. These 22 extra residues are then cleaved by signal peptidase, 
following export to periplasm in a SecYEG dependent manner (Zalucki et al. 
2011). The larger of the 2 domains has a beta-propeller motif consisting of 6 
blades. It is within this beta-propeller domain that E.coli Pal interacts with 
TolB (Cascales et al. 2007). Additionally, it has a smaller N-terminal domain, 
the key feature of which is the intrinsically disordered N-terminus (figure 1.3). 
This disordered N-terminus has been found to a site of interaction between 
E.coli TolB and TolA (Bonsor et al. 2009), something that will be further 
discussed in subsequent chapters.  
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Figure 1.3 Cartoon representation of structure of E.coli TolB bound to 
E.coli Pal. E.coli TolB (cyan, residues 22-430) structure as determined by 
protein crystallography. N-terminal strand involved in the interaction between 
TolA and TolB (red, residues 22-34) is in ordered (bound back) conformation 
when TolB is bound to Pal (orange, residues 65-173). (PDB ID: 2W8B) 
(Bonsor et al. 2009). 
 
1.9 E.coli Pal (Peptidoglycan-associated lipoprotein) 
 
Pal is a 13kDa outer membrane anchored lipoprotein that is believed to be 
important for the Tol system’s native function (Cascales et al. 2007). As it’s 
name suggests, Pal associates with the peptidoglycan layer in the periplasm 
of E.coli cells, and as it is anchored to the outer membrane of the cell with a 
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lipoyl tether which is connected to the protein by a 40 residue disordered 
linker, and thus may act to anchor the PG layer to the outer membrane 
(Cascales et al. 2004). Pal’s fold is that of an OmpA-like domain, which 
means that Pal can interact with the peptidoglycan in a non-covalent fashion 
(figure 1.4). Pal has been reported to interact with both TolA and TolB, as 
well as peptidoglycan (Cascales et al. 2007), although the interaction 
between TolA and Pal remains controversial (Bonsor et al. 2009). In work by 
Bonsor et al. it has been suggested that E.coli Pal may act as an off switch 
for the E.coli TolA-TolB interaction, as when E.coli TolB is bound to Pal it is 
unable to interact with TolA (Bonsor et al. 2009). 
 
Figure 1.4 Cartoon representation of structure of E.coli Pal and 
Haemophilus influenza Pal bound to peptidoglycan precursor. E.coli Pal 
structure (orange), as obtained by protein crystallography, residues 65-173. 
PDB ID: 2W8B (Bonsor et al. 2009). Haemophilus influenza Pal (red), 
residues 20-153 bound to UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-
meso-2,6-diaminopimeloyl-D-alanyl-D-alanine (shown as sticks). PBD ID: 
2AIZ (Parsons et al. 2006). 
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1.10 E.coli YbgF 
 
YbgF is a periplasmic protein of the Tol family with a tetratrico peptide repeat 
(TPR)-like structural motif of unknown function (Krachler et al. 2010). The 
TPR structural motif has been found to mediate protein–protein interactions 
and the assembly of multiprotein complexes. The motif consists of between 
3 and 16 tandem repeats of 34 amino acids residues, the consensus 
sequence of which is defined by a pattern of small and large amino acids, 
although there is little specific conservation of residues. These repeats can 
be widely dispersed throughout the protein. Proteins with TPR motifs have 
been found throughout Prokaryotes and Eukaryotes, and are involved in a 
wide range of biological processes, including cell cycle regulation, 
transcriptional regulation and protein transport (For reviews see Andrea et al. 
2003, Schapire et al. 2006). In isolation in the periplasm, YbgF forms a 
homotrimeric complex (figure 1.5), and upon binding TolA, this trimer 
dissociates, and single a YbgF subunit forms a heterodimeric complex with 
TolA. YbgF has been shown to interact with the domain 2 of TolA both in 
vivo and in vitro, however, the function of this interaction is not known.  
(Krachler et al. 2010).  
 
Figure 1.5 E.coli YbgF is a homotrimer. Cartoon representation of three 
E.coli YbgF subunits (residues 35-109) in trimeric state. PDB ID: 2XDJ 
(Krachler et al. 2010). 
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1.11 E.coli YbgC 
 
YbgC is a cytoplasmically located thioesterase that is believed to be involved 
in phospholipid metabolism. It has been reported to have acyl-CoA 
thioesterase activity on malonyl-CoA (demonstrated in vitro), catalysing the 
hydrolysis of the thioester bond. It has also been reported to interact with a 
number of other proteins involved in phospholipid metabolism at the inner 
membrane, however, no interaction with other Tol family proteins has been 
reported (Gully et al. 2006, Krachler 2010).  
 
1.12 The E.coli Tol-Pal complex 
 
Tol-Pal is organised to span across the inner membrane, through periplasm, 
to the outer membrane (figure 1.6). Residing in the inner membrane, TolQ, 
TolR and TolA form the inner membrane complex. TolB and YbgF reside 
within the periplasm and TolB is able to bind the 3rd (C-terminal) domain of 
TolA. YbgF is reported to bind the 2nd (long triple helical) domain of TolA 
(Krachler et al. 2010). Although disputed (Bonsor et al. 2009), TolA’s 3rd 
domain is reported to interact with Pal (Cascales et al. 2000), which although 
periplasmic, is also anchored in the inner leaflet of the outer membrane. Pal 
is also reported to bind TolB (Bonsor et al. 2009). Finally, the YbgC 
component of the Tol operon appears to be located in the cytoplasm (Gully 
et al. 2006), and thus may suggest a function that allows Tol to communicate 
from the cytoplasm via YbgC, through the inner membrane with TolQRA, 
across the periplasm to the outer membrane via TolA, TolB and Pal, 
however, to date there is no evidence to support this. No function for the Tol-
Pal complex has been confirmed.  
 
Work by Goemaere et al. has indicated that the transmembrane domains of 
TolQ and TolR may form a network of ionisable and hydophillic groups that 
promote the transit of protons through a pore channel contained within the 
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2nd and 3rd TMD’s of TolQ (Goemaere et al. 2007). It has also been 
suggested that TolQ/R may regulate TolA’s interaction with other proteins. 
While the role of pmf in Tol function is unresolved it is known to influence the 
interactions of TolA with TolB and Pal (Goemaere et al. 2007). There is 
some debate in the literature regarding both the localisation and organisation 
of Tol, as well as the interactions between the respective protein 
components. Work by Henry et al. (Henry et al 2004) suggest that the N-
terminal domain of TolA is localised within the peptidoglycan layer, whereas 
Lazzaroni et al. (Lazzaroni et al. 2002) contend that both TolB and Pal is 
located with the PG layer. Due to the length of TolA domains and the report 
that TolA and Pal interact in vivo it is likely that TolA can span the periplasm, 
potentially interacting simultaneously at both the inner and outer membranes 
(Cascales et al. 2000).  
 
Although the specific function of the Tol complex or the individual Tol 
proteins is not known, speculated Tol functions can be categorised into 3 
main areas. Tol has been shown to be involved in the maintenance and 
stabilisation of the outer membrane of Gram negative bacteria and is 
involved in the import of both colicins and bacteriophages from the 
extracellular environment into the bacterial cell (for review see Cascales et 
al. 2007). Tol and related homologues can also be broadly categorised by 
their function; they are energy transducing proteins that can couple 
electrochemical gradients of the inner membrane to support energy 
dependant processes in the periplasm and outer membrane (Postle et al. 
2007).  
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Figure 1.6 Schematic diagram of organisation of the E.coli Tol complex  
(not to scale). Pal is associated with peptidoglycan and forms a complex 
with TolB. YbgF is a homotrimer and resides in the periplasm. TolQ, TolR 
and TolA form a complex within the inner membrane and YbgC is located in 
the cytoplasm. 
 
A tol phenotype describes the phenotype that arises when any of the tol 
genes (with the exception of ybgf or ybgc) are deleted. Cells display a similar 
phenotype of membrane instability. Specifically, cells are hypersensitive to 
drugs normally excluded by the outer membrane; hypersensitive to 
detergents such as SDS; they release of outer membrane vesicles (OMV’s) 
in excess of normal release activity and release of proteins normally found 
within the periplasm, all of which indicates a “leaky” outer membrane 
(Deprez et al. 2002). In addition, tol minus E.coli cells have problems with 
cell division, specifically they cannot separate into mother and daughter 
cells, and thus form long chains of cells (Bernadac et al. 1998) (Cascales et 
al. 2002) (Gerding et al. 2007). 
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Released outer membrane vesicles have been reported to contain 
lipopolysaccharide, phospholipids from the outer membrane and periplasmic 
proteins. In addition, Henry et al. found that upon deletion of Tol complex, 
release of outer membrane vesicles was vastly increased, leading to the 
possibility for development of a novel technique for harvesting bacterially 
expressed, but non-secreted proteins of interest (Henry et al. 2004).  
 
It has been suggested by some that the Tol system has a role in maintaining 
the structure of the bacterial cell membranes through an architectural 
function; forming a bridge network from the inner membrane, across the 
periplasm and onto the outer membrane (Henry et al. 2004; Cascales et al. 
2007). The outer membrane maintenance function of Tol-Pal requires the 
proton motive force (pmf). (Lloubes et al. 2001; Cascales et al. 2007; 
Goemaere et al. 2007). Other potential functions have been inferred from a 
variety of evidence, including a role in cell division. GFP-Tol protein fusions 
locate to the cell division site, and as previously stated, tol mutant cells have 
cell division problems, such as the formation of long “chains” of cells. As Tol 
proteins may form some kind of transenvelope bridge from outer to inner 
membrane, it has been proposed that Tol proteins may act to pull the outer 
and inner membranes together during cell division, as part of the 
invagination process (Gerding et al. 2007) although this model relies on 
E.coli TolA and Pal forming a complex, something that has not been found in 
vitro (Bonsor et al. 2009). In addition, it has been proposed that Tol-Pal has 
a role in the assembly and localisation of lipopolysaccharide (Gaspar et al. 
2000) and localisation and assembly of outer membrane proteins, in 
particular porins (Cascales et al. 2007).  
 
In particular, lipopolysaccharide (LPS), a core component of the outer 
membrane, has been reported to be at lower levels in the outer leaflet of the 
outer membrane in tol-pal mutant strains of E.coli (Gaspar et al. 2000; 
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Lloubes et al. 2001; Vines et al. 2005; Gerding et al. 2007). It has also been 
reported that in tolA mutants, LPS biosynthesis is not reduced, rather a 
reduction was seen in the levels of LPS in the outer leaflet of the outer 
membrane, likely as a result of the LPS post-synthesis processing and 
transportation (Gaspar et al. 2000). 
 
1.13 The E.coli Ton system 
 
Due to the rarity of the essential molecules and elements such as vitamin B12 
and iron in the extracellular medium, bacteria have evolved a high affinity 
transporter system to transfer them into the cell.  Vitamin B12 is translocated 
across the outer membrane by BtuB, and receptors such as FhuA and FecA 
transport iron complexes. The outer membrane transporters, such as BtuB, 
consist of two domains; a 22-stranded beta-barrel, and a globular “plug” 
domain which is located on the cytoplasmic side of the protein and prevents 
loss of periplasmic contents (Andrews et al. 2003). In order for ligands to be 
internalised, energy is required, however there is no ATP in the periplasm. 
Thus, by use of proton motive force by the Ton system, the cell is able to 
transduce energy to the outer membrane to facilitate transport (Karlsson et 
al. 1993). The Ton system consists of three proteins; TonB, ExbB and ExbD. 
TonB has a single transmembrane domain, which forms an inner membrane 
complex with ExbB and ExbD, and has a long periplasmic domain (Karlsson 
et al. 1993) and a globular C-terminal domain, of which there are numerous 
solved structures (Weiner 2005). ExbB has 3 membrane spanning domains, 
and has both a large cytoplasmic loop, and a small periplasmic domain. 
ExbB is related to TolQ in that it shares 62% sequence homology and 
considerable structural similarity (Braun et al. 1993). ExbD has a single 
transmembrane domain, and a C-terminal periplasmic domain and shares 
66% homology with TolR (Braun et al. 1993). The structure of the C-terminal 
domain as been solved by NMR (Garcia-Herrero et al. 2007).  
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The C-terminal domain of TonB stretches across the periplasm, and comes 
into contact a conserved TonB box epitope on the N-terminal “plug” domain 
of the receptor (Schauer et al. 2008). How exactly the energy of the pmf is 
transduced through TonB to import of Vitamin B12 or iron sideophores is not 
known, although it has been suggested that as ExbB and ExbD of Ton are 
related to MotA and MotB of the flagellal rotor motor, that some form of 
rotation in TonB occurs, pushing the plug out of the way and allowing import 
(Chang et al. 2001).  
 
1.14 E.coli Tol complex homologues  
 
The Tol-Pal and Ton protein families share some sequence identity and Tol 
QRA are structurally similar to TonB/ExbB/ExbD, and it is believed that TolA 
and TonB may share a common evolutionary ancestor (Witty et al. 2002). 
Despite this, mutations in tonB/exbD/exbB do not result in outer membrane 
instability, indicating a different specific function. Although TolA and TonB 
only share approximately 30% sequence identity (despite similar folds) (Witty 
et al. 2002), ExbB and ExbD share considerable sequence homology and 
have very similar transmembrane domains as TolQ and TolR. Both ExbB 
and ExbD have been shown to be capable of partially cross-complementing 
TolQ and TolR (Braun et al. 1993). It should be noted that despite their 
topological similarities TonB and TolA have not been found to be capable of 
cross complimenting one another (Braun et al. 1993). TolQ and TolR are 
also homologous with flagella motility proteins MotA and MotB. MotA and 
MotB are part of the flagella motor complex, and drive rotation of the flagella 
in a proton motive force dependant manner. TolQ and TolR have been 
shown to be influenced by pmf, indicating a potentially similar function to the 
MotA/B (Cascales et al. 2001). Both the Tol and Ton protein complexes can 
be subverted by different groups of bacteriophages and colicins to facilitate 
their entry into the bacterial cell (Bouveret et al. 2002; Lazzaroni et al. 2002; 
Cascales et al. 2007; Goemaere et al. 2007; Postle et al. 2007).  
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In addition to similarities with the Ton and Mot systems, the use by Tol of 
order-disorder signalling is not unique. It is estimated that up to 35% of 
prokaryotic proteins contain some significant degree of disorder (Tompa 
2012). In addition to the intrinsically disordered N-terminus of colicin E9, 
used for binding and translocation of the colicin into the cell (Housden et al 
2005, Bonsor et al. 2009), systems such as the DegS protease undergo 
order-disorder transition to go from an inactive to active state (Wilken et al. 
2004). It has also been documented that the binding of a protein intrinsically 
disordered domains of another can occur at binding sites distal of one 
another. In a recent study it was shown that in the regulation of the bacterial 
phd/doc toxin-antitoxin operon involves the toxin protein Doc as co- or 
derepressor for PhD. A monomer of Doc binding Phd dimers in two 
unrelated and distal binding sites causes the intrinsically disordered C-
terminal domain of Phd to structure its N-terminal DNA-binding domain 
illustrating allosteric coupling between disordered domains (Garcia-Pino et 
al. 2010). 
 
1.15 Tol proteins of other Gram-negative bacteria 
 
As previously stated, the Tol family of proteins are highly conserved 
throughout most Gram-negative bacteria, and although most work to date 
published on the Tol proteins have been also entirely focused on the E.coli 
Tol family. Tol proteins have been confirmed in 31 Gram-negative genera, 
with the proteins in this genera ranging from 10-100% sequence identity with 
E.coli (Deatherage et al. 2009). 
 
The Tol operon of Pseudomonas aeruginosa is arranged in an identical 
order to that of E.coli. However, as little work has characterised 
Pseudomonas aeruginosa Tol proteins, some annotation is lacking of 
specific genes. Like E.coli Tol which is arranged in the order of YbgC-TolQ-
TolR-TolA-TolB-Pal-YbgF, Psuedomonas aeruginosa Tol operon is arranged 
Chapter 1 
   
36 
as pa0968/orf1-tolq-tolr-tola-tolb-oprl-pa0974/orf2 (Dennis et al. 1996). 
PA0968 is of unknown function, however has homology with E.coli YbgC. 
OprL is a homologue of E.coli Pal (Lim et al. 1997), and PA0974 is also of 
unknown function, however is predicted to be a TPR repeat protein, and has 
homology with E.coli YbgF (Winsor et al. 2011). 
 
The only structure available for any Pseudomonas aeruginosa Tol protein is 
a crystal structure published by Witty et al. in 2002 of Pseudomonas 
aeruginosa TolA consisting of domain 3 (C-terminal globular domain) with a 
short region of domain 2 (helical). When compared with E.coli TolA, both 
proteins share a near identical fold, although they only share approximately 
20% sequence identity (Witty et al. 2002). No further information is known on 
either the interactions of Pseudomonas aeruginosa TolA, or it’s function. 
Little is known regarding Pseudomonas aeruginosa TolB. Based on 
homology with E.coli TolB, psTolB is likely to be organised into 2 domains, 
including a C-terminal beta-propeller protein. psTolB shares approximately 
45% sequence identity with eTolB. No further information is available for 
either the interactions of psTolB, it’s function, or structure (Winsor et al 
2011). 
 
Little is known regarding other Pseudomonas aeruginosa Tol proteins 
including Pal/OprL, TolQ, TolR, YbgF/PA0974 or YbgC/PA0968 as no 
structural or function information on these proteins has been reported.  
 
1.16 Bacteriocins and colicins 
 
Colicins are protein based antimicrobial agents that are released by E.coli 
under stress conditions in order to kill competing organisms (For review see 
Cascales et al. 2007). Although colicin only refers to proteins released from 
E.coli, many other gram negative species are capable of releasing cytotoxic 
proteins or peptides, classified under the umbrella term “bacteriocin”. 
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Colicins confer a competitive advantage to the producing culture from a 
plasmid pCol (Hardy et al. 1973). E.coli cells that contain a pCol plasmid are 
termed colicinogenic, and these plasmids are divided into 2 groups; type I 
and type II. Type I are small 6-10 kb plasmids, of which there are 
approximately 20 copies per cell, and mainly encode group A colicins. Type 
II are much larger plasmids, of approximately 40kb, and are usually present 
only as a single copy in bacteria. Type II plasmids mainly encode group B 
colicins (Cascales et al. 2007). Colicins are composed of 3 domains (figure 
1.7); N-terminal translocation domain (T-domain), Receptor binding domain 
(R-domain) and C-terminal cytotoxic domain (may be either nuclease or pore 
forming domain which causes cell death). An additional protein, co-
translated by the E.coli cell that produces the colicin, is called the Immunity 
protein, which binds with very high affinity to the cytotoxic domain to prevent 
suicide in the producing cell (Kleanthous & Walker 2001). Colicins can utilise 
a variety of outer membrane receptors to allow their entry into the target cell, 
including BtuB. OmpF, OmpA and Cir (Braun et al. 2002), and facilitate their 
entry across the periplasm from outer to inner membrane through either the 
Tol (for group A colicins) or Ton (for group B colicins) protein families. As 
mentioned above, Tol proteins are so named due to the Δtol phenotype, 
whereby, in addition to other phenotypes (described below), cells were 
observed to be “tolerant to colicin” (Cascales et al. 2007). Although colicins 
are specific to their outer membrane receptors (for example, colicin E3 
utilises BtuB for initial contact with cell through R-domain, and OmpF to 
translocate across the membrane), it is possible for these domains to be 
swapped between colicins to make them dependent on different receptors. 
Colicin Ia utilises Cir (Colicin I Receptor) as both it’s receptor and 
translocator. When the R-domain of colicin Ia is replaced with that of colicin 
E3 R-domain, the subsequent hybrid is dependant on both BtuB and Cir 
(Jakes et al. 2010). 
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Colicins kill off competing cells through several modes of action; some 
colicins are nucleases, whereby upon entry into the cytoplasm they destroy 
the target cells nucleic acids, both DNA and RNA (Cascales et al. 2007). 
Other colicins, including colicin A, colicin Ia, colicin E1, colicin N and colicin 
B form pores in the target cell’s inner membranes, depolarising the inner 
membrane and destroying ionic gradients, such as the proton motive force 
that are vital for cell survival (Tilley et al. 2006). Colicins are grouped 
according to their method of entry into the cell. All group A colicins subvert 
the Tol-Pal system to facilitate entry. The second class, termed Group B 
colicins act in the same cytotoxic manner as group A colicins, although they 
parasitise the Ton-Exb family of proteins to facilitate translocation (Cascales 
et al. 2007). 
 
In addition to a differing import system, group A and B colicins utilise 
different methods of export from the host cell. Group A colicins are released 
by autolysis through a co-translated lysis protein, causing death of the host 
cell. Group B colicins do not produce lysis proteins and thus are not released 
in this way (Toba et al. 1986). Lysis proteins are small lipoproteins of 27 to 
35 amino acids (Wu et al. 1996), and although each colicin has it’s own 
respective lysis protein, they are highly conserved between each colicin 
subtype. The lysis protein causes lysis through modifications of the structure 
of the cell envelope; activation of OmpLA (outer membrane phospholipase 
A) and ultimately death of the producing cell. This may well be an altruistic 
event, by which the host cell dies for the good of the colony. The cells 
become lysed through activation of OmpLA which promotes the formation of 
lysophospholipids (Pugsley & Schwartz. 1984). Lysophospholipids are 
detergents and permeabilise the outer membrane and, subsequently, the 
inner membrane of the cells. However, it should be noted that both colicin A 
release and lysis occur in the absence of an active OmpLA (Cascales et al. 
2007).  
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Figure 1.7 Three dimensional representation of colicin E3 secondary 
structure and domain organisation. Red helices represent Receptor 
binding domain, green presents cytotoxic RNase domain, cyan represents 
translocation domain (T-domain). N-terminus of T-domain is disordered, and 
divided into 3 distinct regions, 2 OmpF binding sites and a TolB binding box. 
PDB ID: 1JCH (Soelaiman et al. 2001). Figure draw with pymol 0.99a 
(Delano Scientific). 
 
1.17 Cells with impaired Tol-Pal system are tolerant to colicin’s 
 
The Tol proteins are so named after in vivo observations that when tol genes 
(with the exception of pal) were deleted, bacterial cells became tolerant to 
colicin. Both colicins and bacteriophages subvert and parasitise the Tol 
system and outer membrane porins to facilitate their entry into the cell. Other 
proteins formerly had the name Tol, and have since been renamed, but all 
share a common link (like the Tol complex itself) that they confer tolerance to 
colicin when knocked out (Cascales et al. 2007). However, Δtol cells, if 
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placed in environmentally stressful conditions, such as osmotic shock, where 
their outer membrane instability is exacerbated, upon being challenged with 
colicin, were still killed. This indicated that the Tol proteins must have a role 
solely in allowing the translocation of colicin’s across the outer membrane, 
and that once in the periplasm do not have a role in translocating the colicin 
through the periplasm and across the inner membrane (Tilby et al. 1978). 
 
1.18 Pyocins 
 
Pyocins are a type of bacteriocin produced by over 90% of Pseudomonas 
strains of bacteria during environmental stress/competition conditions. Type 
R and F pyocins are similar in structure and function to bacteriophages, 
whereas type S are evolutionarily closer to colicins. It has been reported that 
pyocin S1, S2 and AP41 may share a common ancestor with colicin E2, 
including a C-terminal cytotoxic DNase domain. Like colicins pyocins have 
pore forming, DNase or RNase killing activity. It has been reported that 
pyocin AP41 is dependent on the Pseudomonas aeruginosa Tol protein 
family for translocation, and deletion of Tol proteins yields the “tolerant to 
colicin” phenotype (Michel-Briand et al. 2002).  
 
1.19 Colicin E9 (ColE9) 
 
Colicin E9 is a member of the group A family of colicin’s. When produced by 
the cell, ColE9 co-translated with its immunity protein called Im9. Im9 binds 
the cytotoxic domain of the colicin to prevent suicide in the cell that produced 
the colicin. Im9 dissociates from the colicin upon binding to target cell. ColE9 
enters the cell (figure 1.8) by firstly binding on the outer membrane to BtuB 
with its R-domain. The translocation domain of ColE9 then recruits an OmpF 
trimer by threading it’s N-terminal intrinsically unstructured N-terminus 
through one of the 3 OmpF pores, binding OmpF via one of 2 OmpF binding 
sites (OBS1, OBS2) (Housden et al. 2005). This disordered N-terminus then 
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recruits and binds TolB via a TolB binding epitope (TBE), which in turn 
promotes the interaction of TolA and TolB by driving the N-terminus of TolB 
into a disordered state, making the epitope available to bind TolA (Bonsor et 
al. 2009). It is this process of binding BtuB and OmpF on the outer 
membrane, and recruiting both TolB and TolA in the periplasm that 
somehow drives the uptake of the colicin into the periplasm (Housden et al. 
2005). There are differences in the interactions of colicin E9, colicin N and 
colicin A with the Tol system, despite all 3 colicin’s being dependant on Tol. 
Colicin N interacts solely with the 3rd domain of TolA, and does not interact 
with TolB at all. In addition, colicin N appears to bind TolA domain 3 in a 
similar binding interface as the bacteriophage g3p. Colicin A conversely 
interacts with both TolA domain 3 and TolB separately and does not require 
TolB to interact with TolA, however it requires both proteins in order to 
translocate across the outer membrane (Hecht et al. 2010). It should be 
noted that some colicins appear to mimic the interaction of Pal with TolB in 
order to recruit TolB to an outer membrane pore and thus facilitate the 
formation of a translocon, and ultimately allow import of the colicin cytotoxic 
domain (Bonsor et al. 2007; Cascales et al. 2007; Bonsor et al. 2009). 
 
Although the specific details of how the colicin translocates across the outer 
membrane is not known, some detail is known about how colicin E9 
translocates across the inner membrane. Whereas once pore forming 
colicin’s reach the inner membrane their journey is over, as they create a 
pore in the membrane to de-couple the inner membrane, nuclease colicins 
such as E9 must also translocate across the inner membrane. It is thought 
that following some form of proteolytic processing in the periplasm, the 
colicin may be translocated through the inner membrane AAA+ ATPase (part 
of inner membrane secretion system) and FtsH protease via a direct 
interaction with the inner membrane (Mosbahi et al. 2002; Kleanthous 2010). 
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Figure 1.8 Assembly of colicin E3 bound to outer membrane porins and 
TolB, prior to outer membrane translocation. There are 3 stages for 
group A colicin entry into the cell; firstly the colicin’s receptor binding domain 
(shown in red) binds a specific receptor, such as BtuB in the case of group A 
nuclease colicins. Following this the colicin’s N-terminal translocation domain 
(shown in green) translocates through the outer membrane porin, OmpF. 
Finally the C-terminal cytotoxic domain (shown in cyan), is somehow 
translocated across the porin into the periplasm. It is unknown if the N-
terminal translocation domain remains bound at the outer membrane, or 
translocates across with the C-terminal domain. Tol proteins are also 
subverted in a similar way by bacteriophages to facilitate their entry into the 
cell (Cascales et al. 2007). Figure used and modified with the permission of 
Dr Nicholas Housden, University of York. 
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1.20 Aims  
 
Although the Tol system of Gram-negative bacteria has been studied for 
several decades, a number of key questions have yet to be answered. While 
it is known that the N-terminus of E.coli TolB is involved in it’s interaction 
with the C-terminal domain of E.coli TolA, it is unclear if this is the sole site of 
interaction, as well as the location of the binding site on TolA is unknown. It 
is also unknown if the interaction between TolA and TolB is conserved 
throughout Gram-negative bacteria. Through a variety of biophysical 
techniques this work will seek to confirm the importance of the E.coli TolB N-
terminus, and determine if it is indeed the sole site of interaction with E.coli 
TolA. This work will also determine if the TolA-TolB interaction is present in 
Pseudomonas aeruginosa, and if this interaction is dependent on the TolB 
N-terminus. Finally, it is the intention of this work to determine the binding 
site of TolB on TolA, the structure of which, to date, is unknown.  
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2. Materials and methods 
 
2.1 Molecular Biology 
 
2.1.1 Media and bacterial strains 
 
E. coli cultures were either grown in M9 minimal media, lysogeny 
broth (LB) or plated on LB-agar. LB contained 10 g tryptone, 5 g yeast 
extract and 10 g NaCl per 1000 ml of medium. M9 media contained 4.8 mM 
Na2HPO4, 2.2 mM KH2PO4, 0.7 mM NaCl, 0.2 mM Na2SO4, 1.9 mM NH4Cl, 2 
mM MgCl2, 0.1 mM CaCl2 and 22 mM D-glucose. When plated, 1.5% (w/v) 
final concentration of agar was added to media.  Antibiotic selection was 
performed by use of ampicillin (amp) (100 μg/ml), carbenicillin (car) (100 
μg/ml), chloramphenicol (chl) (34 μg/ml) and/or kanamycin (kan) (50 μg/ml) 
where indicated (Melford). The bacterial strains used in this work are listed in 
table 2.1 
 
Table 2.1 Bacterial Strains 
 
DH5α  
 
(F- φ80lacZΔM15 Δ(lacZYA-
argF)U169 recA1 endA1 hsdR17(rk-, 
mk+) phoA supE44 thi-1 gyrA96 
relA1 λ-) 
 
Competent cells used for 
transformation of plasmids for 
propagation and after ligation.  
 
BL21(DE3)  
 
(F–, ompT, hsdSB (rB–, mB–), dcm, 
gal, λ(DE3)). 
 
Competent cells used for induced 
gene expression from recombinant 
plasmids under the regulation of T7 
promoter. Gene expression controlled 
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by isopropyl-β-D-
thiogalactopyranoside (IPTG). 
 
Rosetta 2 (BL21 (DE3)) 
 
F- ompT hsdSB(rB- mB-) gal dcm 
(DE3) pRARE2 (ChlR) 
Competent cells used for expression 
of genes containing rare codons (E.g. 
Pseudomonas aeruginosa proteins) 
as contained pRARE2 plasmid, which 
encodes rare tRNA’s for AGA, AGG, 
AUA, CUA, GGA, CCC, and CGG. 
Expression of recombinant plasmid 
under regulation of T7 promoter, 
controlled by IPTG. 
 
2.1.2 Vectors and plasmid isolation 
 
pET11c, pET15b and pET21d were purchased from Novagen/Merck 
(Darmstadt). pMA-T was purchased as part of synthetic gene production 
from Geneart (Regensburg). Plasmids were prepared and purified using 
QIAprep Spin Miniprep or QIAgen Plasmid Midi kits (Qiagen). The plasmids 
used and generated in this work are listed and described in appendix table 
7.1. 
 
2.1.3 Preparation of competent cells 
 
Competent cells were prepared from 35 ml E. coli cultures that had 
reached an OD600nm of ~0.3-0.6. Cells were harvested by centrifugation 
(5000g, 15mins 4 °C) washed in 20 ml of ice-cold 20 mM Tris-HCl, 50 mM 
CaCl2, pH 8.0 and left on ice for 1 hour. Cells were harvested again by 
centrifugation and resuspended in 2 ml of ice-cold 20 mM Tris-HCl, 50 mM 
CaCl2, 20% w/v glycerol pH 8.0. Aliquots of 200 μl were made and stored at 
-80 °C.  
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2.1.4 Transformation of competent cells 
 
Aliquot of prepared competent cells were thawed on ice before 
addition of 100 ng of plasmid DNA. Cells were incubated on ice for 30 
minutes, heat shocked at 42 °C for 45-90 seconds and incubated for a 
further 5 minutes on ice. Cells were then incubated at 37 °C for 1 hour after 
the addition of 800 μl of LB. Cells were plated onto LB-agar (containing 
appropriate antibiotic(s)) and incubated overnight at 37 °C. 
 
2.1.5 Genomic DNA 
 
Genomic DNA from Pseudomonas aeruginosa (PA-01 strain) was 
kindly provided by Prof. Ben Luisi, University of Cambridge. Genomic DNA 
from Xanthomonas campesteris was kindly gifted by Dr. Max Dow, 
University College Cork. Genomic DNA from E.coli (K12 strain) was kindly 
gifted by Dr. Anne-Marie Krachler, formerly University of York. 
 
2.1.6 DNA primers 
 
DNA primers were synthesised by Eurofins MWG Operon. See 
appendix table 7.1 for full list. 
 
 2.1.7 Polymerase chain reaction (PCR) 
 
Amplification of the genes and gene fragments of interest was 
performed by the polymerase chain reaction (PCR) using genomic DNA as a 
template. Primers were designed to contain restriction sites flanking the 
region of interest. PCR was performed with an Eppendorf Mastercycler 
Personal Thermal Cycler in a total volume of 50 µl. Typical PCR reaction 
mixture and cycling parameters are listed in table 2.2 and 2.3 respectively. 
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Polymerase used was either Pfu Turbo (Stratagene) or Pfu Ultra II (Aligent) 
and dNTP’s purchased from Invitrogen. 
 
Component  Volume/µl 
Autoclaved Milli-Q water 40 
10× Pfu Turbo/Ultra II Polymerase 
Reaction Buffer 
5 
dNTPs (10 mM stock) 1 
Plasmid template (50 ng/µl) 1 
Forward primer (125 ng/µl) 1 
Reverse primer (125 ng/µl) 1 
Pfu Turbo/Ultra II Polymerase (2.5 U/µl) 1 
Total volume 50 
 
Table 2.2 Typical PCR mixture 
 
 
No. of cycles. Temperature Duration 
1 95°C 2 mins 
   
 95°C 30 secs 
 
30 Primer TM - 5°C 30 secs 
 (typically 55°C)  
 72°C x* min per Kb 
1 72°C 10 mins 
 
* Extension time of 2 min/kb for Pfu Turbo, 1min/kb for Ultra II 
 
Table 2.3 Typical PCR cycling parameters 
 
2.1.8 Custom gene synthesis 
 
Recombinant genes for colicin E9-TolB fusion proteins (plasmids 
pEC7 and pEC8) and Pseudomonas aeruginosa TolB (plasmid pEC9) were 
synthetically made by Geneart AG (Invitrogen), Regensburg, Germany. 
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2.1.9 DNA Restriction digests 
 
Restriction digests of plasmids and PCR products were performed 
using enzymes and buffers purchased from New England Biosciences 
(NEB). Using appropriate buffer and BSA if required, reactions were 
performed in total volume of either 20 µL or 50 µL. Typically for a 50 µl 
digestion 1-2 µg DNA was digested with 10-20 units of each restriction 
enzyme with 0.1mg/ml BSA for 2 hours at 37 °C. Linearised vectors and 
digested PCR products were purified by Agarose gel electrophoresis 
followed by gel extraction using the QIAquick Gel Extraction Kit (Qiagen). 
 
2.1.10 DNA Ligations 
 
Ligation of double stranded DNA was performed using T4 DNA ligase 
(NEB). An excess of PCR product was mixed with linear vector and 
incubated for 1-2 hours at room temperature before transformation in 
competent DH5α cells. Typical ligation mix is listed in table 2.4.  
 
Component Volume/µL 
Linear vector DNA (100ng/µL) 3 
Insert DNA (3x excess) (100ng/µL) 9 
10x T4 ligation buffer  2 
Autoclaved MilliQ water 5.5 
T4 Ligase (50U/µL) 0.5 
Total volume 20 
 
Table 2.4 Typical DNA ligation 
 
2.1.11 Agarose Gel-electrophoresis 
 
Electrophoresis grade Agarose (Invitrogen) was dissolved in Tris-
Borate-EDTA-buffer (TBE) to make up appropriate percentage gel, typically 
2% for small PCR products (100-800bp) and 0.5% for plasmids. 5 µl of 
SYBR Safe (10000× concentrate) (Invitrogen) was added per 50 ml of gel. 
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Gels were run in TBE at a constant voltage of 80 V until sufficient resolution 
had been achieved. 
 
2.1.12 Whole plasmid mutagenesis   
 
Whole plasmid mutagenesis was used to introduce either point 
mutations or in-frame deletions into existing plasmids. PCR reactions were 
assembled as described in table 2.5. and run according to the program in 
table 2.6. Mutagenesis primers were designed to contain the mismatch in the 
centre of the sequence and to have a melting temperature greater than 60 
°C. Melting temperature was calculated using the following formula: 
 
Tm = 81.5 + (0.41 × %GC) – (675/N)  
Where %GC is the percentage of guanine and cytosine and N the number of 
bases in the primer sequence. 
10 μl of PCR product were analysed on 0.7% (w/v) agarose gel to check for 
amplification of the plasmid relative to the negative control. For plasmids that 
were successfully amplified, 1 μl of DpnI (20U/μl, NEB) was added to the 
reactions and incubated at 37 °C for 2 hours. 5 μl of DpnI treated PCR 
product was transformed into competent DH5α cells. 
 
Component  Volume/µl 
Autoclaved Milli-Q water 40 
10× Pfu Turbo/Ultra II Polymerase 
Reaction Buffer 
5 
dNTPs (10 mM stock) 1 
Plasmid template (50 ng/µl) 1 
Forward primer (125 ng/µl) 1 
Reverse primer (125 ng/µl) 1 
Pfu Turbo/Ultra II Polymerase (2.5 U/µl) 1 
Total volume 50 
Table 2.5 A typical PCR reaction mixture 
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No. of cycles. Temperature Duration 
1 95°C 30 secs 
 95°C 30 secs 
 
16 Primer TM - 5°C 30 secs 
 (typically 55°C)  
 67.5°C x* min per kb of plasmid 
1 72°C 10 mins 
   
 
* Extension time of 2 min/kb for Pfu Turbo, 1min/kb for Ultra II 
 
Table 2.6. PCR cycling parameters for whole plasmid mutagenesis.  
 
 
2.2 Sub-cloning 
 
2.2.1 Cloning of tagless Pseudomonas aeruginosa TolA domain 3 
(pEC1) 
 
The region encoding TolA domain 3 (identified by homology with 
E.coli TolA domain 3, residues 226-347) was PCR amplified from 
Pseudomonas aeruginosa genomic DNA (PA-01 strain) using appropriate 
primers (see appendix table 7.2 for primers). The PCR amplified fragment 
was then purified by gel electrophoresis/extraction, digested with BamHI and 
NdeI, and subsequently ligated into pre-digested pET11c, to make pEC1. 
 
2.2.2 Cloning of tagless Xanthomonas campesteris TolA domain 3 
(pEC3) 
 
The region encoding TolA domain 3 (based on homology with E.coli 
and Pseudomonas aeruginosa, residues 224 - 345) was PCR amplified from 
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Xanthomonas campesteris  genomic DNA (8004 strain) using appropriate 
primers (see appendix table 7.2 for primers). The PCR amplified fragment 
was then purified by gel electrophoresis/extraction, digested with BamHI and 
NdeI, and subsequently ligated into pre-digested pET11c, to make pEC3. 
 
2.2.3 Cloning of non-cleavable his-tagged Pseudomonas aeruginosa 
TolA domain 3 (pEC4) 
 
The region encoding TolA domain 3 (residues 226-347) was PCR 
amplified from Pseudomonas aeruginosa genomic DNA (PA-01 strain) using 
appropriate primers (see appendix table 7.2 for primers). The PCR amplified 
fragment was then purified by gel electrophoresis/extraction, digested with 
BamHI and NdeI, and subsequently ligated into pre-digested pET21d (to 
introduce C-terminal 6xHis tag), to make pEC4. 
 
2.2.4 Cloning of colicin E9-E.coli TolB fusion protein (TolA replacing 
TolB binding epitope, pEC7) 
 
DNA fragment of the region encoding the N-terminus of colicin E9 
(residues 1-83, with the addition of KpnI site at the 5’ end and XhoI site at 3’ 
end, encoding for OmpF binding site 1), TolA binding site from disordered N-
terminus of TolB (EVRIVIDSGVDS) in place of TolB binding site, followed by 
OmpF binding site 2 was synthesised by Geneart AG. This fragment was 
subsequently excised from Geneart delivery plasmid (pMAT-EC7) with KpnI 
and XhoI and ligated into pre-digested pCS4 (mutated through whole 
plasmid mutagenesis to introduce KpnI site). This ligation yielded pEC7, 
which encoded for full length colicin E9 (with respective Immunity protein, 
Im9), with TolA binding epitope from TolB in place of TolB binding epitope. In 
all other respects, this colicin E9 mutant was as wild type.  
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2.2.5 Cloning of colicin E9-E.coli TolB fusion protein (N-terminal TolA 
binding epitope, pEC8) 
 
DNA fragment of the region encoding the N-terminus of colicin E9 
(residues 1-83, with the addition of KpnI site at the 5’ end and XhoI site at 3’ 
end), to encode for TolA binding site from disordered N-terminus of TolB 
(EVRIVIDSGVDS) in place of OmpF binding site 1, TolB binding site with 3 
key residues mutated to abolish TolB binding (D35A, S37A, W39A), followed 
by OmpF binding site 2 was synthesised by Geneart AG. The DNA fragment 
was subsequently excised from Geneart delivery plasmid (pMAT-EC8) with 
KpnI and XhoI and ligated into pre-digested pCS4 (mutated through whole 
plasmid mutagenesis to introduce KpnI site). This ligation yielded pEC8, 
which encoded for full length colicin E9 (with respective Immunity protein, 
Im9), with TolA binding epitope from TolB in place of TolB binding epitope. In 
all other respects, this colicin E9 mutant was as wild type.  
 
2.2.6 Cloning of colicin E9-E.coli TolB fusion protein (N-terminal TolA 
binding epitope, TolB binding epitope present, pEC12) 
 
A mutant based on pEC8, where the TolB binding epitope was 
mutated back to wild type by whole plasmid mutagenesis to reintroduce TolB 
binding to this protein. In all other respects plasmid is as pEC8. 
 
2.2.7 Cloning of his-tagged Pseudomonas aeruginosa TolB (pEC14) 
 
The region corresponding to Pseudomonas aeruginosa TolB 
(residues 22 – 432, with the addition of BamHI site at the 5’ end and XhoI 
site at 3’ end) was synthesised by Geneart AG. The DNA fragment was 
subsequently excised from Geneart delivery plasmid (pMAT-psTolB) with 
BamHI and XhoI and ligated into pre-digested pET21d. This ligation 
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introduced codons for a C-terminal 6xHis tag onto the TolB gene, to make 
pEC14. 
 
2.2.8 Cloning of Pseudomonas aeruginosa Peptidoglycan associated 
lipoprotein (pEC15) 
 
The region corresponding to periplasmic soluble domain of Pal 
(residues 60-168, mature protein predicted by bioinformatic analysis, see 
appendix section 7.2 for details) was PCR amplified from Pseudomonas 
aeruginosa genomic DNA (PA-01 strain) using appropriate primers. The 
PCR amplified fragment was purified by gel electrophoresis and 
subsequently digested with NcoI and XhoI, and subsequently T4 ligated into 
pET21d to make pEC15. 
 
2.2.9 DNA sequencing 
 
Fidelity of all DNA constructs were verified by T7 forward and reverse 
primer sequencing, performed by Beckman Coulter (Takely, UK). 
 
2.3 Protein Purification 
 
2.3.1 Expression and purification of tagless E.coli TolA domain 3 
(pAK108) 
 
The plasmid pAK108 (supplied by Anne-Marie Krachler, Bonsor et al. 
2009) was transformed into BL21(DE3) pLysS competent cells for 
expression and purification of TolA (domain 3, residues 293-421). A 1:1000 
dilution of a 50 ml overnight from a single colony was used to inoculate 
(typically) 6 flasks (0.8 L per flask, giving a total of 4.8 L). Cultures were 
grown at 37 °C on a Innova 2300 platform shaker (New Brunswick Scientific) 
at 120 rpm until an OD600nm of ~ 0.6 was reached. Gene expression was 
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induced with IPTG (Melford) (Figure 2.1) at a final concentration of 1 mM. 
Cells continued to grow on the orbital shaker at 37 °C for a further 4 hours 
before harvesting (SLC-6000 rotor, 4500 rpm, 4 °C for 12 minutes). Cell 
pellets were resuspended in 40 ml (total) 50 mM Tris-HCl pH 8.0, PMSF (1 
mM), DNase-I (40 μg/ml) magnesium chloride (5 mM) and lysozyme (60 mg) 
were added. Cells were sonicated on ice using a S-4000 sonicator with ½ 
inch stud horn titanium probe (Misonix) with 60 x 3 seconds pulses at 70 W 
(a 7 second “off” spacing between pulses). The cell debris was pelleted 
(19776 rotor, 10000 rpm, 4 °C for 30 minutes) and supernatant decanted. 
The supernatant was then subjected to two ammonium sulphate ((NH4)2 
SO4) fractionations at 4°C; a 40 % saturation was achieved by the slow 
addition of (NH4)2 SO4 (22.6 g/100ml of sample) over 10 mins, whilst being 
gently stirred. This was left to equilibrate for 1 hour at 4 °C before 
centrifugation to remove precipitated proteins (19776 rotor, 10000 rpm, 4 °C 
for 30 minutes). The supernatant was decanted and a second (NH4)2 SO4 cut 
was performed (70 % saturation) by the addition of 18.7 g/100 ml of 
supernatant. This was left for a further hour at 4 °C before centrifugation (as 
before). The supernatant was removed and precipitated proteins were re-
dissolved in ~20 ml of 50 mM Tris-HCl pH 8.0 and subsequently dialysed in 
the same buffer overnight at 4 °C to remove excess ammonium sulphate. 
The protein solution was loaded onto a 10 ml pre-equilibrated (50 mM 
Tris-HCl, pH 8.0) DE52 anion exchange column (Whatman Resin). The 
unbound flow-through was collected before the elution of bound proteins with 
application of a 50 mM Tris-HCl pH 8.0, 1 M NaCl, gradient. Flow-through 
fractions were pooled and dialysed against 50 mM Tris-HCl, 250 mM NaCl, 
pH 7.5 overnight at 4 °C for size exclusion chromatography. 
TolA was further purified by gel filtration using a Hiload 26/60 Superdex 
75 column (GE Healthcare). Ten ml of protein were injected onto the pre-
equilibrated S75 column (50 mM Tris-HCl, 250 mM NaCl, pH 7.5) and eluted 
at a flow rate of 3 ml/min. Protein elution was monitored by absorbance at 
280 nm. All peaks were analysed by SDS PAGE to verify presence of 
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protein. Peak fractions were pooled and dialysed against 50 mM Sodium 
Acetate, pH 5 overnight at 4 °C. 
Following dialysis, sample was loaded onto a pre-equilibrated 5/50 
Mono S cation exchange column (GE Healthcare), and once unbound 
material had been collected in the flow-through, a NaCl gradient (1M) was 
applied over 10 column volumes. Fractions were analysed by SDS PAGE, 
peak fractions pooled, and once protein concentration had been estimated 
by absorbtion spectrophotometry, samples were divided into 1ml aliquots 
and stored at -20°C. 
 
 
Figure 2.1 IPTG induction for gene expression Under normal conditions 
(A), the Lac repressor protein is translated from the constituitively expressed 
LacI gene. This Lac repressor protein binds to the T7 promotor region of the 
target gene preventing expression of the target gene. Upon addition of IPTG 
(B), the IPTG molecule binds to the Lac repressor protein, causing it to 
dissociate from the promotor region, allowing the T7 RNA polymerase to 
bind the promotor and translate the mRNA of the target gene (Bell et al. 
2000). 
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2.3.2 Expression and purification of tagless, cytoplasmic E.coli TolB 
(pDAB18) 
 
pDAB18 was transformed into BL21(DE3) pLysS competent cells for 
expression and purification of E.coli TolB (residues 22-430, with the addition 
of single N-terminal Methionine residue, Clone supplied by Dr Daniel 
Bonsor). A 1:1000 dilution of a 50 ml overnight from a single colony was 
used to inoculate (typically) 6 flasks (0.8 L per flask, giving a total of 4.8 L). 
Cultures were grown at 37 °C on a Innova 2300 platform shaker (New 
Brunswick Scientific) at 120 rpm until an OD600nm of ~ 0.6 was reached. 
Protein expression was induced with IPTG (Melford) at a final concentration 
of 1 mM. Cells continued to grow on the orbital shaker at 37 °C for a further 
4 hours before harvesting (SLC-6000 rotor, 4500 rpm, 4 °C for 12 minutes). 
Cell pellets were resuspended in 40 ml of 50 mM Tris-HCl pH 8.0 and PMSF 
(1mM), DNase-I (40 μg/ml) magnesium chloride (5 mM) and lysozyme (60 
mg) were added. Cells were sonicated on ice using a S-4000 sonicator with 
½ inch stud horn titanium probe (Misonix) with 60x3 seconds pulses at 70 W 
(a 7 second “off” spacing between pulses). The cell debris was spun out 
(19776 rotor, 10000rpm, 4 °C for 30 minutes) and supernatant decanted. 
The supernatant was then subjected to an ammonium sulphate ((NH4)2 SO4) 
fractionation at 4°C; a 40 % saturation was achieved by the slow addition of 
(NH4)2 SO4 (22.6 g/100ml of sample) over 10 mins, whilst being gently 
stirred. This was left to equilibrate for 1 hour at 4 °C before centrifugation to 
remove precipitated proteins (19776 rotor, 10000 rpm, 4 °C for 30 minutes). 
The supernatant was removed and precipitated proteins were re-dissolved in 
~20 ml of 50 mM Tris-HCl pH 8.0 and subsequently dialysed in the same 
buffer overnight at 4 °C to remove excess ammonium sulphate. 
The protein solution was loaded onto a 10 ml pre-equilibrated (50m M 
Tris-HCl, pH 8.0) DE52 anion exchange column (Whatman Resin). The 
unbound flow-through was collected before elution of bound proteins with 
application of 50 mM Tris-HCl, 1 M NaCl, pH 8.0 gradient. Flow-through was 
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pooled and dialysed against 50 mM Tris-HCl, 250 mM NaCl, pH 7.5 
overnight at 4 °C for size exclusion chromatography. 
TolB was further purified by gel filtration using a Hiload 26/60 Superdex 
75 column (GE Healthcare). 10 ml of protein was injected onto the pre-
equilibrated S75 column (50 mM Tris-HCl, 250 mM NaCl, pH 7.5) and was 
eluted at a flow rate of 3 ml/min. Protein elution was monitored by 
absorbance at 280 nm. All peaks were analysed by SDS PAGE to verify 
presence of protein. Peak fractions were pooled, and once protein 
concentration had been estimated by absorbtion spectrophotometry, 
samples were divided into 1ml aliquots and stored at -20°C. 
 
2.3.3 Expression and purification of tagless Pseudomonas aeruginosa 
TolA domain 3 (pEC1)  
 
pEC1 was transformed into BL21 (DE3) competent cells for 
expression and purification of tagless Pseudomonas aeruginosa TolA3. A 
1:1000 dilution of a 50 ml overnight from a single colony was used to 
inoculate (typically) 6 flasks (0.8L per flask, giving a total of 4.8L). Cultures 
were grown at 37 °C on Innova 2300 platform shaker (New Brunswick 
Scientific) at 120 rpm until an OD600nm of ~ 0.6 was reached. Gene 
expression was induced with IPTG (Melford) at a final concentration of 1 
mM. Cells continued to grow on the orbital shaker at 37 °C for a further 4 
hours before harvesting (SLC-6000 rotor, 4500 rpm, 4 °C for 12 minutes). 
Cell pellets were resuspended in ~30 ml 50 mM Tris-HCl pH 8.0. PMSF 
(1mM), DNase-I (40 μg/ml) magnesium chloride (5 mM) and lysozyme (60 
mg) were added. Cells were sonicated on ice using a S-4000 sonicator with 
½ inch stud horn titanium probe (Misonix) with 60x3 seconds pulses at 70 W 
(a 7 second “off” spacing between pulses). The cell debris was spun out 
(19776 rotor, 10000 rpm, 4 °C for 30 minutes) and supernatant decanted.  
The supernatant was subsequently loaded onto a 10 ml pre-equilibrated 
(50m M Tris-HCl, pH 8.0) DE52 anion exchange column (Whatman Resin). 
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The unbound flow-through was collected before elution of bound proteins 
with application of 50 mM Tris-HCl, 1 M NaCl, pH 8.0 gradient. Flow-through 
was pooled and dialysed against 50 mM Tris-HCl pH 9, overnight at 4 °C. 
This sample was then loaded onto a pre-equilibrated MonoQ (strong anion 
exchange) column (GE Healthcare). Once unbound material had eluted, and 
280 nm absorbance had returned to baseline, a 0-150mM NaCl gradient was 
applied over 30 column volumes. Eluted fractions were analysed on 16% 
SDS-PAGE gels. Peak fractions were pooled, and dialysed against gel 
filtration buffer (50 mM Tris-HCl, 250 mM NaCl, pH 7.5) overnight at 4 °C.  
This sample was further purified by gel filtration using a Hiload 26/60 
Superdex 75 column (GE Healthcare). 10 ml of protein was injected onto the 
pre-equilibrated S75 column and was eluted at a flow rate of 3 ml/min. 
Protein elution was monitored by absorbance at 280 nm. All peaks were 
analysed by SDS PAGE. Peak fractions were pooled and dialysed against 
50 mM Tris pH 9 overnight at 4 °C for second MonoQ purification step. This 
protein sample was then loaded onto a pre-equilibrated MonoQ (strong 
anion exchange) column. Once unbound material had eluted, and 280nm 
absorbance had returned to baseline, a 0-150 mM NaCl gradient was 
applied over 30 column volumes. Eluted fractions were analysed on 16% 
SDS-PAGE gels. Fractions containing pure protein of interest were pooled 
and stored at -20 °C until further use. 
2.3.4 Expression and purification of non-cleavable his-tagged 
Pseudomonas aeruginosa TolA domain 3 (pEC4) 
  
pEC4 was transformed into BL21 (DE3) competent cells for 
expression and purification of his-tagged Pseudomonas aeruginosa TolA3. 
Growth and harvesting was as pEC1 (2.3.3) with the exception that pelleted 
cells were resuspended in 30 ml 1x binding buffer (40 mM Tris-HCl pH 7.5, 
500 mM NaCl, 5 mM imidazole) prior to sonication.  
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The cell debris was spun out (19776 rotor, 10000rpm, 4 °C for 30 
minutes) and supernatant decanted. The supernatant was subsequently 
loaded onto a 10 ml column containing HisBind resin (Novagen) charged 
with 3 column volumes (c.v.) of 50 mM NiSO4 and equilibrated with 3 c.v. of 
binding buffer. The column was washed with binding buffer at a flow rate of 
1.5 ml/min until the absorbance of the eluate returned to background levels 
(monitored by 280 nm absorbance). Bound protein was then eluted using a 
linear gradient of 5-500 mM imidazole over 10 c.v. Fractions were analyzed 
by SDS-PAGE and those containing the protein of interest were pooled and 
dialyzed against gel-filtration buffer (50 mM Tris-HCl pH 7.5, 250 mM NaCl) 
overnight at 4 °C. 
Protein was further purified by gel filtration using a Hiload 26/60 
Superdex 75 column (GE Healthcare). 10 ml of protein was injected onto the 
pre-equilibrated S75 column (50 mM Tris-HCl, 250 mM NaCl, pH 7.5) and 
was eluted at a flow rate of 3 ml/min. Protein elution was monitored by 
absorbance at 280 nm. All peaks were analysed by SDS PAGE and peak 
fractions were pooled and stored at -20 °C until further use. 
 
 
2.3.5 Expression and purification of colicin E9-E.coli TolB fusion 
protein (pEC7) 
 
pEC7 was transformed into BL21 (DE3) cells and subsequently 
expressed and purified as for pEC4, with the following modification; instead 
of eluting bound protein from HisBind resin with imidazole elution buffer, a 
step elution (100%) with 6 M Guanidinium chloride (GnHCl) was applied. 
Colicin E9 mutants are co-translated with their high affinity binding partner 
Im9, which contains a 6xHis-tag. This complex is translated together, and 
the colicin will remain bound to the immunity protein when it itself is bound to 
the Nickel-NTA resin. 6 M GnHCl is applied to unfold the colicin, so that it is 
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no longer bound to the immunity protein (which remains bound to the 
HisBind resin) and collected in eluted fractions. The eluted fractions of 
interest were extensively dialysed against gel filtration buffer (50 mM Tris-
HCl pH 7.5, 250 mM NaCl, 3x buffer changes) prior to gel filtration on pre-
equilibrated Hiload 26/60 Superdex 200 column (GE Healthcare). 
Subsequent steps are as pEC4. 
 
2.3.6 Expression and purification of colicin E9-E.coli TolB fusion 
proteins (pEC8 and pEC12)  
 
Expression and purification of pEC8 and pEC12 was identical to that 
of pEC7. 
 
2.3.7 Expression and purification of his-tagged Pseudomonas 
aeruginosa TolB (pEC14). 
 
Expression and purification of pEC14 was identical to that of pEC4. 
 
2.3.9 Expression and purification of N-terminal thrombin cleavable his-
tagged Pseudomonas aeruginosa TolA domain 3 (pEC16)  
 
pEC16 was transformed into BL21 (DE3) competent cells for 
expression and purification of thrombin cleavable his-tagged Pseudomonas 
aeruginosa TolA3. Growth and harvesting was as pEC1 (2.3.3) with the 
exception that pelleted cells were resuspended in 30 ml 1x binding buffer (40 
mM Tris-HCl pH 7.5, 500 mM NaCl, 5 mM imidazole) prior to sonication.  
The cell debris was spun out (19776 rotor, 10000rpm, 4 °C for 30 
minutes) and supernatant decanted. The supernatant was subsequently 
loaded onto a 5 ml HisTrap HP column (GE Healthcare) charged with 3 
column volumes (c.v.) of 50 mM NiSO4 and equilibrated with 3 c.v. of binding 
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buffer. The column was washed with binding buffer at a flow rate of 1.5 
ml/min until the absorbance of the eluate returned to background levels 
(monitored by 280nm absorbance). Bound protein was then eluted using a 
linear gradient of 5-500 mM imidazole over 10 c.v. Fractions were analyzed 
by SDS-PAGE and those containing the protein of interest were pooled and 
buffer exchanged with PD10 desalting column (GE Healthcare) into 50 mM 
Tris-HCl pH 7.5, 250 mM NaCl, 2.5mM CaCl2. Sample was then cleaved with 
thrombin for 16 hours at 4°C. Following cleavage, sample was again loaded 
onto pre-equilbrated 5 ml HisTrap HP column to remove the tag. Cleaved 
protein collected in flowthrough.   
Protein was further purified by gel filtration using a Hiload 26/60 
Superdex 75 column (GE Healthcare). 10 ml of protein was injected onto the 
pre-equilibrated S75 column (50 mM Tris-HCl, 250 mM NaCl, pH 7.5) and 
was eluted at a flow rate of 3 ml/min. Protein elution was monitored by 
absorbance at 280 nm. All peaks were analysed by SDS PAGE. Peak 
fractions were pooled and stored at -20 °C until further use. 
2.3.10 Other proteins 
 
Wild type colicin E9 was kindly supplied by Dr Nick Housden, 
University of York. Periplasmically translocated and processed E.coli TolB 
and Δ34 mutant of eTolB (lacking 12 amino acids of disordered N-terminus 
used to bind eTolA) were supplied by Dr Daniel Bonsor (University of 
Maryland). eTolA23 (E.coli TolA domains 2 and 3 with N-terminal Cysteine 
mutation) was kindly supplied by Dr Anne Marie Krachler (University of 
Texas, Southwestern Medical Center at Dallas). 
 
2.3.11 TolA binding epitope synthetic peptides 
 
Synthetic TolA binding epitope peptides were custom synthesised by 
Activeotec (Cambridge, UK) or Pepceuticals (Enderby, UK) in 50 mg or 100 
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mg batches at >95% purity. E.coli TolA binding peptide was of sequence 
EVRIVIDSGVDSWKKK and Pseudomonas aeruginosa TolA binding peptide 
was of the sequence ADPLVISSGNDRWKKK.  
 
2.3.12 SDS polyacrylamide gel-electrophoresis 
 
A stock of 30 % acrylamide and 0.8 % bis-acrylamide (Protogel, 
National Diagnostics) was diluted into 375 mM Tris-HCl pH 8.8 and 0.1 % 
sodium dodecyl sulphate (SDS) to give final acrylamide concentrations 
ranging from 10 – 20 % as required for the running gel. Ammonium 
persulfate and N, N, N’, N’-tetramethyl ethylenediamine (TEMED) were 
added to a final concentration of 0.08 % w/v and 0.13 % v/v, respectively to 
initiate gel polymerisation. Stacking gels were prepared similarly but 
contained 5 % acrylamide and 250 mM Tris- HCl pH 6.8. Samples were 
mixed with loading buffer to give a final concentration of 50 mM Tris-HCl pH 
6.8, 2.5 % β-mercaptoethanol, 2 % SDS, 0.1 % bromophenol blue and 10 % 
glycerol. Samples were usually boiled for 5 minutes prior to gel loading. 
Unstained protein molecular weight marker with a range of 14.4 to 116 kDa 
(Fermentas) was loaded on gels alongside samples to enable approximate 
molecular weight determination of protein samples. Samples were separated 
by gel electrophoresis in 25 mM Tris, 193 mM glycine, 10 % SDS at a 
constant current of 30 mA per gel until sufficient separation had been 
achieved (usually approximately 30 mins). 
Proteins were visualized by staining with 0.2 % Coomassie brilliant blue 
R250 (Pierce) in 10 % v/v acetic acid and 50 % v/v ethanol and destained in 
the same solution lacking Coomassie blue dye. 
2.3.13 Protein estimation 
 
Protein concentrations were measured by the absorbance at 280 nm 
using a Biophotometer (Eppendorf) and the Beer-Lambeth law. Theoretical 
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molar absorbance coefficients (ε280nm) for each protein were calculated 
according to the following formula; 
 
ε280nm = (Ncys × ε280nm of cys) + (Ntyr × ε280nm of tyr) + (Ntrp × ε280nm of trp) 
 
where N is the number of amino acids (cys, cystine; tyr, tyrosine; trp, 
tryptophan) and ε280nm is the molar absorption coefficient for the amino acids 
(Cys, Tyr, Trp; 125 M-1cm-1, 1490 M-1cm-1 and 5500 M-1cm-1 respectively) 
(Pace et al. 1995).  
 
A list of molar absorbance coefficients for the proteins used in this work are 
presented in table 2.7. 
 
 
Table 2.7. List of theoretical molar absorbance coefficients. 
 
2.3.14 Electrospray ionisation mass spectrometry  
 
To verify the molecular mass of purified proteins, sample protein 
(typically 50-100 μM) was dialysed in dH2O overnight and then diluted 1:10 
in 50% acetonitrile, 50% dH2O and 0.1% trifluoroacetic acid prior to analysis 
on either Waters LCT Premier XE or ABI-QStar Tandem Mass spectrometer, 
both connected to electrospray ion source by Berni Strongitharm, Andrew 
Leech, Adam Dowle (University of York Technology Facility) or Renata 
Kaminski (Kleanthous Lab).  
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2.3.15 Formaldehyde cross-linking of purified proteins 
 
Purified proteins were dialyzed overnight against 10 mM sodium 
phosphate pH 6.3-8.5 at 4 C. Individua l protei s and complexes (final 
concentration of 10 μM each) were incubated at 37 C for 15 minut    
addition of formaldehyde (final concentration 1% w/v) to achieve a final 
volume of 10 μl. Proteins were incubated for a further 15 minutes at 37 C 
before the addition of 5 μl of 100 mM Tris-HCl, pH 6.8 to quench the cross-
linking reaction. Samples were mixed with 4 x SDS loading buffer, incubated 
for 15 minutes at 37 C a nd run on 13%       
either Coomassie blue staining or Western blotting. 
 
2.3.16 DSP ((Dithiobis(succinimidylpropionate), Lomants reagent) 
crosslinking of purified proteins 
 
Purified proteins were dialyzed overnight against 10 mM sodium 
phosphate pH 7.0 at 4 C and diluted to final concentrations of 0.5-100 μM. 
80 mg/ml stock of DSP dissolved in DMSO was added to reaction mixture to 
give a 10-fold molar excess (unless stated otherwise). The reaction was left 
to proceed at 22 C for 30 minutes and subsequently quenched by adding a 
100-fold molar excess of Tris-HCl pH 8.0. Samples were analyzed by non-
reducing SDS-PAGE to maintain cross link or reduced by adding 20 mM 
DTT prior to gel loading to abolish crosslink.  
2.3.17 Cross-linked protein mass spectrometry 
 
Purified E.coli TolA3 (eTolA3) was dialysed overnight against 10 mM 
Sodium phosphate, pH 6.3 – 8.5) at 4 C and diluted to final concentrations 
of 0.5-100 μM. Synthetic E.coli TolA binding peptide (eTABp) stock was 
made up to appropriate concentration in identical buffer conditions. eTolA3 
and eTABp were then crosslinked in the presence of either formaldehyde or 
DSP (described in section 2.3.15-16). Following quenching of crosslinking 
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reaction, samples were separated with SDS-PAGE and desired bands 
excised from the gel. Samples were then delivered to Proteomics Lab 
(Technology Facility) where in gel trypsin digest was performed by Adam 
Dowle. Samples were then diluted into 50% acetronitrile, 50% dH2O and 
analysed using MALDI-TOF (ABI-QStar instrument with electrospray 
ionisation) mass spectrometry performed by Dr David Ashford. Trypsinised 
fragments from eTolA3 alone and eTolA3 crosslinked with eTABp were then 
compared and analysed to determine if firstly any additional mass from the 
peptide crosslinking to the protein could be detected, and secondly if any 
trypsin fragments were lost due to protected trypsin digestion site as a result 
of peptide crosslinking to peptide. 
 
2.3.18 Western blotting 
 
Antibodies 
 
All antibodies were supplied by Dr Daniel Bonsor (Bonsor 2009). 
Briefly, polyclonal antibodies raised against E.coli TolA, TolB, Pal and ColE9 
were produced in rabbits (Eurogentec). Antibodies for TolB, ColE9-Im9 and 
tagless Pal were produced against the purified proteins. Anti-rabbit IgG 
peroxidase conjugate (Sigma) was used as secondary antibody for Western 
blots. 
 
Antibody Dilution 
ecTolB 1:100000 
ecTolA3 1:1000 
1:12500 ecTolA2-3 
ecPal 1:1000 
Rabbit IgG 1:2000 
 
Table 2.8 Typical dilutions of antibodies used for Western Blots 
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Blotting procedure  
 
Following protein separation by SDS-PAGE, samples were 
transferred onto nitrocellulose membranes via semi-dry electroblotting. 
Polyacrylamide gels were first incubated in transfer buffer (25 mM Tris, 150 
mM glycine, pH 8.3 in 20 % v/v methanol) for 1 minute and then sandwiched 
between three layers of Quickdraw blotting paper (Sigma), a sheet of 
Hybond-ECL nitrocellulose membrane (GE Healthcare) and another three 
layers of blotting paper, all equilibrated in transfer buffer. The transfer was 
carried out using a V10-SDB semi-dry blotter (Fisher) under a constant 
current of 1 mA/cm2 for 45 minutes. 
 
Blotted nitrocellulose membranes were washed for 3×5 min with 
1×TBS-T (20 mM Tris-HCl pH 7.5, 500 mM NaCl, 0.05 % v/v Tween 20) and 
incubated with blocking buffer (8 % w/v Marvel milk powder in 1×TBS-T) 
overnight. The blot was washed for 3 × 5 min with 1×TBS-T before a one 
hour incubation with 0.25 ml/cm2 membrane of primary antibody diluted into 
1×TBS-T containing 4 % w/v milk powder. The membrane was washed 3 × 5 
min with 1×TBS-T again, followed by incubation with the secondary antibody 
diluted 1:1000 into 1×TBS-T + 4 % w/v milk powder. 
Following another three wash steps, the membrane was incubated 
with ECL western blotting analysis system (GE Heathcare) for one minute 
and immediately exposed to a Kodak BioMax light film (Sigma) for 30 
seconds to 15 minutes inside a Hypercassette (GRI). The film was 
developed using a Compact X4 Film Processor (Xograph Healthcare Ltd.). 
 
2.3.19 Circular Dichroism (CD) 
 
Protein samples were dialysed into buffer (typically 10 mM Sodium 
Phosphate, pH 6.5-9) overnight at 4 °C at concentrations ranging from 5-50 
μM. Spectra were collected on a Jasco J810 CD spectrophotometer with 
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peltier temperature control attachment using 0.1 or 1 mm pathlength quartz 
cuvettes. Scans were performed from 260-190 nm at a temperature of 20 °C 
with a scanning rate of 100 nm/min and a data pitch of 1 nm. 5-10 scans 
were averaged to give final spectra. For thermal denaturation experiments, 
scans were performed in 5 °C increments with an equilibration phase of one 
minute at each temperature and a heating rate of 0.5 °C/min (unless stated 
otherwise) over a temperature range of 20 - 90°C. Samples were 
subsequently cooled to 20 °C, allowed to equilibrate for 10 mins, and spectra 
was collected again. For all proteins, efficiency of refolding was greater than 
95%. 
 
To calculate molar ellipticity (θ, deg cm2 dmol-1), the following formula was 
applied;  
θ = CDsignal[mdeg] / (L x c x n) 
 
(where L = pathlength (mm), c = protein concentration (M) and n = number of 
residues) 
 
2.3.20 Isothermal Titration Calorimetry (ITC) 
 
Purified protein samples were dialysed against appropriate buffers 
overnight at 4 °C, and any precipitates removed by centrifugation (10000g, 
10mins). Concentrations of the samples were measured (typically 100-5000 
μM for syringe sample, 30-500 μM for cell sample), diluted in appropriate 
dialysis buffer and degassed for 10 minutes using a Thermovac degassing 
unit (when using VP-ITC) (Microcal/GE Healthcare). Samples were loaded 
into the cell and syringe of either VP-ITC or ITC-200 microcalorimeter 
(Microcal/GE Healthcare). When using VP-ITC, a typical full titration 
consisted of 35 injections (1x2 μl, 34x8 μl) measured at 20 °C with an 
interval of 270 seconds between injections, and a stirring speed of 307 rpm 
(unless otherwise stated). When using ITC-200, a typical full titration 
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consisted of 20 injections (1x0.4 μl, 19x2 μl) measured at 20 °C with an 
interval of 240 seconds between injections, and a stirring speed of 1000 rpm 
(unless otherwise stated). Heats of dilutions were measured by injecting 
syringe samples into buffer under identical titration conditions and subtracted 
from each data set. Data was analysed using Origin 8.0 software, and fitted 
to single site binding model. Parameters obtained from experiment were 
stoichiometry, Kd, ΔH, ΔS of probed interaction. See appendix section 7.6 for 
details of ITC and single site binding model equation. 
 
2.3.21 Surface Plasmon Resonance (SPR) 
 
To measure binding affinities by SPR between immobilised E.coli 
TolA3 and binding partners, a Biacore T100/200 instrument (GE Healthcare) 
was employed. Protein to be immobilised was an E.coli TolA domain 2 and 3 
(eTolA23) mutant, with the addition of an extreme N-terminal Cysteine 
residue, encoded by pAK123 construct. For preparation of SPR chip and 
protein immobilisation, distilled H2O (dH2O) was used as the running solvent. 
 
To immobilise the protein a C1 SPR chip was activated by two 120s 
injections of 0.1M glycine pH 12 with 0.3 % triton X-100 at a flow rate of 30 
μl/min. All consecutive steps were conducted at a flow rate of 10 μl/min. The 
chip surface was first modified by injecting a 1:1 mixture of freshly thawed 
NHS:EDC (stock of 0.4 M EDC and 0.1 M NHS in dH2O) for 420 seconds. 
This was followed by a 420 second injection of 0.1 M ethylenediamine in 0.1 
M sodium borate pH 8.5 and an injection of 50 mM N-[γ-
maleimidobutyryloxy]sulfosuccinimide ester (sulfo-GMBS) in 0.1 M sodium 
borate pH 8.5 for 240 seconds. eTolA23 at a concentration of 8-10 μM in 10 
mM sodium phosphate pH 7.0 was subsequently injected into the sample 
channel only for 420 seconds, resulting in a typical immobilization of 600 RU. 
Next, reactive groups remaining on both sample and reference channel were 
blocked by injecting 50 mM cysteine in 1 M NaCl, 0.1 M sodium phosphate 
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pH 7.0 for 240 seconds. After changing the running solvent to binding buffer 
(50 mM Hepes pH 7.5, 50 mM NaCl, 0.05 % P20), binding experiments were 
carried out with a flow rate of 10 μl/min at 25 °C. Prior to titration 
experiments to ensure the quality of chip, a 100 μM test sample of eTolB 
was passed over the immobilised eTolA23, ensuring a good response curve 
was obtained. Following a 6 M GnHCl unfolding/regeneration step, to 
remove eTolB from the eTolA23, 300 Response units (RU) of stable eTolA23 
were left attached to the chip, ready for binding experiments. Subsequent 
samples at concentrations ranging from 1-150 μM for protein binding 
partners, and 10-1000 μM for TolA binding peptides were injected for 300 
seconds, followed by an equilibration phase (buffer injection for 300 
seconds). The surface was regenerated after each binding experiment by 
injecting 6 M guanidine chloride in 30 mM Tris-HCl pH 7.5, 5 mM Imidazole, 
200 mM NaCl for 60 seconds, followed by an equilibration period of 600 
seconds prior to the next binding experiment. Binding affinities were derived 
by equilibrium analysis (assuming an equilibrium 4 seconds prior to end of 
the injection) of blank-subtracted sensograms using the Biacore evaluation 
software. See appendix section 7.5 for further details of surface plasmon 
resonance immoblisation. 
 
2.3.22 Protein crystallisation 
 
Numerous attempts to crystallise eTolA3, eTolA3-eTABp complex, 
psTolA3, psTolA3-psTABp complex were made with protein concentrations 
ranging from 1-150 mg/ml (with peptides in 1-10x molar excess), set up in 
MRC-Wilden crystallisation plates using Hydra and Mosquito robots against 
commercially available screens including Peg-Ion 1&2, Hampton 1&2, 
Morpheus, PACT and Index, using the sitting drop method. 
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2.3.23 Analytical ultracentrifugation (AUC) 
 
Analytical ultracentrifugation experiments were performed by Dr 
Andrew Leech, University of York using Beckman Optima XL/I analytic 
ultracentrifuge equipped with Beckman 12 mm path length double sector 
charcoal filled Epon centrepieces and sapphire windows in an AN-60Ti rotor 
(3 cells plus counterbalance). Approximately 420 μl reference buffer and 416 
μl protein sample were loaded into each cell, following which absorbance 
scans were performed at 3000 rpm to verify loading concentrations and 
samples were uniformly distributed. Cells were then removed, agitated, and 
replaced. Samples were then spun at 50000 rpm for 10 hours at 20 °C with 
sample scans collected every 180 seconds at 302 nm until either 
sedimentation was complete, or plateau region had disappeared. Data was 
analysed, fitted and transformed using SEDFIT software (Schuck 2000). See 
appendix section 7.7 for details of AUC fitting. 
 
2.3.24 Nuclear Magnetic Resonance (NMR) 
 
15N eTolA3 and psTolA3 protein expression and purification 
 
Proteins to be used in Nuclear Magnetic Resonance experiments 
were grown in supplemented M9 minimal media for labelling. Briefly, plasmid 
was transformed into BL21 (DE3) cells, from which a single colony was used 
to inoculate a 50ml culture of M9 minimal media, supplemented with 20% 
(w/v) glucose and 8.5% (w/v) Yeast Nitrogen Base (YNB) without amino 
acids or ammonium sulfate (Sigma). A 1 in 20 dilution was used to inoculate 
2x750ml of M9 (as above, with the exception of ammonium chloride was 15N 
enriched (CK Gas Products). Cells were grown at 37 °C on Innova 2300 
platform shaker (New Brunswick Scientific) at 120 rpm until an OD600nm of ~ 
0.6 was reached. Gene expression was induced with IPTG (Melford) at a 
final concentration of 1 mM. Cells continued to grow on the orbital shaker at 
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37 °C for a further 16 hours before harvesting (SLC-6000 rotor, 4500 rpm, 4 
°C for 12 minutes). All subsequent purification procedures were as tagless 
eTolA3 (pAK108 construct) or His-tagged psTolA3 (pEC4 construct). 
 
15N 13C psTolA3 protein expression and purification 
 
Double labelled protein was purified as 15N psTolA3 described above, 
with the exception of glucose used in 750ml cultures was 13C enriched (CK 
Gas Products).  
 
 
NMR Data acquisition and analysis 
 
Following purification and concentration, labelled proteins were 
dialysed against either 50mM Potassium phosphate, 50mM NaCl, pH 7.5 (in 
case of eTolA3) or 20mM Sodium phosphate, pH7.5 (in case of psTolA3) 
overnight at 4 °C. NMR samples were made by mixing 540 μM of protein 
with 60 μl D2O. 0.05% (w/v) Sodium Azide was added as a preservative. 
Final protein concentrations ranged from 200 μM for titration experiments 
and 600-1000 μM for 3D experiments for assignment. Samples were loaded 
into Norell 600MHz tuned tubes (Sigma-Aldrich) and 2D-HSQC experiments 
recorded for titration experiments using singly labelled protein, and 
CBCANH, CBCACONH, HNCO, HNCACO, Trosy-HSQC and NOESY 
experiments (see appendix section 7.8 for details of NMR experiment types) 
recorded with double labelled protein on a 700MHz Avance II Spectrometer 
(Bruker) with triple resonance probe. The probe was operating at 1H 
frequency of 700.13 MHz, 13C frequency of 176.05 MHz and 15N frequencies 
of 70.93 MHz, using pulse sequences supplied and modified by Bruker 
Topspin 3.0 software. All spectra were collected at 20°C. To verify that 
spectra had been successfully collected, data were initially processed with 
Bruker Topspin 3.0 software. Following this, spectra were processed and 
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phased using NMRDraw (Delaglio et al. 1995), converted to Azara format 
using NMRPipe (Delaglio et al. 1995) and analysed with CCPN Analysis 
2.1.5 (Vranken et al. 2005). 
 
2.3.25 In vivo colicin cell killing assay 
 
Bacterial strains (JM83, unless otherwise stated) were grown to an 
OD600 of 0.6, diluted 1:20 into 0.75 % (w/v) top-agar at 42 °C and the 
suspension was spread on top of pre-poured LB-agar plates. Once top-agar 
had set, serial dilutions of wild type colicin E9 or colicin E9 mutants were 
spotted onto the plates. After 16 hours of incubation at 37 °C, zones of 
clearance in the bacterial lawn were indicative of cell death. 
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3. The N-terminus of E.coli TolB is the sole determinant for E.coli TolA 
binding 
 
3.1 Introduction 
In work reported by Bonsor et al (2009), it was shown primarily via 
isothermal titration calorimetry (ITC) experiments that not only was the N-
terminal strand of E.coli TolB (eTolB) a site of interaction with E.coli TolA3 
(eTolA3), but that E.coli Pal (ePal) did not interact with E.coli TolA3, as had 
been previously reported (Cascales et al. 2002). As these two findings 
conflicted with one another, further investigation of the interactions between 
the E.coli TolA, E.coli TolB and E.coli Pal proteins was addressed in the 
following work. In addition, the work of Bonsor et al. (2009) showed that the 
interaction of TolB with TolA is dependent on the instrinsically unstructured 
N-terminus of TolB being in the disordered conformation (Bonsor et al. 
2009). This work also showed that binding of the T-domain of colicin E9 (a 
group A colicin) to TolB caused this instrinsically unstructured N-terminus to 
enter into its disordered conformation and thus promoted it’s interaction with 
TolA (Bonsor et al 2009). To further investigate this phenomenon colicin E9-
TolB fusion proteins were designed to ascertain if TolB could be bypassed 
and a direct interaction between colicin E9 and E.coli TolA could be 
engineered and function, both in vivo and in vitro.  
 
3.1.1 E.coli TolA 
 
E.coli TolA is a 43 kDa, 421 residue, 3 domain protein that spans the 
periplasm of the cell. It consists of domain 1 (residues 1-48), a short 
transmembrane domain that anchors the protein into the inner membrane of 
the cell, domain 2 (residues 48-310), which is a long helical domain arranged 
into a triple helix (Cascales et al. 2007), and domain 3 (residues 311-421), a 
folded globular domain (Lubkowski et al. 1999). Previous work published has 
indicated that it is domain 3 of TolA that interacts with E.coli TolB (Bonsor et 
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al. 2009), however, the binding site on TolA is currently unknown. E.coli TolA 
has been reported to interact with E.coli Pal in a proton motive force 
dependent manner (Cascales et al. 2000; Cascales et al. 2002), however 
this finding was at odds with other work that had shown that there no 
interaction in vitro between E.coli TolA and Pal (Bonsor et al. 2009). A 
crystal structure of TolA domain 3 from Pseudomonas aeruginosa (figure 
3.1B) was the first structure to be published for a TolA protein on its own 
(Witty et al. 2002). In addition, a solution NMR structure for E.coli TolA 
domain 3 has been published (Deprez et al. 2005) (figure 3.1C), as well as 
more recently a crystal structure (Li et al. 2012) (figure 3.1A). As can be 
seen in figure 3.1D, Pseudomonas aeruginosa TolA3 and E.coli TolA3 both 
have a similar fold, despite sharing only 20% sequence identity (Witty et al. 
2002).  
 
3.1.3 E.coli TolB 
 
E.coli TolB is a 44 kDa, 430 residue protein consisting of 2 domains. The 
larger of the 2 domains has a beta-propeller motif consisting of 6 blades. It is 
within this beta-propeller domain that both E.coli Pal and the translocation 
domain of colicin E9 interact with TolB. Additionally, it has a smaller N-
terminal domain, the key feature of which is the natively unstructured N-
terminus (Bonsor et al. 2009). When produced by the cell, E.coli TolB has 22 
additional residues on the extreme N-terminus that direct it for Sec-
dependant export into the periplasm. These 22 extra residues are then 
cleaved by signal peptidase, leaving the mature protein (Isnard et al. 1994). 
The first 12 residues (EVRIVIDSGVDS) on the N-terminus of the mature 
protein have been found to be important for the interaction that occurs 
between TolB and TolA (Bonsor et al. 2009). Without these 12 residues on 
the N-terminus, no binding was detected in vitro (ITC and formaldehyde 
cross-linking) between TolB and TolA (Bonsor et al. 2009). Work on 
subsequent pages refers to a mutant of TolB that lacks the N-terminal 12 
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residues (in addition to the 22 residues removed by signal peptidase) is 
termed “Δ34 TolB mutant”. When TolB is in isolation, these N-terminal 
residues are presumed to be in dynamic equilibrium between an ordered and 
disordered state (from evidence obtained from NMR experiments) (figure 
3.2, b). It is in the disordered state that TolA is predicted to interact with TolB 
(figure 3.2, c). When Pal binds TolB however it causes a conformational 
change in TolB that causes its N-terminus to become ordered and bound 
back to the body of the TolB protein. When in this ordered conformation, the 
N-terminus is unavailable to bind TolA (figure 3.2, a), and thus Pal binding 
can be seen as an “off” switch for the TolA-TolB interaction. Conversely, 
when the translocation domain of colicin E9 binds TolB (in the same site as 
Pal), the opposite occurs, wherein the binding of colicin E9 promotes 
disorder in the TolB N-terminus and therefore promotes the interaction with 
TolA (Bonsor et al. 2009).  
 
3.1.4 E.coli Pal 
 
Pal is a small (173 residue, 19 kDa) protein that is normally attached to the 
outer leaflet of the outer membrane via a lipoyl tether (Lazzaroni et al. 1992). 
The name Pal stands for Peptidoglycan Associated Lipoprotein, and as it’s 
name suggests, Pal has been found to associate with the peptidoglycan 
layer of Gram-negative bacteria (Mizuno 1979). When Pal is bound to the 
beta-propeller domain of TolB, it causes a conformational change in TolB, 
which acts as an allosteric switch to mediate the conformation of the N-
terminus of TolB from that of dynamic equilibrium to ordered state (figure 
3.2, a) (Bonsor et al. 2009). Pal has also been reported to interact with E.coli 
TolA in vivo in a proton-motive force dependent manner, found by in vivo 
formaldehyde cross-linking and immunoprecipitation experiments. This work 
found that when cells were treated with CCCP (abolishing pmf) then the 
TolA-Pal interaction was lost (Cascales et al. 2000). However, this 
interaction has not been verified in vitro (Bonsor et al. 2009). 
Chapter 3 
   
76 
  
 
Figure 3.1 Comparison of 
Pseudomonas aeruginosa 
and E.coli TolA domain 3. (A) 
Crystal structure of E.coli TolA 
domain 3, residues 302-421 
(PBD ID: 3QDP) (Li et al. 2012). 
(B) Crystal structure of 
Pseudomonas aeruginosa TolA 
domain 3 (with short region of 
domain 2), residues 226-347. 
(PDB: 1LR0) (Witty et al. 2002). 
(C) Overlay of E.coli TolA 
domain 3 (green) with 
Pseudomonas aeruginosa TolA 
domain 3 (red), showing near 
identical fold. 
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Figure 3.2 E.coli TolA-TolB-Pal interaction network. (a) When TolB is in 
complex with Pal, it’s intrinsically disordered N-terminus is in ordered 
conformation, unavailable for TolA. (b) When not bound to Pal, the N-
terminus is in dynamic equilibrium between ordered and disordered state. (c) 
In disordered conformation, TolB’s N-terminus can bind TolA.  
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3.1.5 Colicin E9 
 
Colicin E9 is a Tol dependent colicin that kills E.coli cells via a cytotoxic 
DNase action. It is arranged in 3 domains, the intrinsically disordered N-
terminal translocation domain, the receptor domain that binds to BtuB and 
finally the C-terminal cytotoxic DNase domain. The N-terminal translocation 
domain is subdivided into 3 binding sites; OmpF binding site 1 (OBS1), E.coli 
TolB binding site and OmpF binding site 2 (OBS2). To enter into the cell, and 
therefore cause cell death, colicin E9 first binds BtuB through it’s receptor 
domain, secondly threads it’s intrinsically disordered translocation domain 
through OmpF (Housden et al. 2005) (Housden et al. 2010), to bind with 
TolB through TolB’s beta-propeller domain. This binding event promotes the 
N-terminus of TolB into a disordered conformation, driving it’s interaction 
with TolA (Bonsor et al. 2009). By contacting TolA in the periplasm, the 
translocation of colicin E9 across the outer membrane, periplasm and 
ultimately to the inner membrane is somehow driven, allowing the cytotoxic 
DNase domain to enter into the cell (Housden et al. 2005). The specific role 
that the Tol proteins have in this event is currently not known. 
 
3.1.7 The E.coli TolA-TolB-Pal interaction 
 
As reported by Bonsor et al (2009), the eTolA3 interaction with eTolB is 
dependent on the N-terminus of eTolB in the disordered conformation when 
challenged via ITC. Mutants that lack this N-terminus (of sequence 
23EVRIVIDSGVDS34) do not show any heats of binding when titrated against 
with eTolA3. As no structure is currently available for any form of TolA-TolB, 
the binding site of TolB on TolA is not known, nor is it known if the N-
terminus is the sole site of interaction between TolA and TolB. 
 
In addition, when a preformed complex of eTolB and ePal is titrated against 
with eTolA3, no heats are detected (Bonsor et al. 2009). Furthermore, when 
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the crystal structures of eTolB alone (PDB ID: 1C5K) (Carr et al. 2000), and 
eTolB in complex with ePal (PDB ID: 2W8B) (Bonsor et al. 2009) are 
compared, in the presence of ePal, the N-terminal strand of eTolB is in an 
ordered conformation, bound back to eTolB. This indicated that ePal 
controlled the conformation of the disordered N-terminus of eTolB. When the 
N-terminus is in an ordered state (bound back conformation) it is prevented 
from binding with eTolA3. When eTolB is not bound to ePal, the N-terminus 
of eTolB is presumed to be in dynamic equilibrium between ordered and 
disordered state, as NMR data showed that peaks corresponding to the N-
terminus were in slow exchange (i.e. double the number of peaks found in 
spectrum than expected, indicating that the N-terminal peaks were in 2 
populations). When the N-terminal residues were deleted, these peaks were 
lost from the NMR spectrum. Additionally, although previous work had 
suggested that an interaction between eTolA3 and ePal occurred (Cascales 
et al. 2000), work by Bonsor et al. disagreed with these findings. It was the 
aim of this work to independently investigate these findings through an 
alternative biophysical technique (Surface Plasmon Resonance). 
 
3.1.8 Isothermal Titration Calorimetry (ITC) 
 
Isothermal titration calorimetry can be used to measure the thermodynamic 
properties of a protein-protein interaction. ITC determines the binding 
equilibrium of the interaction by measuring the amount of heat released or 
absorbed on association of a ligand with it`s binding partner. From an ITC 
experiment, the binding constant (Ka), stoichiometry (n), enthalpy of binding 
(ΔHb) and entropy of binding (ΔSb) can be determined.  
 
An ITC instrument comprises of 2 identical chambers or cells (one sample 
cell, one reference cell) made from a material with a very high thermal 
efficiency (such as gold), both of which are surrounded by a thermal jacket, 
which is regulated by either a circulating water bath or, more commonly, a 
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Peltier device. A highly sensitive thermocouple monitors the temperature of 
the 2 cells, and regulates the thermal jacket to ensure that both cells 
maintain an identical temperature (figure 3.3).  
 
To perform an ITC experiment, a buffered protein sample is placed into the 
sample cell and allowed to equilibrate in terms of temperature. In the 
reference cell, either a sample of identical buffer without the protein, or water 
is placed. A constant power is applied to the reference cell, creating a 
baseline signal. This controls the sample heater, which reacts to maintain 
the sample cell at the same temperature as the reference. The directly 
observed data for an ITC experiment is the time dependent power level 
applied to the cells to maintain an identical temperature. When a sample is 
injected (titrated) into the sample cell, and binds with the protein in the 
sample cell, heat is either released or absorbed from the environment, 
depending on whether the interaction is exothermic or endothermic, 
respectively. If the interaction (reaction) is exothermic, the temperature of the 
sample cell will rise, causing the sample cell heater to be deactivated (or in 
the case of a Peltier, the device being activated to remove heat). If the 
interaction is endothermic, the opposite will occur, i.e. the temperature in the 
sample cell will drop, causing activation of the sample cell heater to return 
the temperature to that of the reference cell. The amount of power over time 
that is required to do either of these tasks is what is directly measured.  
 
Over the course of an ITC experiment, the amount of heat that is released or 
absorbed by the binding event (injection) is directly proportional to the 
fraction of ligand bound to the sample cell protein. During the initial 
experimental titrations, most of the ligand injected into the sample cell will be 
immediately bound to the sample protein, causing a large change in 
temperature. As more titrant is injected into the sample cell, less sample 
protein will be available for binding, and thus the amount of heat released or 
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absorbed will decrease, until saturation is reached, wherein there is no more 
free sample protein available for binding with the titrant (Pierce et al. 1999).  
 
Figure 3.3 Representation of typical Isothermal Titration Calorimetry 
instrument. ΔT1 compares temperature of reference cell with sample cell 
during ligand injection. ΔT2 compares reference cell with thermal jacket, i.e. 
baseline to ensure that any heat released or absorbed during titration is as a 
result of interaction in sample cell and not changes in the external 
environment (Microcal 2004). 
 
The amount of heat released or absorbed by the addition of a titrated ligand 
into the sample cell can be represented by the following, assuming a single 
site of binding on the target protein: 
 
Q = V0ΔHb[M]tKa[L]/(1+Ka[L]) 
 
Where Q is heat, V0 is the sample cell volume, ΔHb is the enthalpy per mole 
of the titrated ligand, [M]t is the total sample protein concentration including 
bound and free fractions, Ka is the binding constant and [L] is the free titrated 
ligand concentration (Microcal 2004).  
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From the heat trace (energy released or absorbed) of the titration (reference 
cell vs sample cell differential power [μcal / s] against time [s]), it is possible 
to integrate the area of the peaks (representing the total heat released for a 
given injection) and plot them against the molar ratio of ligand and protein, 
creating the binding isotherm (Figure 3.4). From this isotherm, it is possible 
to calculate the stoichiometry of the interaction (at ligand-protein ratio of 1), 
as well as the affinity (1/Kd) and enthalpy (and thus entropy) of binding (Ka is 
obtained from equation fit, ΔS is obtained from Gibbs equation [ΔG = ΔH –
TΔS] using the measured ΔH and ΔG obtained from affinity of interaction  
[ΔG = RTIn(Kd)] (Pierce et al. 1999). For further details of ITC single site 
binding model, see appendix section 7.6. 
 
 
Figure 3.4 Isothermal titration calorimetry binding isotherm 
The heat trace peaks are intergrated in order to give the binding isotherm. 
From this isotherm, the ΔH can be calculated (blue) from the kcal/mol, the 
stoichiometry (green) from the mid-point of the isotherm, and the Kaffinity from 
the slope of the line (red). From the Ka the dissociation constant can be 
calculated (Ka = 1/Kd) (Microcal 2004). 
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3.1.9 Surface Plasmon Resonance (SPR) 
 
Surface plasmon resonance is a technique that can be used to obtain both 
the equilibrium dissociation constant for a given interaction, as well as 
potentially association/dissociation kinetics. SPR occurs when light is 
produced from a high-refractive index medium, such as a prism, toward an 
interface containing a low-refractive index material, such as protein sample 
solution. When a thin film of gold is placed at the interface of the two media, 
an evanescent wave of photons created by the rear illumination of the high-
refractive index media couple with the electrons of the gold film, termed 
plasmons. This coupling can only occur when resonance of the photons 
occurs, which is dependent on the polarisation of the light against the gold 
film, the angle of incidence of the light, and the wavelength of the light. 
Coupling of the photons and plasmons results in an exchange of momentum, 
causing a decrease in intensity of the reflected light at the interface. 
Therefore, at a specific angle, termed the SPR angle (at a specific 
wavelength), minimal reflectivity occurs. Thus, the SPR signal can be 
monitored by the incidence angle or wavelength, and correlated to any 
resultant change in reflectivity (monitored by an optical detector).  
In a given system, if a binding event occurs (i.e. a substrate binds to the gold 
film), a change will occur in the interface by the gold film (the change in 
refraction is sensitive to up to 300 nm at the gold film surface), and thus, 
cause a change in resonance, which will in turn cause a change in the 
intensity of the reflected light. This change in reflected light will cause a 
change in the SPR signal, which is monitored by an optical sensor, and 
transformed into a real-time event, measured in response units (RU) 
(Rusling et al. 2010).  
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Figure 3.5 Surface plasmon resonance Surface plasmon resonance 
(SPR) detects changes in the refractive index in the immediate vicinity of the 
surface layer of a sensor chip, which causes a change in the SPR angle. 
This angle shifts (from I to II) when biomolecules bind to the surface and 
change the mass of the surface layer. This change in resonant angle is 
monitored in real time as a plot of resonance signal/response units 
(proportional to mass change) as a function of time. Figure reproduced from 
(Cooper 2002). 
 
3.1.10 Aims 
 
It is the aim of this work in this chapter to test several hypotheses; (1) to 
confirm that the TolB N-terminus (residues 23-34) is required for it’s 
interaction with TolA; (2) as reported by Bonsor et al in 2009, but in conflict 
with early work (Cascales et al. 2000), that TolA domain 3 does not interact 
with Pal; and finally (3) that binding of Pal to TolB mediates the interaction 
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between TolA and TolB. These questions will be addressed biophysically 
using Surface Plasmon Resonance.  
 
In addition, once the 12 residue N-terminus of TolB has been investigated in 
it’s native interaction with TolA, this work will investigate (4) that when this 
short 12 residue stretch is added to another protein (colicin E9) creating a 
colicin E9-E.coli TolB fusion protein, that this short sequence is capable of 
not only driving a novel interaction between colicin E9 and TolA in vitro, but 
that TolA can complement TolB to drive the in vivo translocation of colicin E9 
fusion proteins (that cannot interact with TolB) into E.coli cells and thus kill 
them.  
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3.2 Results 
 
3.2.1 Probing the interactions of E.coli TolB, TolA and Pal with surface 
plasmon resonance 
 
In order to further investigate the interaction network of E.coli TolA, TolB and 
Pal with SPR, a series of experiments were devised. Firstly genes of interest 
were overexpressed and proteins purified and subsequently characterised in 
terms of their secondary structure (for quality control purposes due to the 
lack of a biochemical assay for activity of any of the Tol proteins). To 
investigate the in vitro interactions of E.coli TolA, TolB and Pal, E.coli TolA 
protein consisting of domains 2 and 3 (with addition of cysteine residue at 
the extreme N-terminus of domain 2) was immobilised on a C1 SPR chip via 
thiol-coupling and titrated against with both E.coli TolB and Pal. This work 
was to confirm the following; that the N-terminus of TolB is required for TolA 
binding, that E.coli Pal does not interact with E.coli TolA (as reported by 
Bonsor et al in 2009, but disputed by Cascales et al. in 2000) and finally, to 
verify that the binding of E.coli Pal to E.coli TolB act as an allosteric switch 
for the E.coli TolA-TolB interaction. When E.coli Pal is bound to E.coli TolB, 
it causes a conformational change driving the N-terminus (presumed to be in 
a state of dynamic equilibrium between ordered and disordered conformation 
when TolB is in isolation) into it’s ordered (bound back onto E.coli TolB) 
conformation, and thus is unavailable for binding with E.coli TolA (Bonsor et 
al. 2009).  
 
3.2.1.1 Purification of E.coli TolA domain 3 (pAK108 construct) 
 
E.coli TolA domain 3, residues 293-421 was purified from BL21 (DE3) cells 
transformed with pAK108, grown in 4.8 L of LB media. Protein was purified 
as described in section 2.3.1, and steps of purification are shown in figure 
3.6. A typical protein yield of 20 mg/L of culture was obtained. Mass 
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spectrometry of data for protein size is reported in table 3.1. Protein 
sequence reported in appendix section 7.3. 
 
 
 
Figure 3.6 Purification of tagless eTolA3 (pAK108 construct) (A) 280 nm 
absorbance profile from DE52 weak-anion exchange chromatography. 
Protein (indicated by arrow) eluted with 1M NaCl step gradient. (B) Gel-
filtration of eTolA3 on Superdex 75 26/60 column. eTolA3 eluted between 
200 and 230 ml. (C) Strong cation exchange (MonoS) chromatography 
purification step, as monitored at 280 nm. 1M NaCl elution gradient applied. 
(D) 16% SDS-PAGE gel of purification steps (arrow indicates expected size 
of eTolA3); D2: 40% Ammonium sulphate precipitated fraction, D3: 40% 
Ammonium sulphate soluble fraction, D4: 70% Ammonium sulphate 
precipitated fraction, D5: 70% Ammonium sulphate soluble fraction, D6/7: 
sample loaded onto DE52 column. (E) 16% SDS-PAGE gel of purified 
eTolA3 following MonoS purification step.  
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3.2.1.2 Purification of E.coli TolB (pDAB18 construct) 
 
E.coli TolB (residues 22-430) was purified from BL21 (DE3) cells 
transformed with pDAB18, grown in 4.8L of LB media. Protein was purified 
as described in chapter 2, section 2.3.2, and steps of purification are shown 
in figure 3.7. A typical protein yield of 40 mg/L of culture was obtained. Mass 
spectrometry of data for protein size is reported in table 3.1. Protein 
sequence reported in appendix section 7.3 
 
Figure 3.7 Purification of tagless eTolB (pDAB18 construct) (A) 280 nm 
absorbance profile from DE52 weak-anion exchange chromatography. 
Protein (indicated by arrow) eluted with 1M NaCl step gradient. (B) Gel-
filtration of eTolB on Superdex 75 26/60 column. eTolB eluted between 190 
and 220 ml. (C) Sample after Am2SO4 cut prior to loading on DE52 column 
(1) and sample (2) following DE52 weak anion exchange chromatography.  
(D) 13% SDS-PAGE gel of purified eTolB following S75 gel filtration 
purification step. Arrow indicates purified protein. 
Chapter 3 
   
89 
3.2.1.3 Mass spectrometry of purified proteins to verify fidelity of mass. 
 
To verify fidelity of purified proteins, electrospray mass spectrometry was 
performed as described in section 2.3.14. Expected and observed values 
indicated in table 3.1. 
 
Protein Expected Mass Observed Mass 
eTolB (pDAB18) 43733 Da 43735 (±4) Da 
eTolA3 (pAK108) 13000 Da 12997 (±7) Da 
 
Table 3.1 Expected vs observed masses of purified proteins 
 
3.2.1.4 Characterisation of secondary structure of purified E.coli TolA3 
and E.coli TolB proteins by circular dichroism spectroscopy. 
 
As there is no functional assay to determine if purified Tol proteins are 
active, biophysical characterisation of proteins is required, to ensure that 
they are folded. Far UV (190-260 nm) circular dichroism spectra were 
collected for eTolA3 (figure 3.8) and eTolB (figure 3.9) proteins. Data was 
corrected for protein concentration to give molar ellipticity, and subsequently 
deconvoluted with CDNN 2.1 (Bohm et al. 1992). CDNN analysis estimated 
that both purified eTolA3 and eTolB had the expected secondary structure in 
comparison to previously reported purifications (Bonsor 2009; Krachler 
2009), indicating that they were correctly folded. Additionally, proteins were 
also characterised by thermal denaturation to determine both their stability of 
fold, and efficiency at refolding. Proteins were incubated from 20-90 °C for 
eTolA3 and 20-70 °C for eTolB with 5 °C spacings before cycle repeated to 
verify efficiency of refolding. Melting temperature for eTolA3 was 55 °C and 
for eTolB was 50 °C. More than 95% of both proteins refolded following 
thermal denaturation (calculated based on total signal from CD spectra).  
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Figure 3.8 Far UV Circular Dichroism spectrum of E.coli TolA3 (pAK108 
construct). CD spectrum recorded for 50 μM eTolA3 in 10 mM Sodium 
phosphate, pH7 at 20 °C (0.1 mm pathlength) indicates high alpha helical 
content (as expected from NMR solution structure; PDB 1S62).  
 
Figure 3.9 Far UV Circular Dichroism spectrum of E.coli TolB (pDAB18 
construct). CD spectrum recorded for 30 μM eTolB in 10 mM Sodium 
phosphate, pH7 at 20 °C (0.1 mm pathlength). 
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3.2.2 Investigating the E.coli TolA, TolB, Pal interactions by Surface 
Plasmon Resonance 
 
To investigate the E.coli TolA3-TolB-Pal interaction (figure 3.10) with surface 
plasmon resonance, E.coli TolA mutant consisting of domains 2 (long helical 
domain) and 3 (C-terminal globular domain involved in interaction with 
eTolB) with additional N-terminal Cysteine residue (at end of long helical 
domain 2, residues 74-421, pAK123 construct, supplied by Dr Anne-Marie 
Krachler) was immoblised on 1 of 2 flow channels on a C1 SPR chip (see 
section 3.2.2.1 for details on immobilisation of eTolA23 to C1 chip, and 
appendix section 7.5 for details of chemistry used for protein immobilisation 
on SPR chip). This immobilised TolA was then challenged with a number of 
potential binding partners; free eTolB (section 3.2.2.2), free ePal (section 
3.2.2.3) and a pre-formed complex of eTolB-ePal (section 3.2.2.4). A binding 
event between the immobilised eTolA23 and the challenging protein would 
cause a change in response units as detected by Biacore T-100 biosensor 
from which affinities of binding could be calculated. The pAK123 construct 
that consists of a cysteine on the end of the long helical domain 2 is 
advantageous for this work as it ensures that the domain 3 of TolA (distal to 
the cysteine) is distant from the chip surface, and thus available for eTolB 
binding.  
 
In addition to eTolA23 immobilisation on flow channel 1, a second channel 
was prepared in an identical manner as eTolA23 channel. However, instead 
of protein, the second flow channel was blocked with free cysteine. This 
ensured that any change in response measured by SPR was due to genuine 
protein binding and not non-specific interactions with C1 chip surface. This is 
particularly relevant as previous SPR work investigating the binding 
interactions of immobilised eTolB had used a CM5 (dextran coated) chip 
(Hands et al. 2005). This approach was not used in this work as anecdotal 
data collected when challenging eTolB to bind eTolA3 immobilised on CM5 
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chip indicated that eTolB binds with equal affinity to both reference and 
protein channel (Dr Anne-Marie Krachler, personal communication). 
Therefore, a C1 chip was chosen for this work, as it only presents single 
carboxyl groups on its surface for immobilisation chemistry. 
 
 
Figure 3.10 Schematic diagram of E.coli TolA/TolB SPR experimental 
setup. TolA (dark green) is immobilized onto C1 SPR chip and challenged 
with wild type TolB and Δ34 TolB mutant (that lacks the disordered N-
terminus, shown here in light green). 
 
Once immobilised on C1 chip, eTolA23 was challenged with increasing 
concentrations of wild type eTolB and Δ34 eTolB (lacking N-terminal strand) 
as well as ePal, and eTolB in pre-made complex with ePal. Work previously 
published reported an affinity of ~40 μM for wild type eTolB – eTolA3 
interaction via ITC. No binding was detected for either Δ34 eTolB, ePal, or 
ePal-eTolB complex (Bonsor et al. 2009). 
 
3.2.2.1 E.coli TolA was successfully immobilised on a C1 SPR chip. 
 
To challenge E.coli TolA domain binding via SPR, eTolA23 (pAK123) was 
immobilised onto a C1 chip. Briefly, C1 SPR was prepared and activated to 
thiol-couple eTolA23 to the chip (see appendix section 7.5 for details). 
Subsequently, any non-coupled (but active) groups were blocked with free 
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cysteine, and the immobilised eTolA23’s binding efficiency was challenged 
with a test injection of eTolB (figure 3.11). The reference channel was also 
prepared by an identical protocol, with the exception that no protein was 
applied, and all activated groups on reference channel were blocked with 
free cysteine. See section 2.3.21 for full details of SPR chip immobilisation 
method. Typically 300 Response Units’s (RU) of eTolA23 was immoblised 
on C1 chip. 
 
 
Figure 3.11 Immobilisation of eTolA23 on C1 SPR chip. (1) Application of 
0.1M glycine pH 12 with 0.3 % triton X-100. (2) Application of EDC:NHS. (3) 
Application of Ethylenediamine. (4) Application of Sulfo-GMBS. (5) 
Application of eTolA23 (~2000 RU’s). (6) Cysteine block step. (7) 100 μM 
Test eTolB injection. (8) 6M GnHCl unfolding/regeneration. (9) Final (stable) 
immobilised eTolA23 (~300 RU’s). 
 
3.2.2.2 The dependence of the E.coli TolA/TolB interaction on the N-
terminus of TolB is confirmed by Surface Plasmon Resonance. 
 
Having successfully immobilised eTolA23 onto C1 chip, and the integrity of 
the chip verified via test injections of eTolB, immobilised eTolA23 was 
challenged with both wild type eTolB, and Δ34 eTolB mutant, which lacks the 
N-terminal 12 amino acids (figure 3.10) under equilibrium conditions. 
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Increasing concentrations of appropriate eTolB from 1-150 μM were titrated 
against the immobilised eTolA23 (as well as simultaneous titrations against 
reference channel), monitoring for change in response units of chip (an 
increase in response units is indicative of a protein complex forming between 
eTolA23 and titrated protein). Following the binding/unbinding event, any 
tightly bound protein complex that formed was dissociated by unfolding the 
proteins with 6 M GnHCl. Once unbound, titrated protein had been washed 
away, immobilised protein was refolded in running buffer (50 mM Hepes, 50 
mM NaCl, pH 7.5, 0.02% P20 detergent). Periodic test injections of 100 μM 
eTolB were also titrated against chip in order to verify the condition of 
eTolA23, to ensure that 6 M GnHCl step did not cause permanent 
denaturation of protein. Average refolding efficiency of eTolA23 over each 
titration data set (full titration of 1-150 μM) was greater than 95%. Results for 
both wild type and mutant eTolB titrations are shown in figures 3.12 and 
3.13. 
 
Figure 3.12 SPR sensorgrams of eTolA23 association/dissociation with 
wild type eTolB and Δ34 eTolB mutant. (1) Association phase, (2) 
Dissociation phase. Black sensorgram indicates change in response units for 
association and dissociation of wild type eTolB with immobilised eTolA23. 
1 
2 
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Shape of sensorgram is indicative of fast on, slow off binding of a weak 
protein complex with 1:1 (Langmuir) binding (Schuck 1997). Red 
sensorgram indicates no binding between eTolA23 and Δ34 eTolB mutant as 
it lacks characteristic association/dissociation phases present in black 
sensorgram. Both eTolB variants at 150 μM in 50 mM Hepes, 50 mM NaCl, 
pH 7.5, 0.02% P20 detergent, flow rate 10 μl/min, temperature: 20° C. 
 
Figure 3.13 SPR titration sensorgrams of eTolA23 association and 
dissociation with various concentrations of wild type eTolB and Δ34 
eTolB mutant. Black sensorgrams indicate change in response units for 
association and dissociation of wild type eTolB with immobilised eTolA23 
with increasing eTolB concentration, from 1-150 μM. Red sensorgram for 
eTolA23 and Δ34 eTolB indicates no detectable binding compared to wild 
type eTolB (black sensorgram) in identical conditions. Conditions: 50 mM 
Hepes, 50 mM NaCl, pH 7.5, 0.02% P20 detergent, flow rate 10 μl/min, 
temperature: 20°C. Protein injected for 300 s, followed by dissociation for 
600 s. Chip surface regenerated with 6 M Guanidine-HCl for 60s following 
each titration.  
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As seen in figure 3.12, black trace of 150 μM eTolB titrated against eTolA3 
shows characteristic association/dissocation shape displayed when protein 
binding occurs and is detected by SPR (Schuck 1997). In addition, as shown 
in figure 3.13, with increasing concentration of eTolB (from 0-150 μM), there 
is a progressive increase in response units. Saturation is reached by 150 
μM. Conversely, at equivalent concentrations of Δ34 eTolB mutant (red 
trace), no increase in response units is correlated to increase in eTolB 
concentration.  
 
This data confirm ITC experiments that the N-terminus of eTolB is important 
for eTolB to interact with eTolA. This titration was then fitted using single site 
binding model (Biacore) to calculate dissociation constant (figure 3.14), 
which was estimated as 10 μM (± 2 μM, calculated from 6 replicate 
experiments). This was in agreement with dissociation constant for eTolA3-
eTolB as estimated from ITC data was 40 μM (Bonsor et al. 2009). These 
SPR data confirmed not only the importance of the N-terminus of eTolB, but 
also that the eTolA-eTolB is a weak interaction in vitro. It should be noted 
that during dissociation phase, sensorgram does not return to zero RU’s, 
and as such it is not possible to analyse this data in terms of kinetics of 
eTolA23-eTolB interaction. Increase or decrease of flow rate did not improve 
quality of sensorgrams.  
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Figure 3.14 SPR titration data of eTolA23 association with various 
concentrations of wild type eTolB at maximal response. Maximal 
response is measured for each eTolB (wild type) concentration and plotted 
against appropriate concentration. Saturation of the TolA23 appears to be 
achieved, as higher TolB concentration response units plateau. When fitted 
single site binding model (Biacore) data yields calculated Kd of 10 μM ± 2 
μM. 
3.2.2.3 No binding is detected in vitro between E.coli TolA and E.coli 
Pal by surface plasmon resonance. 
 
Having confirmed the importance of N-terminus of eTolB in it’s interaction 
with eTolA, the next step was to investigate the ability of ePal to bind eTolA 
in vitro. Although is was previously reported that eTolA interacted with ePal 
(Cascales et al. 2000), this finding has been disputed as no complex was 
found between these two proteins by formaldehyde crosslinking, ITC or NMR 
(Bonsor et al. 2009). Using the same experimental setup as that 
investigating the interactions between eTolA and eTolB, immobilised 
Chapter 3 
   
98 
eTolA23 was titrated against with ePal (from 0-150 μM, figure 3.14). As can 
be seen in figure 3.15, no increase in response units was detected when 
titrated against with ePal, indicating no complex between eTolA23 and ePal 
was formed. Validity of eTolA23 binding was verified during experimental 
timeline with periodic 100 μM eTolB test injections onto chip to confirm the 
ability of immobilised eTolA23 to bind eTolB (data not shown).  
 
 
Figure 3.15 E.coli TolA23 immobilised on C1 SPR chip does not interact 
with E.coli Pal. Black sensorgrams indicate ePal at concentrations from 1-
150 μM. Blue sensorgram indicates 1 μM titration, red indicates 150 μM 
titration. Conditions: 50 mM Hepes, 50 mM NaCl, pH 7.5, 0.02% P20 
detergent, flow rate 10 μl/min, temperature: 20 °C. Protein injected for 300 s, 
followed by dissociation for 600 s. Chip surface regenerated with 6 M 
Guanidine-HCl for 60s following each titration.  
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3.2.2.4 E.coli Pal influences the interaction of E.coli TolB with E.coli 
TolA 
 
Work published by Bonsor et al. in 2009 suggested that the binding of E.coli 
Pal to E.coli TolB acted as an allosteric switch by driving the N-terminus of 
TolB from a disordered to an ordered state, and thus mediating it’s 
interaction with TolA3. SPR titration experiments against immobilised 
eTolA23 were conducted, investigating the effect of ePal on the eTolA-eTolB 
interaction. Using the same experimental setup as that investigating the 
interactions between eTolA and eTolB, immobilised eTolA23 was titrated 
against with a pre-made complex of eTolB-ePal (from 1-150 μM of eTolB, 
with 1.1:1 ePal:eTolB molar ratio to ensure no free eTolB was available in 
solution). As can be seen in figure 3.16, no increase in response units was 
detected when titrated against with ePal, indicating no complex between 
eTolA23 and eTolB-ePal complex was formed. Validity of eTolA23 binding 
was verified during experimental timeline with periodic 100 μM eTolB test 
injections onto chip to confirm the ability of immobilised eTolA23 to bind 
eTolB (data not shown). 
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Figure 3.16 E.coli TolA23 immobilised on C1 SPR chip does not interact 
with E.coli TolB in pre-made complex with Pal. Black sensorgrams 
indicate no binding between eTolA23 and eTolB-ePal complex at 
concentrations from 1-150 μM. Blue sensorgram indicates 1 μM titration, red 
indicates 150 μM titration. Conditions: 50mM Hepes, 50mM NaCl, pH 7.5, 
0.02% P20 detergent, flow rate 10μl/min, temperature: 20 °C. Protein 
injected for 300s, followed by dissociation for 600s. Chip surface 
regenerated with 6M Guanidine-HCl for 60s following each titration.  
 
3.3 Complementing E.coli TolB with E.coli TolA to drive colicin E9 
uptake. 
 
As shown in previous sections (3.2.2.2), as well as in the work of Bonsor et 
al (2009), the N-terminus of eTolB is required for its interaction with eTolA 
and that it must be in the disordered state to be available for binding. In 
addition, colicin E9 requires TolB to translocate across the outer membrane 
and into the cell. This is achieved through the binding of the E9 translocation 
domain (T-domain) in the beta-propellor domain of TolB, in a similar way to 
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Pal. However, whereas Pal binding TolB prevents TolA binding, T-domain 
binding to TolB promotes disorder in the N-terminus, thus promoting TolA 
binding (Bonsor et al. 2009). Some other colicins however, do not require 
TolB for translocation. colicin N is known to be solely dependent on eTolA to 
drive it’s uptake and ultimately it’s ability to kill invaded cells (Hecht et al. 
2009). Colicin A, is dependent on both eTolA and eTolB (Gokce et al. 2000) 
and has separate eTolA and eTolB binding epitopes. Although both colicin N 
and A interact with TolA3 in a TolB-independent manner, they do not share a 
common binding site. The colicins interact with TolA3 on opposite faces of 
the protein. The colicin N binding face is shared with bacteriophage g3p 
(figure 3.17) (Hecht et al. 2010; Li et al. 2012). 
 
The work reported in this section tested a series of hypotheses. Firstly I set 
out to determine if the sequence from TolB’s N-terminus known to be 
required for the interaction with eTolA could drive an in vitro interaction with 
proteins known to not directly interact with eTolA, such as colicin E9. The 
second objective was to determine if this sequence was required to be 
extremely N-terminal, as it is on E.coli TolB, or if location was not relevant. 
The final aim was to determine that providing an interaction was found in 
vitro, if colicin E9-TolB fusion proteins were capable of killing cells in vivo. 
This would prove that by bypassing TolB and interacting with TolA directly, 
TolA is capable of directly and independently driving the translocation of the 
colicin into the cell. 
 
Three cloning strategies (figure 3.18) were devised; the first clone would 
replace the eTolB binding epitope of colicin E9 with the sequence known to 
interact with eTolA3 from the N-terminus of eTolB (sequence: 
EVRIVIDSGVDS); the second construct would replace the OmpF binding 
site 1 with the sequence known to interact with eTolA3 from the N-terminus 
of eTolB, and the eTolB binding epitope would be disrupted; the third 
construct would replace the OmpF binding site 1 with the sequence known to 
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interact with eTolA3 from the N-terminus of eTolB, as well as maintaining the 
eTolB binding epitope. These genes would then be expressed and proteins 
purified. To determine if the eTolA3 binding epitope for the N-terminus of 
eTolB is sufficient create a novel interaction between eTolA3 and the ColE9-
eTolB fusion proteins, the eTolA3 and eTolB in vitro binding was probed via 
ITC, and secondly, these fusion proteins were challenged with in vivo cell 
killing assays, to determine if the interaction with eTolA3 is sufficient to drive 
entry of the colicin E9 into the cell, thus killing the cell. 
 
A      B 
  
Figure 3.17 Colicin A and bacteriophage g3p bind on opposite sides of 
E.coli TolA domain 3. (A) Crystal structure of colicin A (residues 53-107, 
red) in complex with domain 3 (residues 302-421, green) of E.coli TolA. PBD 
ID: 3QDR (Li et al. 2012). (B) Crystal structure of bacteriophage g3p (1-86, 
blue), in complex with domain 3 (residues 295-421) of E.coli TolA. PDB ID: 
1TOL (Lubkowski et al. 1999). 
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Figure 3.18 Summary of colicin E9-E.coli TolB fusion protein 
constructs. Wild type is as encoded by pCS4 construct. Residues 1-83 
contain OmpF binding site 1 (OBS1), TolB binding site, and OmpF binding 
site 2 (OBS2). EC7 fusion (pEC7 construct) consists of E.coli TolA binding 
epitope from disordered N-terminus of E.coli TolB replacing the colicin E9 
TolB binding epitope. EC8 fusion (pEC8 construct) consists of E.coli TolA 
binding epitope from disordered N-terminus of E.coli TolB replacing the 
OBS1, and TolB binding site being knocked out by mutating 3 key residues; 
D35A S37A, W39A (Garinot-Schneider et al. 1997). EC12 fusion (pEC12) 
consists of E.coli TolA binding epitope from disordered N-terminus of E.coli 
TolB replacing the OBS1, with TolB binding epitope being maintained.  
 
3.3.1 Purification of colicin E9-TolB fusion proteins 
 
Colicin E9-TolB mutants (pEC7, pEC8, pEC12 constructs) were purified as 
described in section 2.3.5-2.3.6. Briefly, BL21 (DE3) cells were transformed 
with relevant plasmid and grown up in 4.8L LB media for purification. 
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Example purification (EC12 fusion protein) is displayed in figure 3.19. Other 
purified fusion proteins shown in figure 3.20. Typical yield for each protein 
was 50 mg/ml. Purified protein mass was confirmed by electrospray 
ionisation mass spectrometry (ABI Qstar instrument). 
 
 
Figure 3.19 Purification of colicin E9-TolB fusion EC12 (pEC12 
construct) (A) 280nm Absorbance profile from Ni-NTA affinity 
chromatography. Protein (indicated by arrow) eluted with 6 M GnHCl step 
elution (red). (B) Gel-filtration of EC12 fusion on Superdex 200 26/60 
column. EC12 eluted between 175 and 200 ml. (C) 13% SDS-PAGE gel of 
pure pooled colicin E9 mutant EC12 following S200 gel filtration.  
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Figure 3.20 Purity of colicin E9-TolB fusion proteins. (A) Fusion protein 
EC7 (pEC7 construct: OBS1-TolA site-OBS2). (B) Fusion protein EC8 (pEC8 
construct: (TolA site-ΔTolB-OBS2). Analysed on 13% SDS-PAGE gels 
stained with coomassie blue.  
 
3.3.2 The E.coli TolA binding epitope of E.coli TolB is sufficient for the 
in vitro interaction between colicin E9-TolB fusion proteins and E.coli 
TolA domain 3.  
 
To determine if ColE9-TolB fusion proteins were capable of interacting with 
eTolA3, and if the location of the binding epitope had any impact on the 
binding affinity, ITC titration data were collected for each fusion titrated with 
eTolA3 and eTolB (figure 3.21, table 3.2), in the absence of calcium ions 
(Loftus 2006). 
 
Low heats of binding were detected, and a Kd of 14 (±4) μM, 39 (±9) μM and 
37 (±7) μM for fusions EC7, EC8 and EC12 when titrated against with 
eTolA3 were calculated (figure 3.21 A, B, C, respectively). These are 
comparable numbers as obtained for native eTolA3-eTolB ITC data (43 ± 2 
μM, Figure 3.20E and (Bonsor et al. 2009) and SPR data reported above (10 
μM) (section 3.2.2.2). As binding isotherms (figures 3.21 A, B, C, E) are not 
of the typical sigmoidal shape (figure 3.4), there is potential for error in the 
ΔH and stoichiometry estimations. It is interesting to note that the location of 
the TolA binding epitope appears to be relatively unimportant, given that 
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both orderings of the disordered T-domain yielded similar thermodynamic 
data. The fusion proteins had differing thermodynamics to that of the native 
TolB interaction, most likely due to the fusion already being in disordered 
confirmation, whereas the TolB N-terminus is likely in a state of dynamic 
equilibrium between ordered and disordered state. Additionally, when EC12 
fusion was titrated against eTolB (figure 3.21, D), the Kd was calculated as 
450 nM, which is again similar to the published values (~1 μM in the 
absence of Ca2+ ions) for wild type eTolB with colicin E9 as measured by ITC 
(Loftus 2006).  
 
Components titrated against 
eTolA3 
∆H (kcal 
mol-1) 
∆S (cal 
K-1 mol-1) 
N Kd (µM) 
 
(A) EC7 fusion protein 
(OBS1-TolA site-OBS2) 
 
 
- 0.88 (± 
0.01) 
 
+ 19.3 
(±0.14) 
 
1.12 
(±0.09) 
 
14 (±4) 
(B) EC8 fusion protein 
(TolA site-ΔTolB-OBS2) 
 
- 1.57 
(±0.02) 
+ 14.9 (± 
0.08) 
1.40 
(±0.08) 
39 (±9) 
(C) EC12 fusion protein 
(TolA site-WT TolB site-OBS2) 
 
- 1.42 (± 
0.03) 
+ 15.5 (± 
0.12) 
1.39 
(± 0.2) 
37 (±7) 
(D) Control: eTolB titrated against 
EC12 
 
- 7.13 (± 
0.01) 
+ 5.1 (± 
0.05) 
1.21 
(±0.01) 
0.45 
(±0.01) 
(E) eTolB (Bonsor 2009) + 2.92 
(±0.02) 
+ 30.0 
(±0.1) 
1.00 
(±0.03) 
43 (±2) 
 
Table 3.2 Comparision of eTolB-ColE9 fusion/wild type eTolB protein 
affinities for eTolA3. 
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A B 
  
C D 
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E 
 
Figure 3.21 ITC data for E.coli TolA domain interaction with colicin E9-
TolB fusion proteins. (A) eTolA3 (800 μM) titrated in 19 2 μl into colicin E9-
TolB fusion protein EC7 (40 μM). Kd determined as 14 μM. (Peak 
integrations adjusted for noise, NDH +0.4). (B) eTolA3 (800 μM) titrated in 
into colicin E9-TolB fusion protein EC8 (40 μM).) Kd determined as 39 μM. 
(Peak integrations adjusted for noise, NDH +0.2). (C) eTolA3 (800 μM) 
titrated in into colicin E9-TolB fusion protein EC12 (40 μM).) Kd determined 
as 37 μM. (Peak integrations adjusted for noise, NDH +0.2). (D) eTolB (200 
μM) titrated into colicin E9-TolB fusion protein EC12 (20 μM). Kd determined 
as 450 nM. (Peak integrations adjusted for noise, NDH +0.2). (E) 1.3 mM 
eTolA3 titrated in 34 x 8 μl injections into 60 μM of wild type eTolB. Kd 
determined as 43 μM. Titrations conducted at 20 °C with 240 s spacing (270 
s spacing for (E)) between each injection of eTolA3 (Bonsor 2009). Proteins 
dialysed in 50 mM Hepes, 50 mM NaCl, pH 7.5 prior to experiment. Data 
fitted to single site binding model using Origin 8.0 (Microcal/GE Healthcare). 
 
 
Chapter 3 
   
109 
 
 
3.3.3. Colicin E9-TolB fusion proteins cannot kill E.coli cells without the 
presence of the E.coli TolB binding epitope.  
 
To determine if the TolA binding epitope from TolB is sufficient to for the 
entry of colicin E9 into E.coli cells, cell-killing assays were performed (see 
section 2.3.25 for details). JM83 cells were challenged with various 
concentrations of both wild type colicin E9 and colicin E9-TolB fusion 
proteins. If cells died (creating a zone of clearance) this would mean that 
colicin E9-TolB fusions interacted with eTolA in vivo thereby bypassing 
periplasmic TolB and driving translocation of the colicin into the cell. 
 
As shown in figure 3.22, fusion proteins EC7 and EC8 did not kill cells, even 
at very high concentrations (160 μM). EC12 fusion protein does kill, 
however, killing is severely attenuated. This attenuated killing is due to the 
OmpF binding site being replaced with TolA binding epitope. This attenuated 
phenotype has been previously reported by Housden et al (Housden et al. 
2005), whereby colicin E9 lacking the first OmpF binding site could not bind 
OmpF at the outer membrane as efficiently as wild type, and therefore had 
reduced cell killing ability (although killing was not abolished completely). As 
neither EC7 or EC8 kills cells, whereas EC12 does, this indicates that colicin 
E9 remains dependent on eTolB for translocation, and ultimately cell killing, 
and that eTolA is not sufficient to drive translocation.  
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Figure 3.22 In vivo cell killing assay testing ability of colicin E9-TolB 
fusion proteins ability to kill JM83 cells. 2 μl wild type colicin E9 (WT) or 
colicin E9-TolB fusion proteins were spotted onto JM83 top agar plates in the 
following concentrations; 1) 160 μM 2) 30 μM 3) 6 μM 4) 1.2 μM 5) 250nM 6) 
50nM. Fusion proteins EC7 and EC8 do not kill, even at high concentrations 
(160 μM). Fusion protein EC12 does have partial killing activity at 
concentrations down to 50 nM. 
 
3.4 Discussion 
 
3.4.1 The E.coli TolA-TolB-Pal interaction 
 
Previously published work (Bonsor et al. 2009) had suggested that not only 
did E.coli TolB interact with TolA domain 3 via it’s intrinsically disorder N-
terminus, but that the binding of E.coli Pal to TolB mediated the equilibrium 
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position for the N-terminus. NMR data suggested that when bound E.coli 
TolB was bound to Pal the N-terminus moved from a dynamic position 
between disordered and ordered state, to a state of order (bound back 
position) that prevented TolA domain 3 from binding. This work also 
suggested that when the translocation domain of colicin E9 bound TolB (in a 
common binding site to that of Pal), the N-terminus moved into a state of 
disorder, and thus promoted the interaction between TolB and TolA. Finally, 
contradictory to work published regarding a potential interaction between 
E.coli TolA and Pal (Cascales et al. 2000), no evidence of an interaction 
between these two proteins was found in work published by Bonsor et al. To 
independently validate the dependence of the E.coli TolA-TolB interaction’s 
dependence on the N-terminus, as well as determining if Pal interacts with 
eTolA3 in a manner not detectable through ITC and the effect of Pal on 
TolB’s ability to bind TolA3, SPR experiments were performed. 
 
Having successfully immobilised a mutant of E.coli TolA23 on a C1 SPR 
chip, this TolA was challenged with 3 potential binding partners; TolB alone, 
Pal alone and TolB in complex with Pal. In agreement with work published 
by Bonsor et al., TolB was found to bind TolA, and a Kd of ~10 μM was 
calculated. This value is similar to the value determined by ITC (~40 μM) 
(Bonsor et al. 2009). In addition, and again in agreement to the work of 
Bonsor et al., not only was no binding detected by SPR for either TolA 
titrated against with Pal, and also TolB in complex with Pal. Given that these 
data that show that TolB cannot bind TolA when in complex with Pal again 
confirms the role that Pal plays controlling the ablity of TolB to bind TolA 
(Bonsor et al. 2009).  
 
This work, and the work of Bonsor et al., disagrees with work by Cascales et 
al. (Cascales et al. 2000 and Cascales et al. 2002) suggesting an interaction 
between TolA and Pal. In addition, yeast 2 hybrid experiments published by 
Walburger et al. (Walburger et al. 2002) did not find any interaction between 
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TolA and Pal. However, as the work by Cascales et al. also detected a 
complex between TolA and Pal in vivo by coimmunoprecipitation of 
crosslinked TolA and Pal. It is therefore possible that the E.coli TolA-Pal 
interaction is dependent on the proton motive force, which is not present in 
the in vitro work presented in this thesis. Cascales et al. suggest that the 
TolA-Pal interaction is indeed PMF dependent, and that it can be abolished 
with carbonyl cyanide m-chlorophenylhydrazone (CCCP). Alternatively, as 
the coimmunoprecipitation was performed in vivo with chemical crosslinking, 
it is possible that a terniary complex between TolA-TolB and Pal was 
captured. However, in their work published in 2000, Cascales et al. also 
state that they can detect a TolA-Pal complex in vitro, something that both 
the work by Walburger et al., Bonsor et al. and this work, do not. Given the 
work previously published in this area (chemical crosslinking, ITC and NMR), 
as well as the results from this work obtained through SPR, and given the 
limitations of the experimental techniques of work by Cascales et al., it must 
therefore be concluded that there is no interaction between E.coli TolA and 
Pal, in vitro. 
 
3.4.2 Creating novel E.coli TolA domain 3 interactions with colicin E9-
TolB fusion proteins 
 
Having confirmed that the E.coli TolA-TolB interaction is dependent on the 
N-terminus of TolB, I next set out to investigate whether or not this short 12 
residue sequence known to bind E.coli TolA domain 3 was sufficient to 
generate a novel interaction with TolA domain 3 to a protein that it does not 
normally bind (in this case, colicin E9). The aim of this work was two-fold; 
firstly to determine if in vitro the E.coli TolB N-terminal sequence could drive 
a de novo interaction between proteins that would not normally interact. 
Secondly, it was to deterimine if these proteins (E.coli TolA and colicin E9) 
could interact, and if this interaction was sufficient to bypass E.coli TolB and 
drive translocation of colicin E9 into the cell and cause cell killing, in vivo. 
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Using E.coli TolA as the sole translocation mechanism for colicin entry into 
the cell has been reported for colicin N, which does not bind E.coli TolB 
(Gokce et al. 2000). Bacteriophage g3p entry protein has also been reported 
to be solely dependent on TolA for entry into the cell, and thus ultimately 
causing cell death. In addition, colicin A is also dependent on TolA for cell 
killing, however it is also dependent on TolB, although the interaction 
between Col A and TolA is not dependent on TolB, unlike colicin E9, which 
requires an interaction with TolB to drive an interaction with TolA to allow 
translocation into the cell, and cause cell death (Hecht et al. 2010).  
 
Through in vitro ITC experiments it was confirmed that the novel colicin E9-
TolB fusion proteins could interact with E.coli TolA3, and that the interactions 
were similar to that of wild type eTolB-eTolA3 (40 μM), with Kd calculated as 
between 14-39 μM. In addition, not only does it appear as though the 12 
residues in isolation from the N-terminus of eTolB are sufficient to create an 
interaction with eTolA3 in vitro, but it is also not necessary for the eTolA3 
binding epitope to be N-terminal, as it is in eTolB. Whether or not the eTolA3 
binding epitope must be within a disordered region of a protein (as is the 
case of eTolB and these colicin E9-eTolB fusions) or if it could be presented 
as part of a structured domain is unknown. 
 
The in vivo cell killing results however suggested that colicin E9 requires the 
presence of TolB to translocate across the outer membrane, periplasm and 
inner membrane to kill cells through its DNase activity. Fusion proteins EC7 
and EC8 which do not contain the TolB binding epitope, could not kill cells in 
vivo, despite being able to bind E.coli TolA3 in vitro. Fusion protein EC12 
could interact with both E.coli TolA3 and TolB, and this was the only fusion 
protein that could kill cells. Thus it would seem as though E.coli TolA3 is 
insufficient to drive colicin E9 translocation. Although fusion protein EC12 did 
kill cells, its killing was reduced due to the replacement of the OmpF binding 
site 1 with TolA binding site. It has been previously reported that when either 
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of the OmpF binding sites are replaced, colicin E9 can still kill cells, but at 
lower efficiency (due to the reduced efficiency at which colicin E9 can 
translocate across the outer membrane) (Housden et al. 2005).  
 
If fusions EC7 and EC8 which lack the ability to bind TolB, but retain the 
ability to bind TolA3 cannot translocate across the membrane, it may be a 
case of polypeptide length, whereby the T-domain of ColE9-TolB fusions is 
not long enough to reach TolA at the inner membrane, and therefore cannot 
translocate. As estimates put the width of the periplasmic space at between 
100-150 Å (Collins et al. 2007), the disordered N-terminus of the colicin E9 
translocation domain may be of insufficient length, or it may not be able to 
penetrate the peptidoglycan layer to reach TolA at the inner membrane. 
However, TolA is reported to interact with Pal and major outer membrane 
porins, and is also the sole Tol protein required for the translocation of some 
other colicins (colicin N and A are reported to interact directly with TolA 
domain 3, and TolA drives their entry into the cell) (Cascales et al. 2007). 
Therefore it is unlikely that ColE9-TolB fusions are unable to reach TolA, 
unless colicin’s N and A have a specific method of penetrating the PG layer, 
something that the colicin E9 fusions are not capable of, especially as the T-
domain of colicin N is of similar total length (90 residues) (Hecht et al. 2010) 
as the fusion protein T-domains. 
 
Alternatively, it is possible that the colicin E9 is capable of binding TolA in 
vivo, however, the interaction is insufficient to drive translocation. However, 
this would seem to be unlikely, as the in vitro affinity for TolA determined by 
ITC was similar for fusion proteins as for the wild type TolA-TolB. In addition, 
translocation of wild type colicin E9 across the outer membrane is dependent 
on both TolA and TolB. Thus, as fusion protein-TolA is of similar affinity to 
TolB-TolA, this should be sufficient to drive the translocation of the colicin 
across the outer membrane.  
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3.4.3 Summary 
 
The work reported in this chapter has confirmed the importance of the N-
terminus of E.coli TolB for its interaction with E.coli TolA domain 3, and, as 
previously reported (Bonsor et al. 2009), no interaction occurs between 
E.coli Pal and TolA domain 3. In addition, by SPR it has been shown that the 
binding of E.coli Pal to TolB controls the ability of TolB to bind TolA. This is 
likely through mediation of order/disorder equilibrium of eTolB’s N-terminus 
that allows TolA3 to bind when in the disordered (Pal not bound) state, and 
prevents TolA3 binding when in the ordered (Pal bound state) (Bonsor et al. 
2009). This work has also shown that the 12 residues of the N-terminus of 
eTolB known to interact with eTolA3 are sufficient, when engineered onto a 
protein that does not usually interact with eTolA3, can create a novel 
interaction with an engineered colicin E9 fusion protein, in vitro. However, 
despite this novel interaction being of similar affinity to that of wild type 
eTolB-eTolA3, it is not sufficient to drive the entry of a novel colicin E9 fusion 
into the cell in the absence of TolB.  
 
 
 
 
 
Chapter 4 
   
116 
 
4. The Gram-negative TolA-TolB complex 
 
4.1 Introduction  
 
In the previous chapter it was shown that the 12 residues of the N-terminus 
of E.coli TolB are the sole determining factor in it’s interaction with E.coli 
TolA domain 3 and that when engineered onto a protein that does not 
normally interact with E.coli TolA3, it is sufficient to bind TolA3 with similar 
affinity to the native interaction. The aim of the work in this chapter was two-
fold; (1) to determine if a synthetic peptide, corresponding to the sequence of 
the N-terminus of E.coli TolB could, in isolation, interact with E.coli TolA 
domain 3, and (2), if the TolA3-TolB interaction of Pseudomonas aeruginosa 
was conserved. The work in this work aimed to characterise the 
Pseudomonas aeruginosa TolA and TolB interaction, and determine if, like 
their E.coli counterparts, the interaction is dependent on the 12 residues at 
the extreme N-terminus of the TolB. Due to the failure previous attempts with 
protein crystallography to determine the E.coli TolA-TolB complex it was 
hoped that either a complex of the synthetic peptide with E.coli TolA3 or the 
Pseudomonas aeruginosa proteins would be more amenable to complex 
formation, and thus not only determine the site of TolB’s interaction on TolA, 
but to finally obtain the structure of the TolA-TolB complex, something which 
has eluded researchers for several decades.  
 
4.2 The Gram-negative Tol complex 
 
The Tol family of proteins are highly conserved throughout most Gram-
negative bacteria (Sturgis 2001). The tol-oprL genes (OprL is the name for 
Pal in Pseudomonas aeruginosa) are organised into three operons, orf1-
tolQRA, tolB and oprL-orf2, the upstream of which is constituitive and the 
other two of which are under iron regulation. Pseudomonas aeruginosa 
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represents the only bacterium where the tol-oprL operons are known to be 
regulated by the ferric uptake regulator (Fur). In work characterising the orf1-
tolqra operon and investigated the function of Orf1 it was found that it was 
not possible to create tolq and tola knockout strains, and thus they are likely 
to be essential genes (tol genes are not essential in E.coli), A viable orf1 
knockout strain could also be created suggesting a non-essential function. 
This mutant exhibited altered cell and colony morphology (Duan et al. 2000, 
Wei et al. 2009), something that has also been seen in E.coli cells with ybgc 
knocked out (Krachler 2010). 
 
Structural information for some Gram-negative Tol proteins have been 
reported, including the crystal structure of Pseudomonas aeruginosa TolA 
domain 3 (Witty et al. 2002). When compared to the crystal structure 
reported for E.coli TolA domain 3 in complex with bacteriophage g3p 
(Lubkowski et al. 1999), the two structures share a near identical fold (figure 
4.1), with a root mean square fit of 1.5 Å over 69 equivalent atoms. Similarly, 
the recently published crystal structure of E.coli TolA domain 3 appears to 
share a similar fold, with a root mean square fit of 1.7 Å and 2.1 Å, for the 
crystal structure of TolA3-g3p and Pseudomonas aeruginosa TolA3, 
respectively (Li et al. 2012). This similarity in fold between E.coli and 
Pseudomonas aeruginosa TolA3 is despite the fact that they share only 20% 
sequence identity (Witty et al. 2002). When comparing the TolB sequences 
from E.coli and Pseudomonas aeruginosa, these two proteins share 
approximately 44% sequence identity. When comparing over 100 TolA and 
TolB proteins from a variety of Gram-negatives, most TolB’s share 
approximately 45% sequence identity between one another, whereas most 
TolA proteins share approximately 25% sequence identity. To the best of our 
knowledge, this is the first study of the Pseudomonas aeruginosa TolA-TolB 
system. The tol genes in Pseudomonas aeruginosa were first identified in 
1996 (Dennis et al. 1996), and in the same work it was reported that 
Pseudomonas aeruginosa Tol proteins were functionally unable to 
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complement E. coli tol mutants, although Pseudomonas aeruginosa TolQ 
was able to complement the iron-limited growth of an E. coli exbB mutant. 
 
Despite a published crystal structure little else is known about the interaction 
network of Pseudomonas aeruginosa TolA, or if it interacts with 
Pseudomonas aeruginosa TolB. Given that Tol proteins are conserved 
throughout most Gram-negative bacteria (Sturgis 2001), we could therefore 
hypothesize that the interaction between TolA and TolB is conserved, and 
based on homology between Gram-negative TolB’s, that the N-terminus of 
TolB is the site of interaction. Given the lack of success in determining the 
E.coli TolA-TolB complex structure, it was hoped that other Gram-negative 
bacterial Tol proteins would be more amenable to structural determination of 
the complex.    
 
Little is known about Pseudomonas aeruginosa TolB as no biophysical or 
structural data have been published for this protein. It is unknown if, like it’s 
E.coli homologue, it interacts with either Pseudomonas aeruginosa TolA or 
Pal, or if it is parasitised by Pseudomonas aeruginosa bacteriocins (Pyocins) 
to facilite their translocation, although this is likely as the introduction of 
tolqra genes in the tol-like mutant PAO 1652 (which does not display the tol 
phenotype of membrane instability, only that it makes the Pseudomonas 
aeruginosa cells tolerant to pyocins) restored pyocin AR41 killing (Dennis et 
al. 1996). Based on sequence identity with E.coli TolB, the Pseudomonas 
aeruginosa TolB is predicted to be arranged in a similar domain 
organisation; i.e. 2 domains including a C-terminal beta-propeller domain, 
and a second smaller domain that encodes an N-terminal signal peptide (at 
the same residue number as E.coli TolB, between alanine 21 and 22) that is 
cleaved to yield mature protein (Duan et al. 2000). In addition, when 
comparing the N-termini of Pseudomonas aeruginosa TolB to that of E.coli, it 
appears to follow a similar consensus pattern of hydrophobic residues (figure 
4.2).  
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Figure 4.1 Comparison of Pseudomonas aeruginosa and E.coli TolA 
domain 3’s. Overlay of E.coli TolA domain 3 (green), residues 302-421 
(PBD ID: 3QDP) (Li et al. 2012) with Pseudomonas aeruginosa TolA domain 
3 (red), residues 226-347 (PDB: 1LR0) (Witty et al. 2002).  
 
 
Figure 4.2 Alignment of N-termini of mature TolB from E.coli and 
Pseudomonas aeruginosa. Red represents conserved residues. 
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4.3 Aims 
 
The aim of the work in this chapter is to investigate the 12 residue N-terminal 
sequence from E.coli TolB as an isolated synthetic peptide to determine if it 
is capable of recaptitulating the interaction between E.coli TolA domain 3 
and TolB. In addition, this work aims to determine if, as previously 
hypothesised, that the TolA-TolB interaction is conserved in Gram-negative 
bacteria. To achieve these aims two approaches were adopted; a synthetic 
peptide was designed consisting of the E.coli TolA binding box, and through 
a series of in vitro crosslinking and ITC experiments, the peptide’s interaction 
with E.coli TolA domain 3 was characterised. Additionally, as previous 
attempts to determine the E.coli TolA-TolB complex had failed, attempts 
were made through crystallography and nuclear magnetic resonance 
spectroscopy to observe both E.coli TolA domain 3 alone and a complex of 
E.coli TolA binding peptide with TolA domain 3.  
 
Secondly, to investigate the TolA-TolB interaction found in other Gram-
negative bacteria, 2 organisms were chosen to target the Tol system; 
Pseudomonas aeruginosa and Xanthomonas campestris. Using 
bioinformatics analysis, predictions were made in the domain organisation of 
the TolA proteins and constructs were designed to encode both domain 3, 
and a small section of domain 2, identical to E.coli TolA constructs used in 
previous work (Bonsor 2009, Krachler 2010). Pseudomonas aeruginosa 
genes were expressed and proteins purifed (Xanthomonas campestris 
clones failed to express and thus was abandoned, and all work focused on 
Pseudomonas aeruginosa proteins). Having characterised the TolA proteins, 
Pseudomonas aeruginosa TolB constructs were generated. Once purified in 
vitro experiments using chemical crosslinking and ITC were performed to 
characterise any interaction between Pseudomonas aeruginosa TolA 
domain 3 and TolB. In parallel, a synthetic Pseudomonas aeruginosa TolA 
binding peptide was designed and used to probe the interaction between 
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Pseudomonas aeruginosa TolA and TolB. Finally, given the potentially 
conserved nature of the TolA-TolB interaction in Gram-negative bacteria, the 
specificity of the TolA-TolB interaction was probed to determine if any non-
cognate interactions occurred between E.coli and Pseudomonas aeruginosa 
Tol proteins.  
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4.2 Results 
 
4.2.1 Studies of the Pseudomonas aeruginosa TolA-TolB interaction 
 
4.2.1.1 Purification of tagless Pseudomonas aeruginosa TolA domain 3 
(pEC1 construct) and his-tagged Pseudomonas aeruginosa TolA 
domain 3 (pEC4 construct) 
 
Pseudomonas aeruginosa TolA (psTolA3) domain 3 (residues 226-347) was 
purified from BL21 (DE3) cells transformed with pEC1 or pEC4 and grown in 
4.8L of LB media. Proteins were purified as described in section 2.3.3/2.3.4, 
and steps of purification are shown in figure 4.2 (A and B) and figure 4.3. A 
typical protein yield of 1 mg/L of culture was obtained for pEC1 construct, 
and 2 mg/L for pEC4 construct. Electrospray mass spectrometry data 
indicated that proteins were of the expected size (table 4.1) 
 
4.2.1.2 Purification of C-terminal his-tagged Pseudomonas aeruginosa 
TolB (pEC14 construct) 
 
His-tagged Pseudomonas aeruginosa TolB (psTolB, residues 22-432) was 
purified from BL21 (DE3) cells transformed with pEC14, grown in 4.8L of LB 
media. Protein was purified as described in section 2.3.7, and steps of 
purification are shown in figure 4.4. A typical protein yield of 1.5 mg/L of 
culture was obtained. Electrospray mass spectrometry indicated that protein 
was of the expected size (table 4.1) 
 
Unfortunately psTolB is an unstable protein. As part of the purification 
procedure, on two occasions the entire protein preparation precipitated and 
was lost. The limit of solubility for this protein is approximately 50 μM. Even 
at concentrations below 50 μM the protein readily becomes insoluble. 
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Numerous buffer screens were tried to improve solubility, including the 
Optimum Solubility Screen (Jancarik et al. 2004), with little success. The 
buffer that the protein was most stable in is sodium phosphate, in a pH range 
of 7.5-9. This lack of solubilty has caused experimental problems, as will be 
addressed below.  
 
 
Figure 4.2A Purification of tagless psTolA3 (pEC1 construct) (A) 280nm 
absorbance profile from DE52 weak-anion exchange chromatography. 
Protein (indicated by arrow) eluted as part of non-binding flow through. (B) 
16% SDS-PAGE gel to verify presence of psTolA3 (indicated by arrow). (C) 
Strong anion exchange (MonoQ) chromatography purification step, as 
monitored at 280nm. 1M NaCl elution gradient applied (D) 16% SDS-PAGE 
gel to verify presence of psTolA3 (indicated by arrow). 
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Figure 4.2B Purification of tagless psTolA3 (pEC1 construct) (E) Gel-
filtration of psTolA3 on Superdex 75 26/60 column. psTolA3 eluted between 
170 and 200ml. (F) 16% SDS-PAGE gel to verify presence of psTolA3 
(indicated by arrow) (G) Second strong anion exchange (MonoQ) 
chromatography purification step, as monitored at 280nm. 1M NaCl elution 
gradient applied. (H) 16% SDS-PAGE gel to verify presence of pure psTolA3 
(indicated by arrow). 
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Figure 4.3 Purification of C-terminal his-tagged psTolA3 (pEC4 
construct) (A) 280nm Absorbance profile from Ni-NTA affinity 
chromatography. (B) denotes expanded view of elution peak. Protein 
(indicated by arrow) eluted with 0-500mM Imidazole elution over 10 column 
volumes. (C) Gel-filtration histogram of eTolA3 on Superdex 75 26/60 
column. psTolA eluted between 180 and 210 ml. (C) 16% SDS-PAGE gel to 
verify presence of psTolA3 in imidazole elution fraction (indicated by arrow). 
(D) 16% SDS-PAGE gel to verify presence of pure psTolA3 (indicated by 
arrow) after gel filtration.  
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Figure 4.4 Purification of his-tagged psTolB (pEC14 construct) (A) 
280nm Absorbance profile from Ni-NTA affinity chromatography. Protein 
(indicated by arrow) eluted with 500mM Imidazole step elution. (B) 13% 
SDS-PAGE gel to verify presence of psTolB (indicated by arrow). (C) Gel-
filtration of eTolA3 on Superdex 75 26/60 column. psTolB eluted between 
150 and 175 ml. (C) 13% SDS-PAGE gel to verify presence of pure psTolB 
(indicated by arrow). 
 
Protein Expected mass Observed mass 
psTolA3 (tagless, pEC1) 13430 Da 13433 (±9) Da 
psTolA3 (C-terminal 6x his-tag, 
pEC4) 
14495 Da 14492 (±5) Da 
psTolB (C-terminal 6x his-tag, 
pEC14) 
46459 Da 46454 (±8) Da 
 
Table 4.1 Expected vs observed masses of purified proteins 
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4.2.1.4 Pseudomonas aeruginosa TolA domain 3 and TolB proteins are 
folded. 
 
To ensure that not only were purified psTolA3 and psTolB proteins folded, 
but they also had similar secondary structure to their E.coli homologues, far 
UV (190-260 nm) circular dichroism spectra were collected for psTolA3 
(figure 4.5) and psTolB (figure 4.6) proteins, to be compared with CD spectra 
of respective E.coli proteins.  
 
CD spectra were subsequently deconvoluted with CDNN 2.1 (Applied 
Photophysics). CDNN analysis estimated that psTolA3 had 26% helical 
structure, 22% antiparallel, 10% parallel, 15% beta-turn and 29% random 
coil, compared to eTolA had 37% helical structure, 4% antiparallel, 9% 
parallel, 15% beta-turn and 38% random coil. psTolB has 21% helical 
structure, 29% antiparallel, 10% parallel, 15% beta-turn, and 33% random 
coil, compared with eTolB which was estimated to contain 12% helical 
structure, 29% antiparallel, 10% parallel, 15% beta-turn and 37% random 
coil. As these statistics are similar, it can be assumed that both psTolA3 and 
eTolA3 as well as psTolB and eTolB have a similar secondary structure.  
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Figure 4.5 Far UV circular dichroism spectra comparing Pseudomonas 
aeruginosa TolA3 variants (tagless and his-tagged) with E.coli TolA3. 
CD spectrum collected in 10mM Sodium phosphate, pH7 at 20 °C. psTolA3 
(pEC1 construct) is represented in blue, C-terminal his-tagged psTolA3 
(pEC4 construct) is represented in red and eTolA3 (pAK108) is represented 
in green. All proteins at 50 μM final concentration. 
 
Figure 4.6 Far-UV Circular dichroism spectra comparing Pseudomonas 
aeruginosa TolB with E.coli TolB. CD spectrum recorded in 10mM Sodium 
phosphate, pH7 at 20 °C. psTolA3 is represented in blue and eTolB is 
represented in red. All proteins at 50 μM final concentration. 
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4.2.1.5 Pseudomonas aeruginosa TolA domain 3 and Pseudomonas 
aeruginosa TolB interact in vitro 
  
To ascertain whether or not psTolA3 and psTolB interacted in vitro, a simple 
formaldehyde crosslinking experiment was performed (perfomed as 
described in section 2.3.15). psTolA3 and psTolB were incubated both 
together and in isolation (along with E.coli TolA3-TolB positive controls, data 
not shown), and once any complexes had been crosslinked with 
formaldehyde (see appendix section 7.9 for details on crosslinking reaction) 
and excess cross-linker quenched, the samples were loaded onto 13% SDS-
PAGE gels for analysis (figure 4.7). 
 
Figure 4.7 Formaldehyde crosslinking experiment showing interaction 
of psTolA3 and psTolB in vitro. Each protein at 10 μM (final) was 
incubated in presence of formaldehyde crosslinker (presence of crosslinker 
denoted by “+” symbol, “-“ indicates control sample with no crosslinker), as 
described in section 2.3.15. Following quenching of the reaction, samples 
were run out on 13% SDS-PAGE gels, which were subsequently stained 
with Coomassie blue. Crosslinking performed at pH8. 
 
As shown in figure 4.7, there is a band of approximately 60 kDa that 
corresponds to a complex between psTolA3 and psTolB, which is not 
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present in the samples corresponding to individual proteins alone. The band 
corresponding to psTolA3-psTolB was excised from the gel and analysed 
with MALDI mass spectrometry (University of York Technology Facility) to 
confirm presence of both psTolA3 and psTolB in the complex, both of which 
were found to be present. This confirmed that not only did psTolA and 
psTolB interact, but also, like in the E.coli proteins, it is the 3rd domain of 
TolA that is involved in the interaction with TolB.  
 
Having confirmed that psTolA3 crosslinks with psTolB to form a complex, as 
found with E.coli homologues, the next step was to obtain thermodynamic 
data for this interaction, and thus an equilibrium binding constant. However, 
psTolB is an unstable protein, and this proved to be problematic. All attempts 
to obtain thermodynamic data for the psTolA3-psTolB interaction through 
ITC have met with failure. The Pseudomonas proteins typically become 
insoluble during the titration. Numerous alternative buffers, as well as a 
range of protein concentrations, pH’s and temperatures were attempted to 
improve solubility and data quality, to no avail. Further alternative 
experiments were conducted (see section 4.2.3 below for details) in an 
attempt to address the issues with psTolB. 
 
4.2.2 Interactions between TolA domain 3 and TolB are specific  
 
In the previous chapter and section it has been shown that E.coli and 
Pseudomonas aeruginosa TolA domain 3 interact with TolB. To further 
investigate the nature of this TolA3-TolB interaction, and to determine if the 
interaction is specific to the cognate binding partners, or if any non-cognate 
complexes formed between these potential binding partners two in vitro 
experiments were performed. Firstly to capture any potential non-cognate 
complexes, formaldehyde crosslinking was employed, and secondly 
thermodynamic data were collected via ITC.  
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psTolA3-eTolB and eTolA3-psTolB were incubated together (pH range 6.5-
8.5, along with appropriate positive and negative controls), and once any 
complex had been captured by formaldehyde crosslinking and excess cross-
linker quenched, the samples were loaded onto 13% SDS-PAGE gels for 
analysis (figure 4.9).  
 
Despite crosslinks between cognate binding partners in positive controls, no 
non-cognate complex was found between either TolA3/TolB (figure 4.9), 
suggesting that the interaction between TolA3 and TolB is species specific. 
Although the disordered N-termini of TolB have a general consensus 
sequence between the E.coli and Pseudomonas aeruginosa proteins, this 
consensus is not sufficient to drive an interaction with TolA3.  
 
 
 
 
Figure 4.9 Formaldehyde crosslinking experiment attempting to 
capture non-cognate complex formation between E.coli and 
Pseudomonas aeruginosa TolA3/TolB, in vitro. Each protein at 10 μM 
(final) was incubated in presence of formaldehyde crosslinker (presence of 
crosslinker denoted by “+” symbol, “-“ indicates control sample with no 
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crosslinker), as described in section 2.3.15. Following quenching of the 
reaction, samples were analysed on 13% SDS-PAGE gels, which were 
subsequently Coomassie blue stained. Crosslinking performed in the 
presence of appropriate positive controls (not shown).  
 
To confirm these findings, ITC experiments were performed (at a range of 
pHs, from 6.5-8.5), titrating psTolA3 into eTolB. Due to the insoluble nature 
of psTolB, no titrations of eTolA3 into psTolB were attempted.  
 
Again, as found with crosslinking experiments, no heats of binding were 
detected between psTolA3 and eTolB, suggesting that no complex is formed 
between these 2 proteins. This again suggests that the TolA3-TolB 
interaction is specific. 
 
4.2.3. A synthetic peptide of the N-terminus of E.coli TolB can 
recapitulate the E.coli TolA/TolB interaction in vitro.  
 
It has been previously shown that the E.coli TolA-TolB interaction is 
dependent on the N-terminus of TolB, and that this N-terminus of E.coli TolB 
must be in a disordered conformation to bind eTolA3 (Bonsor et al. 2009). 
Furthermore, as reported in section 3.3.2, when the sequence known to be 
involved in eTolA3 binding is engineered onto a disordered region on an 
alternate protein, that the sequence alone is sufficient to bind eTolA3, in 
vitro. To investigate if this sequence in isolation was sufficient to interact with 
eTolA3 a disordered peptide of the sequence, EVRIVIDSGVDS was 
synthesised (peptides produced by either Activeotec, Cambridge, or 
Pepceuticals, Nottingham). A peptide of this sequence alone was insoluble, 
and so the sequence was modified with the addition of 4 extra residues. The 
final sequence of the peptide was EVRIVIDSGVDSWKKK. The red 
sequence originates from the disordered N-terminus of eTolB. Black 
residues denote additional sequence, of which the extra tryptophan residue 
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was used to aid quantification of the concentration of peptide and the 3 C-
terminal lysines were added are to maintain the solubility of the peptide.  
 
To determine if E.coli TolA3 can interact with E.coli TolA binding peptide, 
and to determine if the binding peptide interacts with E.coli TolA3 in the 
same binding site as E.coli TolB, a formaldehyde crosslinking competition 
assay was performed. Briefly, eTolA3 was incubated with both eTolB, and 
also increasing concentrations of eTABp. Any complex formed between 
these binding partners was crosslinked with formaldehyde, and analysed on 
13% SDS-PAGE gels (figure 4.10). 
 
As shown in figure 4.10, a complex formed between eTolA3 and eTolB (as 
expected), but also as the concentration of peptide is increased, the amount 
of eTolA3-eTolB complex decreases, indicating that eTABp is competing 
with eTolB for binding on eTolA3. This also indicates that eTABp and eTolB 
have the same binding site, and that eTABp interacts with eTolA3 in a 
specific manner. Despite this, it is a consideration that at higher contrations 
of peptide, the ratio of protein to peptide is in the order of 1:40, and thus it is 
possible that some non-specific binding event may occur. Having confirmed 
that E.coli TolA3 interacts with the binding peptide with formaldehyde 
crosslinking, this interaction was quantified with isothermal titration 
calorimetry (figure 4.11). 
 
As is shown in figure 4.11, there are heats indicating an interaction between 
eTABp and eTolA3. Following subtraction of heats of dilution, and fitting data 
to single site binding model (Origin 7.0, Microcal/GE Healthcare), a Kd of 
approximately 40 μM (± 7 μM from 5 replicates) was estimated. This figure 
was almost identical to that of the native eTolA3-eTolB interaction, although 
the thermodynamics are different. The thermodynamics of eTolB titrated with 
eTolA3 are +2.92 kcal mol-1 and +30 cal K-1 mol-1 compared with -2.71 kcal 
mol-1 and +11 cal K-1 mol-1 for eTABp titrated into eTolA3 (table 4.2). The 
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native eTolA3-eTolB interaction is endothermic and entropically driven as the 
N-terminus is (presumed) to be in a state of dynamic equilibrium between 
ordered and disordered state. Conversely, the eTolA3-eTABp interaction is 
exothermic and does not require energy as the peptide is already in a state 
of disorder and does not have to make the transition from ordered to 
disordered state. 
 
Components ∆H (kcal mol-1) ∆S (cal K-1 mol-1) N Kd (µM) 
 
eTolB-eTolA3  
 
+ 2.92 (±0.02) 
 
+ 30.0 (±0.1) 
 
1.00 (±0.03) 
 
43 (±2) 
 
eTolA3-eTABp 
 
- 2.71 (±0.04) 
 
+ 11 (±0.1) 
 
0.98 (±0.01) 
 
40 (±4) 
 
Table 4.2 Comparison of thermodynamics and affinities of eTolA3-
eTolB/eTABp complex formation 
 
Finally, the interaction between eTolA3 and eTABp was characterised in 
terms of temperature dependence. At 25°C Kd was determined as 70 μM (± 
6 μM), and at 30 °C Kd was 113 μM (± 9 μM),. Experiments performed using 
ITC200 instrument (Microcal/GE Healthcare) using Origin 8.0 software and 
single site binding model.  
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Figure 4.10 Formaldehyde crosslinking experiment showing 
competition of eTABp and eTolB for binding with eTolA3, in vitro, 
detected by Western blotting on 13% SDS-PAGE gels. (A) eTolA3 (10 
μM) incubated with eTolB (μM), detected with anti-TolA (E.coli) antibody. 
eTolA3 and eTolB complex is incubated both in the absence (no peptide 
lane) and increasing concentration of eTABp (from 10 μM to 400 μM) from 
left to right. Note the progressive loss of TolA3-TolB complex, with complete 
abolition of complex at 150 μM peptide concentration. (B) As (A) except anti-
TolB (E.coli) antibody used for detection. 
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Figure 4.11 ITC titration data for E.coli TolA domain 3 interaction with 
E.coli TolA binding peptide. A stock of 3mM eTABp was titrated in 34 8 μl 
injections against 220 μM eTolA3. Kd was estimated as 40 μM, with a 1:1 
stoichiometry of peptide:protein, ΔH of - 2.7 kcal mol-1 and ΔS 11.1 cal K-1 
mol-1. Data fitted to single site binding model using Origin 7.0 (Microcal/GE 
Healthcare). Titration conducted with VP ITC instrument (Microcal/GE 
Healthcare) at 20 °C with 270 s spacing between each injection of eTABp. 
Protein dialysed prior to experiment in 50 mM Hepes, 50 mM NaCl, pH 7.5. 
Peptide stock dissolved in same buffer. 
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4.2.4 Challenging the in vivo TolA-TolB interaction with the synthetic 
TolA binding peptide.  
 
To determine if the synthetic E.coli TolA binding peptide was capable of 
binding E.coli TolA domain 3 in vivo, it was hoped that the peptide would be 
transported across the outer membrane (Yeaman & Yount 2003, Housden et 
al. 2010) and interact with E.coli TolA, thus abolishing the TolA-TolB 
interaction through competition and causing the tol phenotype. JM83 cells 
were incubated in various conditions (in the presence or absence of 2% 
SDS, and either grown in the presence of peptide, or supplemented with 
peptide prior to plating on LB-Agar) and visually assessed (figure 4.12) for 
presence of Tol phenotype.  
 
 
Figure 4.12 Challenging E.coli JM83 cells with E.coli TolA binding 
peptide. JM83 cells grown to an OD600 of approx. 0.6, then incubated in the 
following conditions; allowed to continue growing for 1 hour at 37 °C then 
plated in triplicate on LB-Agar and LB-Agar supplemented with 2% SDS (top 
row), allowed to continue growing for 1 hour at 37 °C, 500 μM eTABp was 
added just prior to plating in triplicate on LB-Agar and LB-Agar 
supplemented with 2% SDS (middle row), 500 μM eTABp was added to 
cells, which were grown for a further hour at 37 °C, before being plated in 
triplicate on LB-Agar and LB-Agar supplemented with 2% SDS. 
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As shown in figure 4.14, in all conditions, no Tol phenoptype was detected. 
Due to the hydrophobic nature of the peptide, and lack of outer membrane 
porin recognition sequence it is possible that the peptide is unable to cross 
the outer membrane of the cell and enter into the periplasm to interact with 
the Tol system. 
 
4.2.5 A synthetic peptide of the disordered N-terminus of E.coli TolB 
does not interact with E.coli TolB lacking disordered N-terminus. 
 
Having established that the E.coli TolA binding peptide binds E.coli TolA 
domain 3 and abolishes E.coli TolA/B interaction in vitro, I set out to 
determine if this peptide could interact with E.coli TolB Δ34 mutant (that 
lacks the N-terminal strand) in vitro. Wild type eTolB has a pocket in which 
the hydrophobic N-terminus sits when in the ordered conformation (figure 
4.13), and as the Δ34 mutant lacked this disordered N-terminus, I attempted 
to detect any complex that formed if the synthetic peptide bound the pocket 
via ITC. 
 
No heats of binding were detected for eTABp (1mM) titrated into eTolB Δ34 
mutant (50 μM) at pH’s 6.5 – 8.5 at a range of temperatures (15°C - 37°C) In 
addition, crosslinking experiments were performed under similar conditions, 
no complex between eTABp and eTolB Δ34 mutant was found. 
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Figure 4.13 E.coli Pal binding E.coli TolB causes TolB’s N-terminus to 
take up ordered conformation. Pal (gold), TolB (cyan), TolB’s 12 N-
terminal residues (red). PBD ID: 2W8B. (Bonsor et al. 2009). 
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4.2.6 Defining the E.coli TolB binding site on E.coli TolA domain 3 with 
protein crystallography 
 
One of the primary aims of this project has been to define the TolB binding 
site on TolA3 and, if possible, obtain a structure for the complex of TolB-
TolA3. Previous attempts (by both myself, and others in the lab) to solve the 
structure of the E.coli TolB-TolA3 complex with protein crystallography have 
been attempted, to no avail. In addition, further strategies have been 
followed, including E.coli TolA-TolB fusion proteins (Bonsor 2009) to obtain 
this complex, but have met with failure. Therefore, a new strategy to obtain 
structural information on the E.coli TolA-TolB complex was devised, using 
the E.coli TolA binding peptide as a surrogate for E.coli TolB in binding E.coli 
TolA3. Initial screens used eTolA3 at concentrations ranging from 10-150 
mg/ml, preformed in a complex with eTABp in 5-10 fold molar excess. This 
complex was then screened against Peg-Ion 1&2 (YSBL), Hampton 1&2, 
Index (Hampton Research), Morpheus and PACT (Molecular Dimensions). 
Identical screens were also set up with eTolA3 alone. Results of these 
attempts to crystallise the complex are shown in figure 4.14. 
 
 
Figure 4.14 Crystallisation of eTolA3-eTABp complex eTolA3 (10, 20, 30 
and 40 mg/ml, clockwise from top left panel) in complex with eTABp (5-fold 
molar excess) in 0.2 M NaF, 20% PEG3350 (PACT screen), after 9 months 
at constant temperature (22 °C).  
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Crystals were removed from well (only 1 crystal grew in each condition) and 
screened by Justyna Wojdyla on Rigaku MicroMax 007HF generator with an 
RAXIS IV++ imaging plate detector (York Structural Biology Laboratory). 
Unfortunately no diffraction was detected for any of the crystals. No other 
conditions contained crystals, and attempts at replicating crystals failed. 
E.coli TolA domain 3 alone did not crystallise in any condition.  
 
4.2.7 Defining the E.coli TolB binding site on E.coli TolA domain 3 with 
nuclear magnetic resonance spectroscopy  
 
As crystallography had failed as a means of obtaining a structure of E.coli 
TolA3 bound to the binding peptide, nuclear magnetic resonance 
spectroscopy was attempted. Previously a solution NMR structure had been 
published E.coli TolA domain 3 (Deprez et al. 2005) and use of NMR to 
study the interactions of E.coli TolA and colicins has also been documented, 
using residues perturbations to map binding sites onto TolA (Hecht et al. 
2010, 2011).  
 
Spectra for both 15N eTolA3 and 15N eTolA3 – unlabeled eTABp complex 
were collected using a Bruker AVII 700MHz spectrometer (Dept. of 
Chemistry, University of York). 15N eTolA3 (pAK108 construct) was purified 
from BL21 (DE3) cells grown in M9 minimal media supplemented with 15N 
ammonium chloride as described in section 2.3.24. It was subsequently 
purified with a yield of 1.5 mg/ml. Size and fold of the protein was verified by 
mass spectrometry (Molecular Interactions Lab, Technology Facility, 
University of York) and circular dichroism (protocol described in section 
3.1.8.1), respectively. Both methods indicated that protein was of correct 
size and identical fold to unlabeled control eTolA3. As E.coli TolA3 is very 
soluble, it was hoped that the protein would be suitable for NMR 
experiments.  
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However, 2D-HSQC (15N- 1H) spectra collected for eTolA3 alone showed a 
greater number of peaks than would be expected (117 peaks expected, 125 
peaks seen, excluding sidechains) (figure 4.15 A), and in the presence of the 
1.1 molar equivalent peptide this issue was compounded (in excess of 140 
peaks seen, excluding sidechains) (figure 4.15 B), with not only an excessive 
number of peaks detected, but also that compared to the eTolA3 alone 
spectra, virtually every peak had shifted (figure 4.15 C). Whether or not this 
indicated a massive conformational change, or if the proteins peak were in 
slow exchange between two states was unclear. It is also possible that more 
than one eTABp was binding a single TolA perturbing a large number of 
peaks. In addition, a large number of peaks clustered around the central 
region (around 8ppm), which is typical of an unstructured protein (Cavanagh 
2007). It was thought that this TolA construct may have been at least 
partially unstructured, possibly explaining the increased number of peaks. A 
number of different constructs of different lengths of E.coli TolA were also 
attempted, however, this issue of increased number of peaks was not 
reconciled (Luke Hillary, personal communication). 
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Figure 4.15 spectra of E.coli TolA domain 3 both alone, and in presence 
of E.coli TolA binding peptide. (A) 2D-HSQC spectrum of 15N eTolA3 
(pAK108 construct), (B) 2D-HSQC spectrum of 15N eTolA3 in presence of 
1.1x molar equivalent of eTABp, (C) Overlay of 15N eTolA3 alone (black) and 
in presence of peptide (blue). 
 
4.2.8 Defining the E.coli TolB binding site on E.coli TolA domain 3 with 
chemical crosslinking coupled with fragment mass spectrometry  
 
Having been unable to define the TolB binding site on TolA through 
crystallography or NMR, a further technique was employed, inspired by work 
from the Rappsilber lab at the University of Edinburgh. This concerned using 
chemical crosslinking and fragmentation mass spectrometry to obtain 
information about protein complexes, and more specifically, protein-protein 
interfaces. Work has been published to obtain the structure and archecture 
of large protein complexes, the largest of which (at the time) was the 180 
kDa Ndc80 complex (Maiolica et al. 2007) and more recently, the 670 kDa 
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RNA Polymerase II–TFIIF complex (Chen et al. 2010). Briefly, this approach 
employed chemically crosslinking of the target protein complex, which was 
subsequently digested with trypsin, and fragments from each component 
protein identified by mass spectrometry hopefully including additional mass 
from peptide fragmentation that were crosslinked together. This information 
could then be deconvoluted into a map of fragments from each protein that 
were crosslinked together, and thus it would be possible to define areas of 
the protein surface that were crosslinked, and in contact with one another. 
As the eTABp-eTolA3 protein-peptide complex could be reliably captured by 
chemical crosslinking, it was hoped that this approach may give information 
as to the protein surface that the eTABp was interacting with on E.coli TolA 
domain 3.  
 
Thus, eTolA3 and eTABp were incubated together, and crosslinked with 
either formaldehyde or DSP (Dithiobis[succinimidyl propionate], also called 
Lomant’s reagent, which is a reducible crosslinker that works in the same 
way as formaldehyde, through primary amines, but when reduced leaves a 
tell tale mass on the residues that were actually crosslinked (see appendix 
section 7.9 for details of crosslinking chemistry).  
 
Crosslinked samples were separated on 13% SDS-PAGE gels (in non-
reducing conditions in the case of DSP crosslinked samples) and stained 
with Coomassie Blue (figure 4.16). Bands corresponding to eTolA3-eTABp 
complex and eTolA3 alone were excised, digested in gel with trypsin and 
analysed with MALDI-MS (Electrospray source) (see figure 4.17 for expected 
trypsin digest fragments and figure 4.18 for results of actual trypsin 
fragments detected) by Dr Dave Ashford (University of York). Fragments 
from the complex that were detected were then compared to eTolA3 alone 
fragments (figure 4.18). 
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Figure 4.16 E.coli TolA domain 3 – E.coli TolA binding peptide 
formaldehyde cross-linking. (A) eTolA3-eTABp complex (B) eTolA3. 
“+” denotes presence of formaldehyde for crosslinking, “-“ denotes no 
crosslinker. 
 
 
 
Figure 4.17 Map of theoretical trypsin cut sites for E.coli TolA domain 3. 
Red/Blue junction indicates predicted trypsin cleavage site. Predictions 
made using ExPASy PeptideCutter tool (Gasteiger et al. 2003). 
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Figure 4.18 Trypsin digested fragments of formaldehyde crosslinked 
eTolA3-eTABp complex detected by MALDI-MS. (A) eTolA3 only 
(residues 293 – 421), (B) eTolA3 crosslinked with eTABp. Red residues 
indicate those sequences detected by MALDI-MS, black represents 
seequences not detected by MALDI-MS. Blue represents lysine residues 
(K310, K316) not detected as part of tryptic peptide (although 1st lysine 
[K310] also not seen in eTolA3 only sample) when crosslinked eTolA3-
eTABp complex is analysed with MALDI-MS. 
 
Most of the residues detected by MALDI-MS are identical between the 
eTolA3 alone, and the sample crosslinked with eTABp. Although it had been 
hoped that a part of the eTABp would be detected by MALDI-MS, 
crosslinked to the eTolA3, this was not the case. It should noted however, 
that there was a difference in the trypsin digest pattern observed between 
the 2 samples, specifically regarding the second of 2 lysine residues (K316, 
shown in blue in figure 4.20, panel B). As formaldehyde and DSP 
crosslinking both crosslink via lysine residues, that this residue (K316) is lost 
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may indicate that due to crosslinking to this residue, trypsin is no longer able 
to access that specific site, and as a result of the mis-cleavage, the 
ionisation properties of the fragment have changed, which prevents it from 
being detected in MALD-MS. Although this theory is based on a negative 
result, it suggests that the binding peptide comes in contact with the eTolA3 
at some point around K310 or K316 allowing a crosslink to form in the 
presence of formaldehyde or DSP. However, in the construction of the 
eTolA3 binding peptide, it was necessary to include an additional 3 lysine 
residues on the peptide’s C-terminus in order to maintain the solubility of the 
peptide. Due to the chemistry of formaldehyde/DSP crosslinking through 
primary amine’s (such as lysines) it is possible that non-specific crosslinks 
occur between the protein and peptide. It is also possible that as not all the 
tryptic fragments are detected in the mass spec sample for eTolA3 alone 
(either due them not ionizing or flying) and the same fragments are not 
detected for the eTolA3-eTABp complex, that the peptide may crosslink to 
any of these tryptic fragments and they are not detected.  
 
4.2.9 The N-terminus of Pseudomonas aeruginosa TolB is involved in 
its interaction with Pseudomonas aeruginosa TolA domain 3. 
 
Having attempted to use E.coli TolA-TolB to define the binding site of TolB 
on TolA, attention now moved to the Pseudomonas aeruginosa TolA-TolB 
interaction, with the hope that this system would be more ameniable to 
study. 
 
Previously it was shown that processed psTolB interacts (and crosslinks) 
with psTolA3. The next step was determine, if, like the E.coli homologues, 
the N-terminus is the sole site of interaction between the 2 proteins. In 
addition it was to be determined if a synthetic peptide of the equivalent 
Pseudomonas aeruginosa sequence from the N-terminus of TolB can also 
recapitulate the interaction between psTolA3 and psTolB. A synthetic 
Chapter 4 
   
148 
peptide corresponding to the sequence ADPLVISSGNDRWKKK (The red 
sequence originates from the N-terminus of psTolB, the extra tryptophan 
residue is to aid quantification of the concentration of peptide, the 3 C-
terminal lysines are to maintain the solubility of the peptide, and to maintain 
a consistent design with that of the E.coli TolA binding peptide. Additional 
peptides without these extra residues were also synthesised with both N-
terminal amide and C-terminal acid or amide-capping, however, both were 
not soluble in any of the buffers appropriate to this work. Peptides were 
synthesised by Pepceuticals, Nottingham. 
 
4.2.9.1 A synthetic peptide of the N-terminus of Pseudomonas 
aeruginosa TolB can compete with Pseudomonas aeruginosa TolB for 
binding with Pseudomonas aeruginosa TolA domain 3 in vitro. 
 
In order to determine if the psTolA binding peptide could compete with 
psTolB for binding with psTolA domain 3 a simple crosslinking competition 
experiment was performed. psTolA3 and psTolB (10 μM final for each 
protein) were incubated together both in the absence, and the presence of 
increasing Pseudomonas aeruginosa TolA binding peptide (psTABp) 
concentrations, dissolved as a stock in 20m sodium phosphate, pH 8. Any 
complexes formed were captured with formaldehyde crosslinking, and 
analysed on 13% SDS-PAGE gels (figure 4.19). 
 
As shown in figure 4.19, in the absence of psTABp, a complex between 
psTolA3 and psTolB is formed. In addition, as is found with eTolA3-eTolB-
eTABp competition experiment, the psTolA3-psTolB crosslink is decreased 
by the presence of psTABp, and is completely abolished at higher 
concentrations. The concentration dependency on this abolition however is 
different to that of the E.coli proteins. It was estimated that the eTolA3-eTolB 
complex is abolished at 150 μM eTABp, whereas 800 μM of psTABp is 
estimated to completely abolish the psTolA3-psTolB complex; a 4.5 fold 
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increase in concentration. Thus, as the Kd for eTolA3-eTABp was estimated 
at 40 μM, we may therefore conclude that the Kd for psTolA-psTABp is much 
higher. 
 
 
Figure 4.19 Formaldehyde crosslinking experiment showing 
competition of psTolB and psTABp for binding with psTolA3, in vitro, 
detected with Coomassie blue staining on 13% SDS-PAGE gel. psTolA3 
and psTolB were incubated both in the absence (0 μM lane) and in 
increasing peptide concentration of psTABp. Note the progressive loss of the 
TolA/TolB complex at higher concentrations of psTABp, and introduction of 
TolA-peptide band. 
 
To confirm the presence of a crosslink between the psTolA3 and psTABp, 
the band corresponding to this complex was excised from the gel and 
analysed by MALDI-MS (Adam Dowle, University of York Technology 
Facility), which confirmed the presence of both the psTolA3 and psTABp in 
complex. As ITC data for the eTolA3-eTABp complex estimated a Kd of 40 
μM, an extrapolation was made estimating the Kd of psTABp-psTolA3 to 
several hundred micromolar, assuming a similar relationship between the 
TolA binding peptides and TolA3. Unfortunately, when attempting to collect 
100 µM
1 mM
1mM
[psTABp]
0 µM
10 µM
TolB dimer
TolA/TolB complex
TolB
TolA
TolA+peptide
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thermodynamic data for the interaction between psTABp and psTolA3 no 
heats of binding were found upon titration of the peptide. Large heats were 
detected when peptide at high concentrations was titrated into the cell, 
characteristic of some form of dilution induced multimeric dissociation (data 
not shown). These heats caused by (potentially) multimeric complexes of 
psTABp dissociating upon injection into the ITC cell (where peptide was at 
low concentration relative to the needle reservoir) would mask any heats 
created by the formation of a psTolA3-psTABp complex, heats that would 
likely be very small given the likely very weak nature of the psTolA3-psTABp 
interaction.  
 
To further investigate the behaviour of the peptide, Size Exclusion 
Chomatography - Multi-Angle Laser Light Scattering (SEC-MALLS) using 
Wyatt Dawn HELEOS-II 18-angle light scattering detector and Wyatt Optilab 
rEX refractive index monitor linked to a Shimadzu HPLC system (University 
of York Technology Facility) was performed on equivalent high 
concentrations (as used in ITC experiments) of psTABp with Superdex 
peptide HR10/30 column (GE Healthcare). These data appeared to show 
that the psTABp was in dynamic equilibrium between monomer and dimer at 
concentrations above 500 μM (data not shown). Further ITC experiments 
were attempted titrating psTABp into psTolA3 at concentrations ranging from 
250 μM to 2mM, however heats were either too weak to be detected above 
baseline noise (at concentrations below 500 μM, or heats caused by dimer 
dissociation overwhelmed any potential binding heats at concentrations 
above 500 μM. This prevented calculation of affinity for psTolA3-psTABp 
complex. Additionally, as stated in section 4.2.1.6, no thermodynamic data 
was obtained for the native psTolB-psTolA3 interaction. 
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4.2.9.2 Crystallising the Pseudomonas aeruginosa TolA domain 3 - 
Pseudomonas aeruginosa TolA binding peptide complex 
 
Attempts were made at crystallising psTolA3 in the presence of psTABp to 
potentially define the binding site of psTABp on psTABp, using a variety of 
commercially available screens (Peg-Ion 1&2, Hampton 1&2, Morpheus, 
PACT and Index) as well as conditions reported to produce original crystal 
structure of free psTolA3 (5% wt/v PEG 6000, 100 mM Tris-HCl, pH 8.0, and 
1 mM ZnSO4) (Witty et al. 2002). Protein concentrations ranged from 1-14 
mg/ml, in presence of 1-10 fold molar equivalent of peptide. No crystals grew 
in any condition screened, although precipitation was noted in multiple 
conditions. Optimisation of conditions was attempted by Justyna Wojdyla 
(University of York), however, to no success. 
 
4.2.9.3 Characterising the behaviour of Pseudomonas TolA domain 3 in 
the presence and absence of Pseudomonas aeruginosa binding 
peptide with Analytical Ultra Centrifugation 
 
In order to further characterise the behaviour of Pseudomonas aeruginosa 
domain 3, both in the presence and absence of its binding peptide, analytical 
ultracentrifugation experiments were performed, measuring the 
sedimentation velocity of the protein in the presence and absence of the 
peptide, particularly to determine if any aggregation was occurring. This was 
relevant for Nuclear Magnetic Resonance experiments on psTolA3-psTABp, 
discussed in the following chapter.  
 
Thus 3 samples were prepared; psTolA3 at both low (250 μM) and high (800 
μM) concentrations, as well as a sample of psTolA3 at 800 μM in the 
presence of 1.5 molar equivalent psTABp.  
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As shown in figure 4.20B, when analysed with SEDFIT (see appendix 
section 7.7 for details of fitting), the sedimentation co-efficient for psTolA3 at 
800 μM is 1.5 S, with a single peak for it’s sedimentation co-efficient, 
indicating that psTolA3 remains monomeric, with no suggestion of dimers or 
higher order complexes. When transformed with SEDFIT (figure 4.20C) to 
indicate molecular weight, mass is calculated as 14180 Da (± 700 Da), which 
when compared to the expected mass of 14495 Da is within error values. 
Equally, at 250 μM, similar results are found (figure 4.21), indicating protein 
sample is monomer with a calculated mass of 13973 Da (± 1335 Da). 
Finally, when studying the protein’s behavior in the presence of the psTABp, 
it would appear as though the presence of peptide has little effect on the 
protein’s sedimentation co-efficient. This may indicate that the psTolA3-
psTABp complex is very weak and only a small population remain in 
complex during ultracentrifugation. This is consistent with the previous 
crosslinking results which suggest that the psTolA3-psTABp is a very weak 
interaction. Otherwise, in the presence of the peptide, psTolA3 remains 
monomeric, with no indication of higher order complexes forming. The 
peptide would appear to be aggregating, causing a smaller sedimentation 
co-efficient peak (as seen in figure 4.22). This is again consistent with SEC-
MALLS data that suggested that the psTABp was in dynamic equilibrium 
between monomer and dimer. Due to the added absorbance due to the 
addition of psTABp in the sample, no molecular weight can be deconvoluted 
from sedimentation co-efficients. However, when comparing the behavior of 
the psTolA3 in all conditions (figure 4.23 and table 4.3), the psTolA3-psTABp 
sample overlays in a similar manner to psTolA3 only sample, thus it would 
appear to remain monomeric in the presence of the peptide.  
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Figure 4.20 Analytical ultracentrifugation data plots for high 
concentration of free Pseudomonas aeruginosa TolA domain 3. 800 μM 
psTolA3 was sedimented at 50000 rpm for 10 hours at 20 °C, with 
absorbance measured at 302 nm, with absorbance scans collected every 
180 seconds in 20 mM Sodium phosphate buffer, pH 7.5. (A) Sedimentation 
overlay plot with every 10th scan displayed. (B) SEDFIT c(s) analysis plot 
displaying sedimentation Co-efficient, S. Single narrow peak recorded, 
indicating a single species. Sedimentation Co-efficient recorded as 1.49 S 
(1.50 S when corrected for buffer density and viscosity). (C) SEDFIT s(M) 
molecular weight transformation plot indicating single species estimated to 
be 14180 Da (± 700 Da).  
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Figure 4.21 Analytical ultracentrifugation data plots for low 
concentration of free Pseudomonas aeruginosa TolA domain 3. 250 μM 
psTolA3 was sedimented at 50000rpm for 10 hours at 20 °C, with 
absorbance measured at 302 nm, with absorbance scans collected every 
180 seconds in 20 mM Sodium phosphate buffer, pH 7.5. (A) Sedimentation 
overlay plot with every 10th scan displayed. (B) SEDFIT c(s) analysis plot 
displaying sedimentation Co-efficient, S. Single narrow peak recorded, 
indicating a single species. Sedimentation Co-efficient recorded as 1.52 S 
(1.53 S when corrected for buffer density and viscosity). (C) SEDFIT s(M) 
molecular weight transformation plot indicating single species estimated to 
be 13973 Da (± 1335 Da) 
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Figure 4.22 Analytical ultracentrifugation data plots for high 
concentration of Pseudomonas aeruginosa TolA domain 3 in presence 
of 1.5x molar equivalent Pseudomonas aeruginosa TolA binding 
peptide. 800 μM psTolA3 in the presence of 1.5 molar equivalent psTABp 
was sedimented at 50000rpm for 10 hours at 20 °C, with absorbance 
measured at 302 nm, with absorbance scans collected every 180 seconds in 
20 mM Sodium phosphate buffer, pH 7.5. (A) Sedimentation overlay plot with 
every 10th scan displayed. (B) SEDFIT c(s) analysis plot displaying 
sedimentation Co-efficient, S. 2 peaks recorded, indicating a multiple 
species. Sedimentation Co-efficients recorded as 1.50 S (1.51 S when 
corrected for buffer density and viscosity) for psTolA3 and approximately 0.6 
S (0.6 S when corrected for buffer density and viscosity) for psTABp, 
indicating that although protein is monomeric, peptide appears to be 
aggregating.  
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Figure 4.23 Analytic ultracentrifugation data plots for high 
concentration of Pseudomonas aeruginosa TolA domain 3 in presence 
of 1.5x molar equivalent Pseudomonas aeruginosa TolA binding 
peptide. Comparative plot of 800 μM psTolA3 (black trace), 250 μM psTolA3 
(red trace) and 800 μM psTolA3 in the presence of 1.5 molar equivalent of 
psTABp (green). In all 3 conditions, psTolA3 appears to remain monomeric, 
and sediments with very similar Sedimentation Co-efficients, although the 
psTolA3-psTABp profile suggests a small shift to the right, indicating the 
possibility of a higher molecular weight species. 
 
Sample S* S20,w MW (Da) 
 
PsTolA3 (800 µM) 1.49 1.50 14180 (± 700) 
PsTolA3 (250 µM) 1.52 1.53 13973 (± 1335) 
 
PsTolA3 (800 µM) + psTABp 1.50 1.51 N/A 
psTABp 0.60 0.60 N/A 
 
Table 4.3 Comparison of Analytical Ultracentrifugation data collected 
for Pseudomonas aeruginosa TolA domain 3 and Pseudomonas 
aeruginosa TolA binding peptide. S* denotes Sedimentation Co-efficient, 
S20,W denotes Sedimentation Co-efficient corrected for buffer density and 
viscosity. MW denotes molecular weight prediction based on Sedimentation 
Co-efficients, error values in brackets.  
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4.2.10 The interaction of TolA binding peptides is specific to their 
respective TolA’s. 
 
Although it had been shown previously that the TolA binding peptides 
interacted with their respective TolA’s, and that the TolA-TolB interaction is 
specific, I investigated the specificity of the TolA binding peptides for their 
respective TolA’s. Due to the design of the peptide, 3 lysine residues were 
added at the C-terminus to increase solublity (peptides without any 
additional sequence were also synthesised, but they remained insoluble). As 
primary amines (such as Lysine) are active in formaldehyde crosslinking, it 
had been suggested that these 3 lysines were crosslinking in a non-specific 
manner, causing a non-native interaction with TolA3. If this were true, then 
all work regarding crosslinking and TolA binding peptides would be void.  
 
To investigate this, eTolA3 was incubated with crosslinker in the presence of 
psTABp (and conversely, psTolA3 incubated with crosslinker in the presence 
of eTABp). In addition, a competition assay with eTolA3-eTolB was 
performed in the presence of psTABp (and visa versa). Appropriate positive 
controls of eTolA3-eTABp and psTolA3-psTABP were also conducted. All 
whole proteins were 10 µM (final), and in the presence of up to 1mM (final) 
peptide, and crosslinking reactions performed at pH 7.5, 8.0 and 8.5. 
 
In formaldehyde competition assays, neither peptide could abolish the native 
interaction, like the class specific peptide could. In addition, no complex was 
found between either eTolA3 and psTABp or psTolA3 and eTABp in the 
presence of formaldehyde crosslinker, at high concentrations of peptide. 
 
ITC experiments were also performed, titrating psTABp (1mM) into eTolA3 
(250 µM) and eTABp (1mM) into psTolA3 (250 µM) at a variety of pH’s (6.5-
8.5) and temperatures (15 °C - 37 °C), again, no heats were detected 
indicating an interaction (data not shown). 
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4.3 Discussion 
 
4.3.1 The Gram-negative TolA-TolB interaction. 
 
The findings of this work have reported for the first time a complex between 
Pseudomonas aeruginosa TolA and TolB, and that this interaction involves 
the N-terminus of TolB, like that of the E.coli interaction. The Tol protein 
family is highly conserved throughout Gram-negative bacteria (Sturgis 2001), 
yet until the positive crosslinking data presented in this work, other than 
assumptions based on homology with E.coli proteins, it was unknown if other 
Gram-negative Tol proteins interacted in a similar manner to that of the 
E.coli proteins. Given that the Pseudomonas aeruginosa TolA domain 3 
appears to interact with TolB, this suggests that this interaction may be 
conserved throughout Gram-negative bacteria. However, despite this 
positive result, there is still no thermodynamic data available for this 
interaction, as the Pseudomonas aeruginosa Tol proteins appear to be of 
limited solubility, particularly the Pseudomonas aeruginosa TolB. This limit in 
solubility has prevented ITC experiements from being carried out. Having 
suggested that the TolA-TolB interaction is conserved, it begs the question 
as to firstly whether or not psTolB has an intrinsically disordered N-terminus 
like it’s E.coli homologue. Given the psTABp results (discussed below), this 
seems likely. Also, given the near identical fold of psTolA3 and eTolA3, it 
would suggest that psTolA3 would make a good model for study of the TolA-
TolB interaction, especially as a high resolution crystal structure is available 
for psTolA3 (Witty et al. 2002). At the time of the inception of these 
experiments, no crystal structure of E.coli TolA3 in the absence of binding 
partners was available. During the preparation of this manuscript, a crystal 
structure of E.coli TolA3 both in isolation and in complex with colicin A has 
been published (Li et al. 2012). In their work, Li et al. also attempted to 
define the structure of the E.coli TolA3-TolB complex, through both 
crystallography and NMR, but were unsuccessful. This is particularly 
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relevant for subsequent work presented in the following chapter. Additionally, 
given that the E.coli TolA-TolB interaction is blocked by E.coli Pal, it raises 
the question as to whether or not psPal mediates the interaction of psTolA-
psTolB in a similar fashion. However, unfortunately, although the psPal gene 
was cloned in this work it did not express, and thus protein could not be 
purified to test this hypothesis. Again, as psTolA3 and eTolA3 have near 
identical folds (Witty et al. 2002), and both psTolB and eTolB are predicted 
to have similar folds based on comparisons of secondary structure from 
circular dichroism experiments, this would seem to be likely that psPal will 
bind psTolB and may function as an off-switch for the psTolA-TolB 
interaction. In any event, proving a common interaction between both E.coli 
and Pseudomonas aeruginosa TolA and their respective TolB is an exciting 
prospect for further work in this area. 
 
4.3.2 Recapitulating Gram-negative TolA-TolB interactions with 
synthetic peptides. 
 
Having shown in chapter 3 that adding 12 extra residues of the E.coli TolA 
binding epitope of TolB onto the disordered region of colicin E9 is sufficient 
to generate a novel interaction between the eTolA3 and colicin E9 fusion 
protein, the next step was to ascertain if this sequence in isolation in the 
form of a synthetic peptide was sufficient to form a complex with TolA 
domain 3. As reported in section 4.2.3, not only is a peptide of the sequence 
of the E.coli binding epitope sufficient to create a novel interaction with 
eTolA3, but that it is also capable of disrupting the native eTolA3-eTolB 
interaction. Additionally, that when titrated against eTolA3, the 
thermodynamic data obtained suggested that the eTABp bound eTolA3 as 
tightly as the native eTolB binds eTolA3. This would suggest that although 
the N-terminus was known to be important in the interaction between eTolA3 
and eTolB (Bonsor et al. 2009), these data show that the 12 residues on the 
extreme N-terminus of eTolB are the sole site of interaction with eTolA3. The 
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fact that a synthetic peptide representing the N-terminus of psTolB 
(predicted based on homology with eTolB N-terminus) also disrupted the 
native psTolA3-psTolB interaction further suggests that the N-terminus the 
sole site of interaction for the Pseudomonas aeruginosa proteins, and that 
the N-terminus of TolB may well be the sole site of interaction for any TolA3-
TolB in Gram-negative bacteria. Although no thermodynamic data were 
obtained for the psTolA3-psTABp interaction, comparing crosslinking data 
with that of eTolA3-eTABp suggests that like the E.coli interaction, in vitro, 
psTolA3-psTABP/psTolB is a weak (high micro-molar affinity) interaction. 
Given the problems with attempting to capture an eTolA3-eTolB/eTABp 
complex by crystallography or NMR, and given that the psTolA3-psTABp 
interaction appears to mimic that of E.coli, the Pseudomonas aeruginosa 
TolA3-TABp interaction was targeted in an attempt to finally determine the 
TolA-TolB complex, something that has remained elusive for several 
decades.  
 
4.3.3 Summary 
 
In the work reported in this chapter I have shown that the E.coli TolA-TolB 
interaction is solely dependant on the disordered N-terminus of TolB, as 
evidenced by the finding that a synthetic peptide of the sequence of the N-
terminus is not only capable of recapitulating the TolA-TolB interaction in 
vitro, but that the peptides interaction with TolA is of a similar affinity to that 
of the native TolB protein. Unfortunately, attempts to define the structure of 
the E.coli TolA-TolB complex or the site of binding on E.coli TolA domain 3, 
either through the whole proteins, or the E.coli TolA-TolA binding peptide 
complex have been unsuccessful by protein crystallography, nuclear 
magnetic resonance or protein-crosslinking and mass spectrometry. 
However, despite this set back, another, very interesting finding was 
reported in this chapter; for the first time (to our knowledge) we have 
evidence that not only do Pseudomonas aeruginosa TolA and TolB interact, 
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but that their interaction involves the N-terminus of Pseudomonas TolB. 
Given the degree of homology between E.coli and Pseudomonas aeruginosa 
TolA and TolB it is highly likely that the N-terminus is the sole site of 
interaction between Pseudomonas aeruginosa TolA and TolB. In addition, it 
has been found that the interactions between E.coli and Pseudomonas 
aeruginosa TolA and TolB remain specific, and no non-cognate complexes 
were found between them. 
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5. Identifying the Pseudomonas aeruginosa TolB binding site on 
Pseudomonas aeruginosa TolA 
 
5.1 Introduction 
 
As stated in chapters 3 and 4, the structure of both E.coli and Pseudomonas 
aeruginosa TolA3 has been reported, either by nuclear magnetic resonance 
spectroscopy for the E.coli protein (Deprez et al. 2005) or crystallography for 
the Pseudomonas aeruginosa homologue (Witty et al. 2002). Additionally, 
despite structures being reported for E.coli TolB both in isolation, and in 
complex with E.coli Pal or colicin E9 translocation domain (Bonsor et al. 
2009), the structure for either E.coli or Pseudomonas aeruginosa TolA-TolB 
complex has yet to be reported.  
 
Attempts at determining E.coli TolA-TolB complex structure through 
crystallography and solution NMR, as well as the E.coli TolA3-E.coli TolA 
binding peptide complex structure have been unsuccessful, thus attention 
thus turned to the Pseudomonas aeruginosa TolA-TolB complex. The 
Pseudomonas aeruginosa TolA and TolB have been shown interact in a 
similar manner to that of the E.coli proteins (Section 4.2.9), and given that 
their structures are so similar, it was hypothesised that Pseudomonas 
aeruginosa proteins could act as a model for not only the E.coli interaction, 
but given the potentially conserved nature of the TolA-B complex, all Gram-
negative bacteria.  
 
Attempts were made to crystallise the psTolA3-psTolB complex, however, 
due to the highly unstable nature of the psTolB, most conditions yielded 
nothing but heavy precipitation. Buffer screens were conducted to improve 
the solubility of the psTolB (as well as psTolA-psTolB complex), however no 
improvement was achieved. Given the unstable nature of the psTolB, it was 
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decided that further characterisation of the psTolA-B complex should focus 
on psTABp acting as surrogate for psTolB. Although no thermodynamic data 
had been collected for this interaction, crosslinking experiments (section 
4.2.9.1) as well as preliminary NMR data on psTolA3-psTABp were 
convincing enough to focus on the psTolA3-psTABp complex. Attempts were 
made to crystallise the psTolA3-psTABp complex, however, these failed to 
yield crystals in any conditions (section 4.2.9.2). Having been unable to 
crystallise the psTolA-B complex, nuclear magnetic resonance spectroscopy 
was the next avenue of structural biology to be explored.  
 
5.1.1 Pseudomonas aeruginosa TolA constructs 
 
Having characterised the psTolA3-psTolB/psTABp interaction with chemical 
crosslinking (section 4.2.1.5 and 4.2.9.1), this same construct of psTolA3 
(pEC4) was chosen to be isotopically labelled in this work. This construct 
consists of residues 226-347 of psTolA and encodes all of domain 3, as well 
as 40 residues of domain 2. It has a C-terminal his-tag, and has been both 
purified and it’s fold characterised in the previous chapter (section 4.2.1.4). 
Apart from an additional single C-terminal residue just before the his-tag 
(Glu124, as a result of cloning), it is identical to the construct used in the 
crystallisation of psTolA3 as described by Witty et al. in 2002.  
 
5.1.2 Pseudomonas aeruginosa TolA binding peptide 
 
The psTABp is as described in section 4.2.9, and is of sequence 
ADPLVISSGNDRWKKK. As described in section 4.2.9.1, it is capable of 
forming a complex with psTolA3 (which can be captured by chemical 
crosslinking), and is capable of disrupting the native psTolA3-psTolB 
complex.  
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5.1.3 Nuclear Magnetic Resonance spectroscopy 
 
Nuclear Magnetic Resonance spectroscopy works by monitoring the 
disruptions to the magnetic field or spin on a specific nuclei. In order for a 
nucleus to be probed with NMR, it must have a non-zero nuclear spin, 
something that is inherent to having an odd number of neutrons. Without a 
magnetic field applied, all individual nuclei spins are random. In an NMR 
magnet, when the strong magnetic field (B0) is applied, all spins are aligned 
along (or against) the axis of the field and the system is said to be in 
equilibrium. Although all NMR active nuclei are aligned in the same axis, 
they still have a specific spin, termed precession (the nuclei process around 
the field). The frequency of this precession is dependent on the strength of 
the magnetic field and the gyromagnetic ratio of the nuclei (an inherent 
property of the nucleus) and is called the Larmor frequency. When a short 
power pulse of radio frequency is applied to the system, it is at the Larmor 
frequency, which causes an oscillation in the magnetic field or the spin of the 
nuclei. This is why a relatively low power radio frequency pulse can 
overcome the strong magnetic field and cause a change in the spin on a 
nucleus. This change causes an excitation in the system which decays over 
time, back to equilibrium. This decay signal (detected by receiver coils) is 
acquired (acquisition time) and is called the free induction decay (FID). In 
modern NMR, to visualise the spectra a Fourier transform is applied to the 
FID. As a single FID is so weak, it is insufficient to overcome signal to noise 
of the environment, and thus the multiple FIDs are collected and added 
together and thus their cumulative signal will be stronger. As noise is 
random, it will not increase in a cumulative manner as quickly as the FIDs 
do. The number of FIDs collected is referred to as “scans”. Following the 
FID, the system is allowed to return to equilibrium. The time this takes is the 
relaxation delay, typically several seconds for small molecules, and longer 
for larger ones. 
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The most powerful attribute of NMR is its ability to selectively probe specific 
nuclei by applying a specific radio frequency pulse which only effects that set 
of nuclei. For example, a pulse is applied to the system that only causes 
excitation of 1H, and thus only FID signal from the 1H is detected. Single 
nuclei excitation is the basis of a 1D experiment.  
 
In a system where there are only two 1H, if both protons are in the same 
chemical environment, then their behaviour will be identical. However, if the 
chemical environment is different in any way (such as surrounded by other 
nuclei which may act to shield the nucleus from the applied magnetic field), 
then the two nuclei will return to equilibrium in a differing way. It is this 
difference in the behaviour of nucleus spin returning to equilibrium which can 
be quantified as the chemical shift (measured in ppm). If a system has 
multiple 1H nuclei to be probed with a radiofrequency pulse, again, if all the 
1H are in the same chemical environment then they will all have the same 
chemical shift. The chemical shift is the resonant frequency of the nucleus 
relative to an internal standard. However, in the case of a folded protein not 
only are there many hundreds of 1H, they will each be in their own individual 
chemical environment, and thus will have different chemical shifts. However, 
a 10 kDa protein will have thousands of 1H, and if only the 1H are probed, 
then it is impossible to differentiate between single nuclei. An example of this 
is shown in figure 5.1.  
 
Therefore it is necessary to probe different types of nuclei, so that a second 
or third dimension can be added to the spectra. As 1H is the only highly 
abundant naturally occurring NMR active nucleus (over 99.9% natural 
abundance), it is necessary to introduce additional NMR active isotopes into 
the target. In the case of protein NMR, the most commonly used isotopes 
are 15N and 13C. 15N and 13C are only naturally abundant at 0.37% and 
1.07%, respectively (Harris et al. 2001). 
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Figure 5.1 Example 1-D Proton NMR spectrum. 1D proton spectrum of 
ubiquitin (8.5 kDa) in 95%/5% (v/v) H2O/D2O solution (Breukels et al. 2011). 
 
An isotope labelled protein sample can then probed using a specific pulse 
programme that only excites specific nuclei, and as a result through transfer 
of magnetisation it is possible to correlate nuclei spin systems that are 
coupled together. For example, in the case of a protein that has been 
labelled with 15N, it is possible to correlate NH groups through transfer of 
magnetisation from N to H. This correlation of NH groups is the basis of 1H-
15N Heteronuclear Single-Quantum Correlation (HSQC) experiment. This 
HSQC experiment has two dimensions (1H, 15N) and a peak is correlated to 
a single NH pair. As every amino acid (with the exception of Proline) has an 
NH group, and thus in a 1H 15N HSQC spectrum each peak will represent a 
single amino acid. In addition, -NH2 groups asparagine and glutamine side 
chains will also be seen in the HSQC spectra as a set of double peaks, 
usually in the top right hand corner of the spectrum. Furthermore, -NH2 side 
chain peaks for tryptophan are usually found in the bottom left of the 
spectrum. Like the 1H 1D experiments, if all the NH groups are in identical 
chemical environment in a 2D HSQC experiment, then all the chemical shifts 
would be identical. However, if the chemical environments were different, 
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such as within a folded protein, then the chemical environment would be 
different, and as such, the chemical shifts would be highly dispersed. A 
typical 1H - 15N HSQC spectrum is displayed in figure 5.2.  
 
 
Figure 5.2 Example 2D-HSQC spectrum for a folded protein. 2D HSQC 
spectrum of Pseudomonas aeruginosa TolA domain 3 (13 kDa) in 
90%/10% (v/v) H2O/D2O solution (this work). 
 
In addition, if the chemical environment of an amino acid (and thus it’s 
representative peak) changes, such as upon a binding event, this peak may 
enter chemical exchange. There are 3 main types of chemical exchange; 
fast, slow and intermediate. These regimes are dependant on the timescale 
of the NMR experiment, which is dependant on the strength of the magnet 
used. If a peak is in fast exchange, the peak will move from it’s original 
position to a new position (figure 5.3 A). This means that the residue is in a 
single population, all in the new environment. Alternatively, if a residue is in 2 
separate populations, chemical exchange is said to be slow (figure 5.3 B). 
Thus the residue will have 2 peaks, representing the 2 chemical 
environments. Finally, a peak may be in a hybrid of the 2 regimes, termed 
intermediate (figure 5.3 C). This regime is a mixture of the 2, and as a result 
may broaden out and be indistinguishable from the noise.  
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Figure 5.3 Chemical exchange regimes. In slow exchange (A), there are 2 
populations and thus 2 peaks for the given residue. In intermediate 
exchange (B), the peak is in a hybrid situation between fast and slow 
exchange, and thus a weak, broad peak is populated. In fast exchange, 
residue is in a single population (C). (Figure adapted from Bain 2003). 
 
Although a 2D spectra deconvolutes the spectrum to the point where it is 
possible to differentiate individual amino acids, for proteins greater than 
30kDa this information is still insufficient to determine which peak is 
attributed to a specific amino acid. To do this, a 3rd dimension is added to the 
acquired spectra, recording the chemical shift of carbon nuclei within an 
amino acid. For each experiment type (HNCO, HNCACO, CBCANH, 
CBCACONH, see appendix section 7.7 for specific magnetisation transfer), 
magnetisation is transferred from one nucleus to the next. For example, in 
HNCACO experiments, magnetisation is transferred from the Nitrogen 
nucleus to it’s proton, and from the C-alpha carbon nucleus of the amino 
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acid to the CO carbon atom (and back again), so resonances are detected in 
3 dimensions; 1H, 15N, 13C. Because the nitrogen is coupled to both its own 
C-alpha, and the C-alpha of the preceding residue, magnetisation transfers 
from the nitrogen to both C-alpha’s, as well as from C-alphas to their 
respective COs. This means that via transfer of magnetisation, it is possible 
to follow the linkage of both the molecule, and it’s predecessor. This type of 
linkage information is termed “i” for current residue, and “i-1” for preceding 
residue. By combining these carbon dimension experiments, it is possible to 
move both forward and backward from the residue of interest and identify 
residues that they are linked to. In addition, as each experiment type has a 
different scheme of magnetisation transfer, it is possible to identify individual 
amino acids by the transfer that occurs. For example, some amino acids 
have multiple carbon atoms that will lead to multiple resonances in the 
carbon dimension. Also, the chemical shift for Carbon nuclei varies 
depending on the chemical environment (residue type) that they are in, and 
for many residue types, these carbon chemical shifts are very distinctive, 
such as threonine, which has a C-alpha peak at around 60 ppm and a C-
beta peak at around 70 ppm. Other distinctive carbon chemical shifts are 
those of alanine, which only has a single C-alpha peak at ~20 ppm and 
glycine with a single C-alpha at 45 ppm. These distinctive chemical shifts 
can act as starting points with which to walk forward or backward from, 
particularly if further distinctive carbon chemical shifts are found just before 
or afterward it (see appendix section 7.7 for full list of chemical shifts). Once 
peaks are assigned, this data can then be mapped back onto HSQC spectra 
(Cavalli et al. 2007) (Keller 2005) (Knowles et al. 1976).  
 
5.1.4 Aims  
 
It is the aim of this chapter to investigate the binding of the Pseudomonas 
aeruginosa TolA binding peptide with Pseudomonas aeruginosa TolA 
domain 3 by NMR. psTolA3 was purified in two isotope labelled forms (15N 
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only and 15N13C). With this material, HSQC spectra were recorded, both in 
the absence of peptide (as a starting point of comparison, as well as to 
ensure protein is folded), and also in it’s presence. Once it was determined 
that the binding of the peptide affected the pattern of peaks seen in HSQC 
spectra, these spectra were attempted to be fully assigned using three 
dimensional experiments. Once assigned, peaks that were perturbed by 
peptide binding were identified and mapped onto the known crystal structure 
(Witty et al. 2002) in an attempt to map the peptide binding site of psTolA3.  
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5.2 Results 
 
5.2.1 Purification of 15N labeled Pseudomonas aeruginosa TolA3 (pEC4 
construct) 
 
His-tagged Pseudomonas aeruginosa TolA domain 3 (psTolA3) was purified 
from BL21 (DE3) cells transformed with pEC4, grown in 1.5L of M9 minimal 
media supplemented with 15N Ammonium Chloride (Cambridge Isotope 
Laboratories). Protein was purified as described in section 4.2.1.2, with the 
following difference; cells were grown to OD600  of ~0.6 (usually 6-8 hours 
following inoculation), induced with 1 mM IPTG, then grown for a further 16 
hours. Steps of purification are shown in figure 5.4. A typical protein yield of 
4 mg/L of culture was obtained. Mass spectrometry of protein indicated that 
protein was of the expected size, assuming isotope labelling had been 
successful and uniform (>95%). 
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Figure 5.4 Purification of 15N C-terminal His-tagged psTolA3 (pEC4 
construct) (A) 280 nm Absorbance profile from Ni-NTA affinity 
chromatography. (B) denotes expanded view of elution peak. Protein 
(indicated by arrow) eluted with 0-500 mM Imidazole elution over 10 column 
volumes. (C) Gel-filtration histogram of eTolA3 on Superdex 75 26/60 
column. psTolA eluted between 180 and 210 ml. (D) 16% SDS-PAGE gel to 
verify presence of psTolA3 in imidazole elution fraction (indicated by arrow). 
(E) 16% SDS-PAGE gel to verify presence of pure psTolA3 (indicated by 
arrow) after gel filtration.  
 
5.2.2 Purification of 15N 13C labeled Pseudomonas aeruginosa TolA3 
(pEC4 construct) 
 
His-tagged Pseudomonas aeruginosa TolA domain 3 (psTolA3) was purified 
from BL21 (DE3) cells transformed with pEC4, grown in 1.5 L of M9 minimal 
‘media supplemented with 15N Ammonium Chloride and 13C Glucose 
(Cambridge Isotope Laboratories). Protein was purified as described in 
section 4.2.1.2, and in all other respects as 5.2.1. Purified protein is shown in 
figure 5.5. A typical protein yield of 4 mg/L of culture was obtained. Mass 
spectrometry of protein indicated that protein was of the expected size, 
assuming successful and uniform labelling (>95%). 
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Figure 5.5 Purified 15N 13C C-terminal His-tagged psTolA3 (pEC4 
construct) 16% SDS-PAGE gel to verify presence of pure psTolA3 
(indicated by arrow) after gel filtration.  
 
5.2.4 Pseudomonas aeruginosa TolA domain 3 is folded and stable, 
and it’s stability can be monitored by Nuclear Magnetic Resonance 
 
2D 1H-15N HSQC spectra were collected for singly labelled (15N) psTolA3 to 
determine if the spectra corresponded to a folded protein, and if so, as a 
starting point from which to compare peptide bound spectrum. 2D HSQC 
showed a dispersive peak pattern consistent with that of a folded protein 
(figure 5.6). CD spectra of protein was also collected and compared to 
previously acquired CD spectra for psTolA3, and found to be almost identical 
(section 4.2.1.4).  
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Figure 5.6 2D HSQC spectrum of 15N Pseudomonas aeruginosa TolA 
domain 3. HSQC spectra collected for 220 μM psTolA3, recorded in 20 mM 
sodium phosphate, pH7.5, at 25 °C.  
 
In the HSQC spectra of psTolA3 alone, 147 peaks were picked and counted. 
Approximately 30 were judged by their position in the spectra (as well as 
presence of corresponding doublet peaks) to be sidechain peaks. psTolA3 
has 130 residues in total (although the protein has 7 proline residues that are 
not present in HSQC spectra due to lack of amide protons, as well as the N-
terminal residue which will not be seen due to the protonation of the terminal 
amino group). This means that there should be 122 peaks corresponding to 
protein backbone resonances, and considering there are 147 peaks, 
discounting the 30 peaks which are likely to correspond to sidechains, there 
are approximately 117 peaks in the spectra out of the expected 122.  
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In addition, HSQC spectra were collected before and after each 3D 
experiment acquisition set, which indicated that the psTolA3 protein (at ~800 
μM) was stable for over 3 weeks at 298K/25 °C. No change in position, 
number or intensity of peaks was detected over this period. In addition, 
samples of psTolA3 protein at ~800 μM were analysed on 16% SDS-PAGE 
gels at regular intervals following 3D spectra acquisition, the protein 
appeared to be intact with no hint of degradation products (figure 5.7).  
 
 
Figure 5.7 15N 13C labeled Pseudomonas aeruginosa TolA3 did not 
degrade during 3D data acquisition. Double labelled psTolA3 prior to (A) 
and after over 3 weeks (B) at 298K/25 °C inside NMR magnet. 
 
5.2.5 Binding of Pseudomonas aeruginosa TolA binding peptide 
perturbs a population of peaks in Pseudomonas aeruginosa TolA 
domain 3 HSQC spectrum 
 
Having confirmed that the Pseudomonas aeruginosa TolA domain appeared 
to be folded and stable, I set out to ascertain if the binding of the 
Pseudomonas aeruginosa TolA binding peptide affected the spectra of the 
psTolA3 protein. The use of synthetic peptides study protein residue 
perturbations has been used in the past great success. Work in 1992 used 
1D 1H NMR to map the binding of the inhibitory region of troponin I, 
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represented by a synthetic peptide, onto the C-terminal domain of troponin C 
(Slupsky et al. 1992). More recently, in 2012, work was published on the use 
of short synthetic peptide dimers to mimic the Cro protein of bacteriophage 
λ, that not only causes similar NMR chemical shift perturbations in vitro, but 
that in vivo also bound to DNA operator sequences with similar selectivity to 
the Cro protein, potentially paving the way for novel synthetic transcription 
factors (Mazumder et al. 2012). 
 
HSQC spectra were acquired for Pseudomonas aeruginosa TolA domain 3 
at 220 μM incubated in the presence of 1.5 molar equivalent (330 μM) 
Pseudomonas aeruginosa TolA binding peptide. This spectra (figure 5.8) 
showed a similar number of peaks to that of the unbound spectra (144 peaks 
in bound spectra compared with 147 peaks in unbound), however, when the 
two spectra were overlaid and compared (figure 5.9), subtle differences were 
distinguishable in that a small population of peaks (approximately 10-20) 
were perturbed by the presence of the peptide. These perturbed peaks 
appeared to be in a variety of exchange regimes, with some peaks 
appearing, some disappearing, and some shifting position (see appendix 
section 7.7 for details on types of exchange regime). The majority of other 
peaks remained at constant intensity and position. 
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Figure 5.8 2D HSQC spectrum of 15N Pseudomonas aeruginosa TolA 
domain 3 in complex with Pseudomonas aeruginosa TolA binding 
peptide. HSQC spectra collected at 700 MHz for 220 μM psTolA3 in 
complex with 1.5 molar equivalent psTABp, recorded in 20 mM sodium 
phosphate, pH 7.5, at 25 °C.  
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Figure 5.9 2D HSQC overlay spectra of 15N Pseudomonas aeruginosa 
TolA domain 3 and 15N Pseudomonas aeruginosa TolA domain 3 in 
complex with Pseudomonas aeruginosa TolA binding peptide. HSQC 
spectra collected at 700 MHz of free 220μM psTolA3 (black) and in complex 
with 1.5x molar equivalent (red). Spectra recorded in 20mM sodium 
phosphate, pH7.5, at 25 °C. 
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Figure 5.10 Pseudomonas aeruginosa TolA binding peptide perturbs 
Pseudomonas aeruginosa TolA domain 3 resonance peaks. (A) shows 
different populations of peaks; those that disappear in the presence of 
peptide (slow/intermediate exchange), those that appear in the presence of 
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peptide (slow/intermediate exchange), and those that remain the same. (B) 
Movement of single peak in fast exchange from left to right as a function of 
peptide titration. 
 
In order to define the binding site of the peptide on psTolA3, a series of 
titrations at increasing concentration were performed. This would allow 
identification of the first peaks to be affected by the presence of the peptide, 
and thus the likely binding site of the peptide. In addition, it would also to 
ensure that increasing concentrations of peptide did not perturb further 
peaks, and thus the protein was saturated with peptide. psTolA3 was 
incubated for 10 mins at 25 °C with increasing concentrations of psTABp 
(0.2, 0.5, 0.7, 1, 1.5, 2, and 5 molar equivalent of psTolA3) and HSQC 
spectra acquired for each peptide concentration. As shown in figure 5.9, 
approximately 20 distinct peaks in total were found to be affected by peptide 
binding (at 1.5 molar equivalent peptide). At 2 molar equivilents of peptide, 
no further peaks appeared to be affected by peptide binding. At 5 mol. eqv. 
of peptide, quality of spectra had decreased significantly due peak 
broadening and was unusable.  
 
In addition, it was noted that the very intense peak at approximately 7.7 ppm 
in proton dimension and 126 ppm in nitrogen dimension appeared to be in 
fast exchange during the peptide titration (figure 5.10B). Whereas other 
peaks decreased in intensity, this peak stayed at uniform intensity, and its 
position moved from bottom right (at position 7.7, 126 ppm) to top left 
(position 7.8, 125.7 ppm). However, this particular peak is located at a 
position that the C-terminal residue peak is usually found (Cavanagh 2007). 
The C-terminal peak is also usually of high intensity. In this particular 
construct, the 6xHis tag is located at the C-terminus, and thus it is likely that 
this intense peak corresponds to the extreme C-terminal histidine residue. 
As this peak seems to be affected by peptide binding, this is either due to a 
global conformational change in the protein, or that the peptide is associating 
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with the C-terminus of the protein. Whether or not this suggests the location 
of the peptide binding site is on a particular face of the protein or not is 
unclear, a full assignment of peaks was completed to identify those other 
peaks that are involved in peptide binding, to ultimately identify the peptide 
binding site.   
 
5.2.6 Assigning backbone residues of unbound 15N 13C Pseudomonas 
aeruginosa TolA domain 3 
 
To fully assign protein residues of HSQC, the following 3 dimensional (1H, 
15N, 13C) spectra were collected from 15N 13C labelled psTolA3 using the 
following experimental types; HNCO, HNCACO, CBCANH, and 
CBCACONH. Acquisition parameters for each experiment are reported in 
materials and methods. Once acquired, spectra were processed and phased 
using NMRDraw (Delaglio et al. 1995). Spectra were then converted to 
Azara format using NMRPipe (Delaglio et al. 1995) and CCPN Analysis 
(Vranken et al. 2005) was used to analyse and assign residues from carbon 
sequential walks (figure 5.11, see appendix section 7.7 for details of 
experiment types and sequential backbone assignment).  
 
Of 130 residues in the protein, 7 prolines are present, and thus no peak is 
seen in HSQC. In addition, 1 peak is also lost as N-terminus, leading to 122 
residues to be assigned. There were 147 peaks in total in HSQC spectra, of 
which 27 were confirmed as sidechains. Therefore 119 peaks were counted 
and picked in HSQC spectra (not counting sidechain peaks), indicating that 3 
peaks were missing from HSQC spectra. Of the 119, 110 peaks were 
unambiguously assigned to protein residues using sequential walk 
assignment method using combination of CBCACONH with CBCANH and 
HNCO with HNCACO. As 110 resonances were assigned, statistically, the 
HSQC spectra is over 90% assigned. 12 resonances remain unassigned 
which are the following: Ala2, Ser28, Leu29, Leu36, Val37, Ser38, Asn49, 
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Gly50, Arg101, Lys116, Glu118, Asp119, Leu120. These resonances were 
unassignable due to either the quality of 3D spectra, or degenerate nature of 
carbon chemical shifts, leading to difficulty in differentiating between residue 
types. Additional 3D spectra (15N NOESY and HCCCONH experiments, as 
well as Trosy-based pulse sequence of CBCANH) were acquired in an 
attempt to assign missing residues, however they failed to yield any further 
assignments. Assignments were mapped onto HSQC spectra, and these are 
shown in figure 5.12A/B. In addition, assigned residues were mapped onto 
psTolA3 crystal structure to show assignment coverage using PyMOL 0.99 
(Delano Scientific) (figure 5.13). Assignments for residues 2 to 40 which are 
shown as a long alpha-helical strand in the psTolA3 crystal structure are 
found to be in the central (8.0 to 8.5 ppm in proton dimension) region of the 
HSQC spectra, a region that resonances consisting disordered/unstructured 
protein areas are usually clustered (Cavanagh 2007). Additionally, these 
peaks appear to be very intense in 3D experiments. This would suggest that 
rather than being alpha-helical as in the crystal structure (Witty et al. 2002), 
the stretch from residues 2 to 40 is unstructured. As stated previously, this 
same region appears to be unstructured in the solution NMR structure of 
E.coli TolA domain 3 (Deprez et al. 2005). 
 
Figure 5.11 Example of sequential walk method used in assigning 
Pseudomonas aeruginosa TolA3 NMR spectrum. 
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Figure 5.12A 2D HSQC spectra of 15N Pseudomonas aeruginosa TolA 
domain 3 labelled with residue assignments.  
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Figure 5.12B Zoomed in view of central (7.2 – 9.2 ppm) region of 2D 
HSQC spectra of 15N Pseudomonas aeruginosa TolA domain 3 labelled 
with residue assignments.  
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Figure 5.13 Assigned residues of unbound Pseudomonas aerugionsa 
domain 3 from NMR mapped onto crystal structure. psTolA3 (PDB ID: 
1LR0) displayed in ribbon format with assigned residues (red) and 
unassigned residues (green) mapped onto structure to indicate assignment 
coverage. Cyan indicates C-terminal 6xhis tag. 
 
5.2.7 Predicting and comparing Pseudomonas aeruginosa TolA domain 
3 chemical shifts with Sparta+ and ShiftX2. 
 
To verify the backbone resonance assignments for the unbound form of 
Pseudomonas aeruginosa TolA domain, as the crystal structure for this 
protein was already known, chemical shift predictions were made. The PDB 
co-ordinates (1LR0) were modified to include hydrogen atoms using 
MolProbity online software (Chen et al. 2010), and subsequently analysed 
with both Sparta+ (Shen et al. 2010) and ShiftX2 (Han et al. 2011). Sparta+ 
and ShiftX2 use a neural network algorithms to make chemical shift 
predictions based on a database chemical shifts for known protein structures 
(Shen et al. 2010, Han et al. 2011). When comparing predicted and 
Chapter 5 
   
186 
observed chemical shifts it was noted that Sparta+ yielded significantly better 
predicted chemical shifts (figure 5.14 for proton and figure 5.15 for nitrogen) 
when compared to predicted residues. Expected error values were 
calculated from the standard deviation of predicted errors divided by the 
square root of the number of shifts. All predictions in both dimensions, with 
the exception of Gln15 in the Nitrogen dimension were within expected error 
values, and thus predictions were considered to be of high confidence. For 
proton dimension, the average root mean square distance between 
predicted and observed values was 0.412 ppm and for nitrogen dimension it 
was 2.750 ppm. Given that most 1H shifts are in the range of 7.0 – 9.5 ppm 
(a range of 2.5ppm), this would indicate that there is approximately 16% 
error in the proton dimension. In the nitrogen dimension, given that most 
shifts are between 110 – 130 ppm (a range of 20 ppm), this would give an 
error of approximately 14%. It should be noted that for residues 1-40 in the 
proton dimension, the agreement between observed and predicted chemical 
shifts is poor in comparison to the rest of the protein. While the crystal 
structure these residues are structured (alpha-helical), in the NMR spectra it 
would appear as though this stretch unstructured due to their location 
between 8.0 and 8.5 ppm in 1H dimension. Thus, as the chemical 
environment is different than expected, the chemical shift prediction will be 
different. It is possible that these residues are structured in the crystal 
structure due to crystal packing. 
 
Given that the predicted chemical shifts match well within the expected 
parameters of prediction with those observed experimentally, it gave good 
confidence that the backbone assignments were correct. 
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Figure 5.14 Graphical representation of Sparta+ proton chemical shift 
predictions compared with observed chemical shifts. (A) Predicted 
chemical shifts (black) against observed (blue). (B) Comparison of predicted 
and observed absolute chemical shifts.  
 
 
 
 
 
 
 
B 
Chapter 5 
   
188 
 
 
Figure 5.15 Graphical representation of Sparta+ nitrogen chemical shift 
predictions compared with observed chemical shifts (A) Predicted 
chemical shifts (black) against observed (blue). (C) Comparison of predicted 
and observed absolute chemical shifts.  
 
5.2.8 Assigning bound Pseudomonas aeruginosa TolA domain 3 in 
complex with Pseudomonas aeruginosa TolA binding peptide 
 
Having assigned greater than 90% of peaks found in the HSQC spectra of 
unbound psTolA3, a further set of 3 dimensional spectra were acquired on 
15N-13C psTolA3, using the following experiment types; HNCO, HNCACO, 
CBCANH, and CBCACONH. As the majority of peaks were unaffected by 
binding, the unbound assignments were used as a basis for bound 
assignments, although all bound backbone assignments were verified 
through sequential walks.  
 
B 
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144 peaks were picked in bound HSQC spectra, of which 21 were 
sidechains. Like the unbound spectra, there were 122 residues to be 
assigned, of which 103 were assigned unambiguously using unbound 
assignments as a basis with sequential carbon linkage walks to confirm 
connectivity. The 19 unassigned residues were either not present in the 
unbound assignment (12 residues), or their identity could not be confirmed 
by independent sequential walks. The bound spectra are therefore 85% 
assigned (figure 5.16A/B).  
 
The quality of the 3D bound spectra was worse than that of the unbound 
spectra. It is possible that at higher concentrations of peptide (i.e. when the 
protein is saturated) then some form of dimerisation/ multimerisation/ 
aggregation occurs, causing the reduction in spectra quality. Although it was 
possible to confirm through sequential walks the assignments of the bound 
spectra based on the unbound, no new assignments were obtained, i.e. the 
12 unassigned resonances from the unbound psTolA3 (Ala2, Ser28, Leu29, 
Leu36, Val37, Ser38, Asn49, Gly50, Arg101, Lys116, Glu118, Asp119, 
Leu120). Those peaks that were perturbed in the presence of the peptide 
clustered into 2 groups; those that were perturbed at lower concentrations of 
peptide (potentially the initial site of interaction between peptide and protein 
as they seemed to cluster between residues 53 and 57) and those that were 
perturbed at higher concentrations of peptide. These additional residues may 
be perturbed at higher concentrations of peptide for a number of reasons. 
Firstly, it is possible that as a result of peptide binding protein there is a 
conformational change in the psTolA3. Secondly, it is possible that the 
peptide is either binding to a second, lower affinity site on the protein, or it is 
binding to the protein in a non-specific manner. Residues affected by 
binding, and the peptide concentration at which they are perturbed is 
displayed in figure 5.17.  
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Figure 5.16A 2D HSQC spectra of 15N Pseudomonas aeruginosa TolA 
domain 3 bound to Pseudomonas aeruginosa TolA binding peptide 
labelled with residue assignments. psTABp at 2 molar equivalent to 
psTolA3. 
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Figure 5.16B Zoomed in view of central (7.2 – 9.2 ppm) region of 2D 
HSQC spectra of 15N Pseudomonas aeruginosa TolA domain 3 bound 
to Pseudomonas aeruginosa TolA binding peptide labelled with residue 
assignments. psTABp at 2 molar equivalent to psTolA3. 
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Residue 
 
Mol. Eqv. of peptide when perturbed 
  0.5x 0.7x 1x 1.5x 2x 
Val34           
Arg42           
Arg43           
Ser52           
Val53           
Glu54           
Val55           
Ile57           
Glu58           
Thr66           
Ser74           
Gly75           
Phe79           
Ala83           
Val87           
Arg88           
Tyr108           
Arg112           
Ile113           
Ile114           
Phe115           
Ser121           
 
Figure 5.17 Residues perturbed by Pseudomonas aeruginosa TolA 
binding peptide. Red colour indicates residue not perturbed in presence of 
peptide, green indicates that it is.  
 
 
Chapter 5 
   
193 
5.2.9 Mapping residue assignments perturbed by Pseudomonas 
aeruginosa TolA binding peptide onto Pseudomonas aeruginosa TolA 
domain 3 crystal structure.  
 
Having confirmed that the peptide perturbs a small population of peaks, and 
that those peaks seem to cluster between psTolA3 residues 53-57 (see table 
5.1 for protein secondary structure), the residues affected by peptide binding 
were mapped onto psTolA3 crystal structure (PBD ID 1LR0, (Witty et al. 
2002)). 
 
Residue 
number 
Assignment 
number 
Secondary 
structure 
228 – 265 2 – 39 1st alpha helix 
278 – 284 52 – 58 1st beta strand 
288 – 297 62 – 71 2nd beta strand 
302 – 315 76 – 89 2nd alpha helix 
319 – 323 93 – 97 3rd alpha helix 
326 – 332 100 – 106 4th alpha helix 
334 – 340 108 – 114 3rd beta strand 
342 – 347 116 - 121 5th alpha helix 
 
Table 5.1 Pseudomonas aeruginosa TolA domain 3 (residues 226 – 347) 
secondary structure features (Uniprot ID: P50600). 
 
Upon the addition of 0.7 mol. eqv. psTABp, residues Val53 to Ile57 are 
perturbed. These residues map (figure 5.18) onto a β-sheet forming a “small 
pocket”. Additionally, residues in close proximity to this β-sheet are also 
perturbed. This would suggest that assigned residues Val53 to Ile57 are part 
of the binding interface between psTolA3 and psTABp. Adding up to 2 mol. 
eqv. psTABp, more residues were perturbed, and when mapped onto the 
crystal structure (figure 5.19), they are found to be not only highly dispersed 
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around the protein, but primarily in both in isolated positions and loop 
regions, suggesting that these perturbations are as a result of a 
conformational change in the psTolA3 upon binding of psTABp. It is also 
possible that these dispersed perturbations are as a result of multiple 
additional peptide bindings, potentially of a non-specific nature. 
 
 
 
Figure 5.18 Pseudomonas aeruginosa TolA domain 3 residues 
perturbed by Pseudomonas aeruginosa TolA binding peptide mapped 
onto secondary structure of Pseudomonas aeruginosa TolA domain 3 
crystal structure. (A) 0.7 molar equivalent (B) 2 molar equivalent. Residues 
perturbed by binding coloured cyan. Unperturbed residues grey. PDB ID: 
1LR0.  
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Figure 5.19 Pseudomonas aeruginosa TolA domain 3 residues 
perturbed by Pseudomonas aeruginosa TolA binding peptide mapped 
onto molecular surface of Pseudomonas aeruginosa TolA domain 3 
crystal structure. (A) 0.7 molar equivalent (B) 2 molar equivalent. Residues 
perturbed by binding coloured cyan. Unperturbed residues grey. PDB ID: 
1LR0. 
 
As seen in figure 5.19A/B when mapped onto a molecular surface of crystal 
structure, at low concentration of peptide, a line of perturbed residues cluster 
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within a pocket, of 19 Å in length. Given that the peptide is 16 residues long 
(if in elongated linear conformation), it would suggest that the protein 
residues clustered around Val53 to Ile57 are the peptide binding site. As 
seen in figure 5.19C/D all further perturbations at higher concentrations of 
peptide are distributed throughout the protein, and thus are likely to occur 
due to a conformational change in the psTolA3 due to association of peptide.  
 
5.3 Discussion 
 
This NMR perturbation mapping data is the first indication of any structural 
information regarding the TolA-TolB interaction of Gram-negative bacteria. 
Although the E.coli TolA binding site on E.coli TolB had been defined as the 
intrinsically disordered N-terminus (Bonsor et al. 2009), the TolB binding site 
on TolA has not been reported, in either E.coli, Pseudomonas aeruginosa or 
any other Gram-negative bacteria. Until very recently no crystal structure 
had been reported for E.coli TolA. All structural information for the protein 
had been based on either an NMR solution structure of eTolA3 (Deprez et al. 
2005), or the crystal structure of psTolA3 (Witty et al. 2002). The recently 
published E.coli TolA3 crystal structure will be discussed in the following 
chapter. Despite much research, no structural information for the TolA-TolB 
complex has been reported. In this work (as well as by previous members of 
this lab), attempts were made to crystallise E.coli TolA3 alone, E.coli TolA3-
TolB complex, E.coli TolA3-TolB-colicin E9 T-domain complex, E.coli TolA3 
fusion proteins that included eTolB disordered N-terminus fused via a flexible 
linker to TolA3), E.coli TolA3-TolA binding peptide complex as well as 
Pseudomonas aeruginosa TolA3-TolA binding peptide complex. All of these 
approaches have met with failure. This is likely due to the highly soluble 
nature of the E.coli TolA3, which even at 150mg/ml concentration could not 
be crystallised, coupled with the very weak nature of the TolA-TolB 
interaction, which is reported to be in the order of 10-40 μM for E.coli, and 
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estimated to be in the order of several hundred μM for Pseudomonas 
aeruginosa Tol proteins, in vitro.  
 
This mapping appears to show that the psTABp (and thus by analogy the 
potentially disordered N-terminus of psTolB) interacts with the 1st beta strand 
of psTolA3 (and surrounding residues on the same face), as these are the 
residues that are first perturbed by the binding of the psTABp. Following this, 
at higher concentrations of peptide, further chemical shift perturbations are 
found in other regions of the protein, however, these are in isolated patches, 
suggesting that rather than caused by a binding event, these perturbations 
are caused by a small conformational change in the protein in response to 
binding.  
 
When assigning backbone resonances to the HSQC spectra it became 
apparent that most of the N-terminal residues of psTolA3 were found in the 
middle section of the spectra (between 8.0 – 8.5 ppm), typically where peaks 
corresponding to disordered regions of proteins are found (Cavanagh 2007). 
This suggested that whereas in the crystal structure, the N-terminus of 
psTolA3 was of alpha helical structure, in the NMR sample, it was not. This 
is not without precedence, as the solution NMR structure published for E.coli 
TolA domain 3 also showed it’s N-terminus to be in a disordered 
conformation (Deprez et al. 2005). 
 
As the peak (which likely corresponds to the C-terminal histidine) was 
affected by binding, an additional psTolA3 construct was made. In this 
constuct the his-tag was moved to the opposite end of the protein (onto the 
long N-terminal strand, shown as alpha-helical in the crystal structure, but 
suggested to be disordered in these NMR spectra) and was also made to be 
thrombin cleavable. However, this construct (pEC16) was unstable, and 
proved to be problematic during purification. Additionally, a tagless variant of 
psTolA3 was made earlier in this work (pEC1), that was identical to the 
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construct used in this NMR assignment (pEC4), however, as shown in 
section 4.2.1.1, this protein was very difficult to purify and of low final yield. 
As a result an isotope labelled version of the protein was not attempted. 
 
5.3.1 Summary 
 
In the two previous chapters, attempts to define either the structure of the 
TolA-TolB complex from E.coli have not been successful. Although it was 
shown that Pseudomonas aeruginosa TolA and TolB interact with one 
another, I was unable to crystallise this complex, either with both whole 
proteins, or with the Pseudomonas aeruginosa TolA binding peptide as a 
surrogate for TolB. In chapter 5, I have used NMR to define the binding site 
of Pseudomonas aeruginosa TolB (represented by the TolA binding peptide) 
on TolA. An isotopically labelled Pseudomonas aeruginosa TolA was found 
to be stable in NMR experiments, and, when in the presence of the binding 
peptide, approximately 10-15% of it’s residues are perturbed, with some 
residues being perturbed at lower concentrations of peptide to others. 
Following 3D spectra acquisition, over 90% of the unbound Pseudomonas 
aeruginosa TolA domain 3 was assigned (85% for the bound form) and once 
the residues that were perturbed by peptide were identified, they were 
mapped onto the published crystal structure of Pseudomonas aeruginosa 
TolA. This showed that the binding site on TolA is likely to be along the 1st 
beta strand (residues Val53 – Ile57) within a narrow pocket. This binding site 
is within the same location as bacteriophage g3p and colicin N proteins bind 
E.coli TolA, likely mimicking the native interaction between TolA and TolB.  
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6. General discussion 
 
This work has set out to characterise and define the interaction between 
E.coli and Pseudomonas aeruginosa TolA and TolB. This interaction is vital 
to the stability of the outer membrane, and without either one of these 
components, the integrity of the membrane is compromised (Lloubes et al. 
2001). This interaction spans the periplasm allowing communication 
between the inner and outer membranes. This interaction is also subverted 
by colicins to facilitate their entry into the bacterial cell.  
 
Numerous functions for the Tol system have been suggested, with varying 
degrees of evidence. The Tol system may have a role in maintaining the 
structure of the bacterial cell membranes through an architectural function; 
forming a bridge network aiding envelope cohesion from the inner 
membrane, across the periplasm and onto the outer membrane (Henry et al. 
2004; Cascales et al. 2007). Other potential functions have been inferred 
from a variety of evidence, including a role in cell division, as Tol-Pal 
complex has been localised to junction points between the outer and inner 
membrane and may act in drawing the peptidoglycan layer in contact with 
inner and outer membrane (Gerding et al. 2007), assembly and localisation 
of lipopolysaccharide (Gaspar et al. 2000) and localisation and assembly of 
outer membrane proteins, in particular porins (Cascales et al. 2007). It has 
also been reported that Tol-Pal may be involved in the transfer of structural 
components from the inner to the outer membrane, which again is likely to 
be tied to the tol-pal mutants lacking proper outer membrane stability 
(Lloubes et al. 2001; Goemaere et al. 2007). In particular, lipopolysaccharide 
(LPS), a core component of the outer membrane, has been reported to be at 
lower levels in the outer leaflet of the outer membrane in tol-pal mutant 
strains of E.coli (Gaspar et al. 2000; Lloubes et al. 2001; Vines et al. 2005; 
Gerding et al. 2007). Other work has reported that in tolA mutants, LPS 
biosynthesis is not reduced, rather a reduction was seen in the levels of LPS 
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in the outer leaflet of the outer membrane, likely as a result of the LPS post-
synthesis processing and transportation (Gaspar et al. 2000).  
 
In my own opinion it seems likely that the Tol proteins are involved in the 
catalysis/remodelling of carbohydrates or the transport of carbohydrates 
from the inner to outer membranes. Given that TolB is a beta-propeller 
protein, and that beta-propellor proteins are often enzymes or transporters it 
would suggest that TolB has one of these functions. In bacteria, several 
beta-propeller proteins, such as sialidase in Salmonella typhimurium and 
glucose dehydrogenase in Acinetobacter calcoaceticus are known to bind 
carbohydrates (Jawad & Paoli 2002). The organisation of the Tol system 
also lends itself to a role in transport of ligands from the inner to the outer 
membrane. Energised by TolQ and TolR, TolA when in complex with a 
ligand bound TolB (within it’s beta-propeller domain) transports the TolB 
across the periplasm, delivering it to the outer membrane, where TolB then 
binds Pal, which not only causes the dissociation of TolA from TolB, but in 
Pal binding in the beta-propeller domain, causes dissociation of the ligand. In 
addition, rather than delivering a ligand to the outer membrane, as TolB 
associates with Pal at the peptidoglycan layer, it is possible that the 
transported ligand is component of peptidoglycan, such as NAG, NAM, or a 
branched derivate. Further evidence to support this theory comes from the 
similarities between the Tol and Ton systems. The TonB-ExbB-ExbD inner 
membrane complex is an energised transporter of Vitamin B12 and iron 
sideophores (Braun et al. 1993) and given that TolQRA is organised in a 
nearly identical manner it would seem likely that TolQRA provides energy to 
TolB for some form of transport to from the inner to the outer membrane. 
This however, as yet there is no evidence to support this theory and suggest 
that TolB binds any specific ligand, other than the protein interactions 
reported above.  
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It has been documented that colicin’s appear to mimic native protein-protein 
interactions in order to subvert the system to allow uptake of the colicin into 
the cell (Bonsor et al. 2009). In the case of translocation of colicin E9 into the 
periplasm the translocation domain of the colicin threads through OmpF to 
contact E.coli TolB binds with the beta-propeller domain of eTolB. This 
interaction mimics the interaction of ePal with eTolB, wherein ePal also binds 
within the beta-propellor domain. However, rather than promote order in the 
N-terminus of the eTolB as ePal does, it promotes disorder, driving the 
interaction with eTolA (Bonsor et al. 2009). It has been commonly assumed 
that this is not a unique factor to colicin E9, rather all colicins may mimic a 
native interaction of Tol proteins. Thus, as colicin A, colicin N and 
Bacteriophage G3P interact with TolA independently of TolB, it has been 
assumed that one of these proteins may mimic the native TolA-TolB 
interaction. However, although colicin N and bacteriophage interact with 
TolA on the same face (Lubkowski et al. 1999) (Hecht et al. 2009), and in the 
same binding site, conversely, ColA interacts with TolA on the opposite side 
(Hecht et al. 2010). When comparing the perturbation mapping of the 
psTABp on psTolA against the crystal structures of eTolA3 interacting with 
either ColA or g3p, it would appear as though at high concentrations of 
peptide there are two clusters of chemical shift perturbations, one for each 
side corresponding to either ColA or g3p binding (figure 6.1, 6.2). However, 
when considering perturbations that occur at lower concentrations of 
peptide, given that they cluster along residues 52 to 58 (as well as surround 
residues), this would suggest that the psTABp binding is similar to that of 
g3p (and thus ColN) as they too interact on the same face as residues 52-58 
present. This would again suggest that like colicin E9, both colicin N and g3p 
are mimicking a native interaction of the Tol system. It should however be 
noted that although ColN interacts with eTolA on the same surface as 
psTABp binds psTolA3, it has been reported that ColN causes a large 
conformational change in eTolA, potentially unfolding it (Hecht et al. 2009). 
Whether or not the unfolding of eTolA by ColN is unique (and a result of 
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ColN’s translocation method) is unknown, but it seems likely as no other 
evidence of unfolding has been reported for eTolA when binding either eTolB 
or other colicins. Thus it is likely that although the native TolA-TolB 
interaction has been hijacked by ColN and g3p and they both bind in a 
similar pocket to that of TolB, their subsequent effects on TolA are different. 
In a recent development, a group investigating the E.coli TolA domain and its 
interactions with colicin A and TolB have confirmed these findings (Li et al. 
2012). Work by Li et al has reported for the first time a crystal structure for 
E.coli TolA domain 3. This was achieved through the reductive methylation 
of surface lysine residues in order to make the protein more ameniable to 
crystallisation. In addition, Li et al. attempted to use a synthetic peptide 
corresponding to the disordered N-terminus of E.coli TolB in a similar 
approach to this work. Although they were unable to obtain either a 
crystallisable complex or an assigned NMR spectrum they have reported 
that the pattern of residue perturbations recorded for 15N labelled eTolA3 in 
the presence of their eTABp was similar to the pattern of residue 
perturbation when the labelled eTolA3 was in the presence of colicin N. 
colicin N interacts with eTolA3 on the same face as bacteriophage g3p 
protein. Thus the work by Li et al. supports the work I have reported above 
(figure 6.1) in that I suggest that the binding site of TolB on TolA is identical 
to the binding site of colicin N and g3p (Li et al. 2012).  
 
It should be noted that the NMR data collected for Pseudomonas aeruginosa 
TolA3-TABp interaction suggested that there may be a second site of 
interaction between the protein and peptide. If this is the case, then it 
possible that colicin A is utilising a second, lower affinity binding site, as 
evidenced by a small cluster of residues that were found to be perturbed at 
higher concentrations of peptide which sit directly underneath the colicin A 
binding site. If this is indeed the case, then as with colicin N and g3p 
potentially mimicking TolB binding in the primary higher affinity site, that 
colicin A may be mimicking the lower affinity site. 
Chapter 6 
   
203 
 
 
Figure 6.1 Pseudomonas aeruginosa TolA domain 3 residues perturbed 
by 0.7x molar equivalent Pseudomonas aeruginosa TolA binding 
peptide mapped onto molecular surface of Pseudomonas aeruginosa 
TolA domain 3 crystal structure docked with colicin A and 
Bacteriophage g3p (N1 domain) Residues perturbed by binding coloured 
cyan, Unperturbed residues grey, colicin A red and bacteriophage g3p (blue) 
PDB ID: 1LR0 (psTolA3), 1TOL (g3p), 3QDR (ColA).  
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Figure 6.2 Pseudomonas aeruginosa TolA domain 3 residues perturbed 
by 2x molar equivalent Pseudomonas aeruginosa TolA binding peptide 
mapped onto molecular surface of Pseudomonas aeruginosa TolA 
domain 3 crystal structure docked with colicin A and Bacteriophage 
g3p (N1 domain) Residues perturbed by binding coloured cyan, 
Unperturbed residues grey, colicin A red and bacteriophage g3p (blue) PDB 
ID: 1LR0 (psTolA3), 1TOL (g3p), 3QDR (ColA).  
 
In the preparation of this manuscript, a new structure has been reported for 
TolA, in Vibrio cholera. This TolA is a crystal structure of the complex 
between the CTXphi pIII N-terminal domain and the Vibrio cholerae TolA 
domain 3 (figure 6.3). When comparing this structure of the Vibrio cholerae 
TolA structure to that of E.coli or Pseudomonas aeruginosa it shares a 
remarkably similar fold. This lends further weight to the argument that the Tol 
systems, and in particular the TolA-TolB interaction is conserved throughout 
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Gram-negative bacteria. In addition, when comparing the CTXphi-Vibrio 
cholerae TolA structure (Ford et al. 2012) with that of the colicin A-E.coli 
TolA3 (Hecht et al. 2010), it would appear as though they share a similar site 
of interaction, on the opposite side to the colicin N-g3p-putative TolB site. 
Whether or not these two proteins are mimicking a native interaction on TolA 
is unknown. 
 
 
 
Figure 6.3 Crystal structure of a complex between the CTXphi pIII N-
terminal domain and the Vibrio cholerae TolA C-terminal domain. The 
filamentous bacteriophage CTX (pink, residues 3-105) interacts with TolA 
domain 3 from Vibrio cholera (green, residues 254 – 355). PDB ID: 4G7X 
(Ford et al. 2012).  
 
For the future direction of work in this area, there are still a number of 
avenues left to explore. Althought the work of Li et al (Li et al. 2012) has 
attempted to identify the location of the TolB binding site on TolA through a 
similar synthetic peptide route as this work, they have been unable to 
determine the structure of this complex. As the Pseudomonas aeruginosa 
TolA was very stable for long periods of time in the NMR magnet, a future 
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direction could be the solvation of the psTolA3-psTABp complex through a 
solution NMR structure. Although this work reports that the N-terminus of 
Pseudomonas aeruginosa TolB is a site of interaction with TolA, it remains 
unclear as to whether or not it is in dynamic equilibrium like the E.coli TolB 
N-terminus is presumed to be in. This could be achieved through NMR and 
labelled Pseudomonas aeruginosa TolB. However, the issues that 
Pseudomonas aeruginosa TolB has in regard to solubilty and poor gene 
expression (despite codon optimisation for E.coli cells) is something that 
would have to addressed first. It would also be interesting to investigate if 
Pseudomonas aeruginosa Pal (also called OprL) binds TolB in a similar 
manner to the E.coli system, and potentially regulates the allosteric transition 
of the N-terminus from ordered to disordered state. During this work I 
attempted to clone and purify Pseudomonas aeruginosa Pal, but to without 
success. Like many of the Pseudomonas aeruginosa genes do not express 
in E.coli cells.  
 
The ultimate unanswered question in the Tol system is to finally determine 
its function. Many functions have been suggested, be it a function in 
tethering the outer and inner membrane together, organising outer and inner 
membranes during cell division, or acting as a ligand transporter. Recently it 
was suggested that E.coli TolB may bind fragments of the peptidoglycan 
layer (Greg Papadakos, personal communication), which, if true, would 
suggest a role for TolB as a binding protein of peptidoglycan, assisting in 
either the transport or turnover. If proven, then this could yet be the 
breakthrough in the area of Tol biology that we have been waiting for. 
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7. Appendix 
 
7.1 List of plasmids 
 
Plasmid Encodes Cloning 
sites 
Backbone 
pEC1 Pseudomonas aeruginosa TolA (226-347) BamHI/NdeI pET11c 
pEC2 Xanthomonas campesteris TolA (224 - 
345) 
BamHI/NdeI pET11c 
pEC3 Xanthomonas campesteris TolA (224 - 
345) 
BamHI/NdeI pET11c 
pEC4 Pseudomonas aeruginosa TolA (226-
347), C-terminal 6xHis tag 
BamHI/NdeI pET21d 
pEC5 Pseudomonas aeruginosa TolB (22-432), 
C-terminal 6xHis tag 
BamHI/NdeI pET21d 
pEC6 Pseudomonas aeruginosa TolA (226-
347), thrombin cleavable C-terminal 
6xHis tag 
BamHI/NdeI pET21d 
pEC7 Colicin E9-TolB fusion protein EC7, C-
terminal 6xHis tag on Im9 
KpnI/XhoI pCS4 
pEC8 Colicin E9-TolB fusion protein EC8, C-
terminal 6xHis tag on Im9 
KpnI/XhoI pCS4 
pEC11 Pseudomonas aeruginosa TolB (22-432), 
C-terminal 6xHis tag 
BamHI/NdeI pET21d 
pEC12 Colicin E9-TolB fusion protein EC12, C-
terminal 6xHis tag on Im9 
KpnI/XhoI pCS4 
pEC13 Pseudomonas aeruginosa TolB (22-432), 
C-terminal 6xHis tag 
BamHI/NdeI pET21d 
pEC14 Pseudomonas aeruginosa TolB (22-432), 
C-terminal 6xHis tag. Codon optimised for 
E.coli expression 
BamHI/XhoI pET21d 
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pEC15 Pseudomonas aeruginosa Pal (60-168), 
C-terminal 6xHis tag 
NcoI/XhoI pET21d 
pEC16 Pseudomonas aeruginosa TolA (226-
347), thrombin cleavable N-terminal 
6xHis tag 
BamHI/NdeI pET15b 
pAK108 E.coli TolA (293-421) NcoI/XhoI pET21d 
pDAB18 E.coli TolB (22-430) NcoI/XhoI pET21d 
pCS4 Colicin E9 (1-582) and Im9 (1-86, with C-
terminal 6xHis tag) 
NdeI/XhoI pET21a 
 
7.2 List of primers 
 
EC12FWD: AAGTGGTGGTGCTTCTGATGGTTCAGGATGGAGTTCGGAAAATAACC 
EC12REV: GGTTATTTTCCGAACTCCATCCTGAACCATCAGAAGCACCACCACTT 
 EC78KPNIFWD: TTCCGGTGGTGGCTCGGGTACCGGCGGTAATTTGTCAG 
 EC78KPNIREV: CTGACAAATTACCGCCGGTACCCGAGCCACCACCGGAA 
 PTOLB_EC5_TEV_FWD1: GAATTCGTTCAGGTAAGGGGACCAGGAAGG 
  PTOLB_EC5_TEV_REV1: GTGGTGGTGGTGGTGGTGCTCGAGTCCCTGGAAGTAGAGATTCTC 
PTOLA3_EC6_FWD: GGATCCGCATTGGCCGAGTTG 
   PTOLA3_EC6_REV: CTCGAGTCACAGACTCAAATC 
   PTOLB_EC5_FWD: GGATCCATGGCCGACCCGCTGGTGA 
  PTOLB_EC5_REV: GAATTCGTTCAGGTAAGGGGA 
   PTOLB_EC5_TEV_FWD: TCCCCTTACCTGAACGAATTCGAGAATCTCTACTTCCAGGGA 
PTOLB_EC5_TEV_REV: GAGAATCTCTACTTCCAGGGACTCGAGCACCACCACCACCACCAC 
XANTOLA3EC3 :ACTGCGTCAGGTGGCGGCGCATATGGCGCAGCAGGCG 
 XANTOLA3EC4: ACACACCTCCGGATCCTTACTGATCCTGCGCGGT 
  XANTOLA3EC1: ACTGCGTCAGGTGGCGGCGCATATGGCGCAGCAGGCGAGCAG 
 XANTOLA3EC2: ACACACCTCCGGATCCCTGATCCTGCGCGGT 
  PSETOLA3EC1: GGCTGCCGAGGACAAGCATATGCGGGCATTGGCCGAGTTGC 
 PSETOLA3EC2: TTTTTTGGATCCTTACAGACTCAAATCCTCCGGTTT 
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7.3 List of protein sequences 
 
pAK108 (E.coli TolA, residues 293-421) 
 
ADDIFGELSSGKNAPKTGGGAKGNNASPAGSGNTKNNGASGADINNYAG
QIKSAIESKFYDASSYAGKTCTLRIKLAPDGMLLDIKPEGGDPALCQAALAA
AKLAKIPKPPSQAVYEVFKNAPLDFKP 
 
pDAB18 (E.coli TolB, residues 22-430) 
 
MEVRIVIDSGVDSGRPIGVVPFQWAGPGAAPEDIGGIVAADLRNSGKFNPL
DRARLPQQPGSAQEVQPAAWSALGIDAVVVGQVTPNPDGSYNVAYQLVD
TGGAPGTVLAQNSYKVNKQWLRYAGHTASDEVFEKLTGIKGAFRTRIAYVV
QTNGGQFPYELRVSDYDGYNQFVVHRSPQPLMSPAWSPDGSKLAYVTFE
SGRSALVIQTLANGAVRQVASFPRHNGAPAFSPDGSKLAFALSKTGSLNLY
VMDLASGQIRQVTDGRSNNTEPTWFPDSQNLAFTSDQAGRPQVYKVNIN
GGAPQRITWEGSQNQDADVSSDGKFMVMVSSNGGQQHIAKQDLATGGV
QVLSSTFLDETPSLAPNGTMVIYSSSQGMGSVLNLVSTDGRFKARLPATD
GQVKFPAWSPYL 
 
pEC1 (Pseudomonas aeruginosa TolA, residues 226-347) 
 
MALAELLSDTTERQQALADEVGSEVTGSLDDLIVNLVSQQWRRPPSARNG
MSVEVLIEMLPDGTITNASVSRSSGDKPFDSSAVAAVRNVGRIPEMQQLPR
ATFDSLYRQRRIIFKPEDLSL 
 
pEC4 (Pseudomonas aeruginosa TolA, residues 226-347, C-terminal 6x 
His tag) 
 
MALAELLSDTTERQQALADEVGSEVTGSLDDLIVNLVSQQWRRPPSARNG
MSVEVLIEMLPDGTITNASVSRSSGDKPFDSSAVAAVRNVGRIPEMQQLPR
ATFDSLYRQRRIIFKPEDLSLLEHHHHHH 
  
pEC14 (Pseudomonas aeruginosa TolB, residues 22 – 432, C-terminal 
6x His tag) 
 
MADPLVISSGNDRAIPIAVVPFGFQGGNVLPEDMSNIIGNDLRNSGYFEPLP
RQNMISQPAQASEVIFRDWKAVGVNYVMVGNIVPAGGRLQVQYALFDV 
GTEQQVLTGSVTGSTDQLRDMSHYIADQSFEKLTGIKGAFSTKMLYVTAER
FSVDNTRYTLQRSDYDGARPVTLLQSREPIVSPRFSPDGRRIAYVSFEQKR
PRIFIQYVDTGRREQITNFEGLNGAPAFSPDGNRLAFVLSRDGNPEIYVMDL
GSRALRRLTNNLAIDTEPFWGKDGSTLYFTSDRGGKPQIYKMNVNSGAVD
RVTFIGNYNANPKLSADEKTLVMVHRQQGYTNFQIAAQDLQRGNLRVLSN
TTLDDSPTVAPNGTMLIYATRQQDRGVLMLVSINGRVRIPLPTAQGDVREP
SWSPYLNLEHHHHHH 
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7.5 Surface Plasmon Resonance immobilisation 
 
To couple the protein of interest to the sensor chip surface thiol coupling was 
used. Coupling occurs through reactive thiol-disulfide exchange with the 
introduced cysteine at the N-terminal end of E.coli TolA domain 2 (the 
ligand) and the prepared surface of the C1 sensor chip. A C1 chip has a 
simple flat carboxylated surface with no dextran matrix. This chip was 
chosen due to its lack of dextran coated surface, as described above. For 
coupling to occur, the C1 surface must have reactive disulfide groups 
introduced onto it and then coupling is mediated by maleimide reagents, 
resulting in a thioether bond between the ligand and the chip surface (figure 
7.1). 
 
Figure 7.1 ligand immobilisation onto C1 chip. The carboxylated C1 chip 
surface is activated by 1-ethyl-3-[dimethylaminopropyl]carbodiimide (EDC) 
and modified by N-hydroxysuccinimide (NHS) to form a NHS-ester, which is 
further modified with ethylenediamine through amine-coupling, presenting a 
free amine group. This free amine reacts with N-[ϒ-maleimidobutyryloxy]-
sulfosuccinimide ester (Sulfo-GMBS) which forms an irreversible thiol couple 
with the cysteine of the ligand. (Figure adapted from GE Healthcare Biacore 
Surface Sensor Handbook, 2008). 
 
7.6 ITC single site binding model 
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During an ITC experiment, a protein sample (P) is placed into the ITC cell, 
which has a working volume (V0). A ligand (L) is injected into it this cell, 
which remains at constant calorimetrically detected volume (V0) due to the 
displacement of volume into the communication tube (ΔV), through which the 
ligand has been titrated.  
 
As the total amount of P does not change during the experiment,  
 
Pt 0V0 = Pt V0 + (Pt 0 + Pt)  ΔV 
           2 
To account for the volumetric change after each injection, Origin uses two 
equations; Pt and Lt: 
 
The total concentration of P in V0 after each injection can thus be calculated, 
 
 
 
In addition, and assuming that all L stays in V0 , the concentration of L after 
each infection can be calculated thus,  
 
       as           
 
The single site binding model is expressed in the following form, 
 
L+P = LP 
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With the binding constant being represented by, 
 
KA = [LP]  
       [L][P] 
 
The binding constant can also be expressed in terms of Θ, the fraction of 
sites occupied by L, 
 
KA =     Θ      a 
       (1 – Θ)[L] 
 
This can be rearranged to give the concentration of free ligand, [L], 
 
[L] =     Θ      a 
       (1 – Θ)KA 
 
The total amount of ligand (Lt) can be calculated thus, 
 
Lt = [L] + n Θ Pt 
 
Which, when combined with equation for [L] and rearranged into a quadratic, 
gives the following equation, 
 
 
 
Q, the total heat content of the solution in the cell (V0) when only partially 
saturated Θ is expressed as (where ΔH is the molar heat of binding), 
 
Q = n Θ Pt ΔH V0 
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If Θ is substituted with the term from the above equation (deriving by solving 
the above quadratic equation), then Q can be expressed as, 
 
 
 
The heat after ith injection, Q(i), can be calculated by using hypothetical 
values for n, ΔH and KA. The heat released during the ith injection can be 
calculated as the difference between the Q(i) and the Q(i-1) (previous 
injection) thus, 
 
 
 
This equation accounts for the fact that V0 after the i-1 injection will not be 
the same as the V0 following the ith injection. It will however, contribute 
approximately 50% heat as the ith volume (Vi), which remains V0. Initially 
values for n, ΔH and KA are assumed and from this the Q(i) and ΔQ(i) for 
each injection are calculated. The experimental data is then fitted based on 
these theoretical calculated heat differences. The experimental data is then 
fitted again using fit optimisation based on the Levenberg-Marquardt 
algorithm (also known as damped least squares method) until no further 
improvement in fit is seen (Microcal 2004). 
 
7.7 Analytical Ultracentrifugation correction (SEDFIT) 
 
The SEDFIT program calculates the estimated uncorrected sedimentation 
coefficient (S*) distribution of the sample by fitting the predicted 
sedimentation behaviour of trial sedimentation coefficient distributions to the 
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experimental data collected for the sample of interest (Schuck 2000). The 
uncorrected sedimentation coefficient are then corrected for buffer density 
and viscosity to zero protein concentration (S020,w). The density and viscosity 
correction is expressed thus, 
 
S20,w = S*(1 – ν ρw) ηb / (1 – ν ρb) ηw 
 
Where S* is the uncorrected sedimentation coefficient, v is the partial 
specific volume of the protein, ρ is the density, η is the viscosity, and w and b 
refer to water and buffer respectively. 
 
7.8 NMR experiments types 
 
(All figures reproduced from http://www.protein-nmr.org.uk/solution-
nmr/spectrum-descriptions) 
 
1H-15N HSQC 
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CBCANH 
 
 
CBCACONH 
 
 
HNCO 
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HNCACO 
 
 
H-H NOESY 
 
 
 
7.9 Formaldehyde Crosslinking 
 
Formaldehyde crosslinking is a method of forming a covalent (not non-
thermostable) bond between polypeptides. A brief description of crosslinking 
chemistry is displayed below (Figure 7.2), and structure of DSP is displayed 
in figure 7.3. 
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Figure 7.2 Reaction scheme of protein crosslinking with formaldehyde.  
Protein is modified by the addition of formaldehyde (A), which, which in the 
presence of another protein (B) forms a methylene bridge. Specifically, 
primary amines (such as Lysine) react with formaldehyde and and nearby 
peptide to form methylene bridge and thus form crosslink (C). Figure 
adapted from Kiernan 2000.  
 
 
Figure 7.3 Dithiobis(succinimidylpropionate) [DSP] 
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List of abbreviations 
 
ampR ampicillin resistance 
ATP adenosine tri-phosphate 
AUC Analytical ultracentrifugation 
bp base pair 
BSA bovine serum albumine  
c.v. colume volume 
calc calculated 
CCCP carbonylcyanide m-chlorophenylhydrazone 
CD circular dichroism (spectroscopy) 
cps capsular polysaccharide 
dNTPs deoxynucleotide triphosphates 
DSP dithio-bis(succinimidyl propionate) 
ePal E.coli Pal 
eTABp E.coli TolA binding peptide 
eTolA(3) E.coli TolA (domain 3) 
eTolB E.coli TolB 
ESI electrospray ionization 
GlcNAc N-acetyl-β-D-glucosamine 
HMM Hidden Markov Model 
Hsp heat shock protein 
IM inner membrane 
IPTG isopropyl-β-D-thiogalactopyranoside 
ITC isothermal titration calorimetry 
kb kilo base (pair) 
kDa kilo Dalton 
KDO 3-deoxy-manno-2-octulosonic acid 
LB lysogeny broth 
LPS lipopolysaccharide 
MALDI matrix assisted laser desorption/ionization 
min minutes 
MS mass spectrometry 
MurNAc N-acetylmuramic acid 
Mw molecular weight 
NMR nuclear magnetic resonance (spectroscopy) 
OD600 optical density at 600 nm 
OM outer membrane 
OMP outer membrane protein 
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ORF/orf open reading frame 
P promoter 
PAGE polyacrylamide gel electrophoresis  
Pal peptidoglycan associated lipoprotein  
PCR polymerase chain reaction 
PEG polyethyleneglycol 
PG peptidoglycan 
pmf proton motive force 
PMSF phenylmethanesulfonyl fluoride 
psPal Pseudomonas aeruginosa Pal 
psTABp Pseudomonas aeruginosa TolA binding peptide 
psTolA(3) Pseudomonas aeruginosa TolA (domain 3) 
psTolB Pseudomonas aeruginosa TolB 
res. residue 
rmsd root mean square deviation 
SDS sodium dodecyl sulfate 
SEC-MALLS size exclusion chromatography-multi angle laser light scattering  
SPR surface plasmon resonance 
SRP signal recognition particle 
TBS Tris-buffered saline 
TMD trans-membrane domain 
TPR tetratricopeptide repeat 
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